<SEC-DOCUMENT>0001104659-26-018314.txt : 20260223
<SEC-HEADER>0001104659-26-018314.hdr.sgml : 20260223
<ACCEPTANCE-DATETIME>20260223064627
ACCESSION NUMBER:		0001104659-26-018314
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20260222
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260223
DATE AS OF CHANGE:		20260223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		26662019

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm267044d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:GILD="http://gilead.com/20260222">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_GILD_gilead.com_20260222 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20260222_20260222 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000004" name="dei:EntityCentralIndexKey">0000882095</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-02-22" id="xdx2ixbrl0017" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gild-20260222.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-02-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-22</xbrli:startDate>
        <xbrli:endDate>2026-02-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.55pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 2.6pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20260222__20260222_zKbjeAvzn3R"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.5pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.1pt 0pt 176.35pt; text-align: center; text-indent: -0.05pt"><b>Pursuant
to Section 13 or <br/>
15(d) of<br/>
The Securities Exchange <br/>
Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>DATE
OF REPORT (DATE OF EARLIEST EVENT REPORTED)</b>: <b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20260222__20260222_zJUesVL4agF7"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">February 22, 2026</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span><b></b></span></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_907_edei--EntityRegistrantName_c20260222__20260222_zXpOVE6zOkr2"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000011" name="dei:EntityRegistrantName">GILEAD SCIENCES, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt 0pt 7.6pt; text-align: center">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20260222__20260222_zltomOysVCUi"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityFileNumber_c20260222__20260222_z9jMdQojHpe4"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000013" name="dei:EntityFileNumber">0-19731</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20260222__20260222_zQA7Jdc6QvQh"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000014" name="dei:EntityTaxIdentificationNumber">94-3047598</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction<br/>
 of
    incorporation)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission File No.)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br/>
&#8239;Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20260222__20260222_zp5HA7gMU6Fe"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000015" name="dei:EntityAddressAddressLine1">333 LAKESIDE DRIVE</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20260222__20260222_zvYMNjmBavI9"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000016" name="dei:EntityAddressCityOrTown">FOSTER CITY</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20260222__20260222_z7Y46Y1LTsZe"><span style="-sec-ix-hidden: xdx2ixbrl0017">CALIFORNIA</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Address of principal executive offices)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20260222__20260222_zIRgFCi5NJn"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000018" name="dei:EntityAddressPostalZipCode">94404</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center">(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b>(<span id="xdx_90C_edei--CityAreaCode_c20260222__20260222_ztCkLQFV1l6i"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000019" name="dei:CityAreaCode">650</ix:nonNumeric></span>)</b><b>
<span id="xdx_902_edei--LocalPhoneNumber_c20260222__20260222_zb6jR9mNAEC9"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000020" name="dei:LocalPhoneNumber">574-3000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.45pt; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.75pt 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_909_edei--WrittenCommunications_c20260222__20260222_zU6kkM3ffoRj" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span>
&#8239;&#8239;&#8239;&#8239;&#8239;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_908_edei--SolicitingMaterial_c20260222__20260222_zk3ZsUU0ANw" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span>
&#8239;&#8239;&#8239;&#8239;&#8239;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20260222__20260222_zO1Sllh78uJ8" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt:booleantrue" id="Fact000023" name="dei:PreCommencementTenderOffer">x</ix:nonNumeric></span>
&#8239;&#8239;&#8239;&#8239;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20260222__20260222_ziLhhf6XN0N"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span> &#8239;&#8239;&#8239;&#8239;&#8239;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 36%; font-size: 10pt; text-align: center">Title of each class</td>
<td style="border-top: Black 1pt solid; border-right: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center">Trading Symbol(s)</td>
<td style="border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: center; width: 32%">Name of each exchange on which<br/>
 registered</td></tr>
<tr style="vertical-align: top">
<td style="border: Black 1pt solid; font-size: 10pt; text-align: center"><b><span id="xdx_901_edei--Security12bTitle_c20260222__20260222_zxgliB705Th4"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></b></td>
<td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b><span id="xdx_90E_edei--TradingSymbol_c20260222__20260222_zLqzptoKXMmj"><ix:nonNumeric contextRef="AsOf2026-02-22" id="Fact000026" name="dei:TradingSymbol">GILD</ix:nonNumeric></span></b></td>
<td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b><span id="xdx_909_edei--SecurityExchangeName_c20260222__20260222_z1C2jB79Sqs"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">Emerging
growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20260222__20260222_z0IWZd008Li4"><ix:nonNumeric contextRef="AsOf2026-02-22" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-top: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Agreement and Plan of Merger</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February&#160;22, 2026, Gilead Sciences,&#160;Inc.,
a Delaware corporation (&#8220;<span style="text-decoration: underline">Parent</span>&#8221; or &#8220;<span style="text-decoration: underline">Gilead</span>&#8221;), entered into an Agreement and Plan of Merger (the
&#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), among Parent, Arcellx,&#160;Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), and
Ravens Sub,&#160;Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Merger Agreement, and upon the
terms and subject to the conditions thereof, Purchaser will commence a tender offer (the &#8220;<span style="text-decoration: underline">Offer</span>&#8221;), to acquire all of
the issued and outstanding shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of common stock, par value $0.001 per share, of the Company, other
than any Shares owned immediately prior to the effective time of the Merger (as defined below) by the Company (including shares held in
the Company&#8217;s treasury) and any Shares owned both as of the date of the commencement of the Offer and immediately prior to the effective
time of the Merger by Parent, Purchaser or any other direct or indirect wholly owned subsidiary of Parent, for (i)&#160;$115.00 per Share
(the &#8220;<span style="text-decoration: underline">Closing Amount</span>&#8221;), net to the seller in cash, without interest, subject to any applicable withholding tax, and
(ii)&#160;one contractual contingent value right (a &#8220;<span style="text-decoration: underline">CVR</span>&#8221;), which represents the right to receive one contingent payment
of $5.00 per CVR, in cash, without interest, upon the achievement of a specified milestone in accordance with the terms and subject to
the conditions of a contingent value rights agreement (the &#8220;<span style="text-decoration: underline">CVR Agreement</span>&#8221;), to be entered into with a rights agent
selected by Parent and reasonably acceptable to the Company (the &#8220;<span style="text-decoration: underline">Rights Agent</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Offer will initially remain open for a minimum
of 20 business days from the date of commencement of the Offer, subject to possible extension pursuant to the terms of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligation of Purchaser to consummate the Offer
is subject to the satisfaction or waiver of customary conditions, including, among others, (i)&#160;there being validly tendered, and
not validly withdrawn, in the Offer a number of Shares that, considered together with all other Shares owned by Purchaser and its affiliates,
represent one more Share than 50% of the total number of Shares outstanding at the time of the expiration of the Offer, (ii)&#160;the
accuracy of the representations and warranties of the Company contained in the Merger Agreement (subject to certain materiality exceptions),
(iii)&#160;material compliance by the Company with its covenants under the Merger Agreement, (iv)&#160;the expiration or termination of
the waiting period applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other specified
notices, approvals or clearances in accordance with foreign antitrust laws having been given and obtained, (v)&#160;the absence of any
law or order prohibiting the consummation of the Offer or the Merger in any jurisdiction in which Parent or the Company has material business
operations and (vi)&#160;other customary conditions set forth in Annex I to the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As soon as practicable following the consummation
of the Offer and subject to the terms and conditions of the Merger Agreement, Purchaser will merge with and into the Company pursuant
to Section&#160;251(h)&#160;of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;), with the Company
being the surviving corporation (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;). At the effective time of the Merger, each Share (other than (i)&#160;Shares
owned by the Company (including shares held in the Company&#8217;s treasury), (ii)&#160;Shares owned both as of the date of the commencement
of the Offer and immediately prior to the effective time of the Merger by Parent, Purchaser, or any other direct or indirect wholly owned
subsidiary of Parent, (iii)&#160;Shares irrevocably accepted for purchase pursuant to the Offer and (iv)&#160;Shares held by stockholders
who have properly exercised and perfected their demands for appraisal of such Shares in accordance with the DGCL and have neither withdrawn
nor lost such rights prior to the effective time of the Merger) will be converted into the right to receive (A)&#160;the Closing Amount
in cash, in each case without any interest thereon, subject to any withholding of taxes, plus (B)&#160;one (1)&#160;CVR (the &#8220;<span style="text-decoration: underline">Merger
Consideration</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Merger Agreement includes customary representations,
warranties and covenants of the Company, Parent and Purchaser.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From the date of the Merger Agreement until the
earlier of the Effective Time and the termination of the Merger Agreement in accordance with its terms (the &#8220;<span style="text-decoration: underline">No-Shop Period</span>&#8221;),
the Company is subject to customary &#8220;no-shop&#8221; restrictions on its ability to solicit alternative acquisition proposals from
third parties and engage in discussions or negotiations with third parties regarding alternative acquisition proposals. Notwithstanding
the limitations applicable during the No-Shop Period, prior to the acceptance of the Shares validly tendered and not validly withdrawn
pursuant to the Offer, the Company may under certain circumstances provide, pursuant to an acceptable confidentiality agreement, information
to, and engage in or otherwise participate in discussions or negotiations with, third parties with respect to a bona fide unsolicited
written alternative acquisition proposal that the board of directors of the Company has determined in good faith, after consultation with
its financial advisor and outside legal counsel, constitutes or would reasonably be expected to result in a Superior Offer (as defined
in the Merger Agreement), if failing to do so would be inconsistent with the board&#8217;s fiduciary duties under applicable legal requirements.&#160;Parent
and Purchaser have agreed to use reasonable best efforts to take actions that may be required in order to obtain antitrust approval of
the proposed transaction, subject to certain limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Merger Agreement also includes customary termination
provisions for both the Company and Parent, and provides that, in connection with the termination of the Merger Agreement under specified
circumstances, including termination by the Company to accept and enter into an agreement with respect to a Superior Offer, the Company
will pay Parent a termination fee of $260,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Merger Agreement
and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger
Agreement, which is filed as Exhibit&#160;2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed
to provide information to investors regarding its terms. It is not intended to provide any other factual information about Parent, Purchaser
or the Company, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation
of the Offer, the Merger or the other transactions contemplated by the Merger Agreement. The Merger Agreement and this summary should
not be relied upon as disclosure about Parent or the Company. None of the Company&#8217;s stockholders or any other third parties should
rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or
conditions of Parent, Purchaser, the Company or any of their respective subsidiaries or affiliates. The Merger Agreement contains representations
and warranties that are the product of negotiations among the parties thereto and that the parties made to, and solely for the benefit
of, each other as of specified dates. The assertions embodied in those representations and warranties are subject to qualifications and
limitations agreed to by the respective parties and are also qualified in important part by confidential disclosure letter delivered in
connection with the signing of the Merger Agreement. The representations and warranties (i)&#160;may have been made for the purpose of
allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject
to standards of materiality applicable to the contracting parties that differ from what an investor may view as material and (ii)&#160;may
have been made only as of the date of the Merger Agreement or as of another date or dates as may be specified in the Merger Agreement,
and information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement,
which subsequent information may or may not be fully reflected in the public disclosures of the Company or Parent, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Contingent Value Rights Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to the time at which Purchaser irrevocably
accepts for purchase all Shares validly tendered (and not validly withdrawn) pursuant to the Offer, Parent and the Rights Agent will enter
into the CVR Agreement. Pursuant to and subject to the terms and conditions of the Merger Agreement, holders of Shares (other than (i)&#160;Shares
owned by the Company (including shares held in the Company&#8217;s treasury), (ii)&#160;Shares owned both as of the date of the commencement
of the Offer and immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or indirect wholly owned
subsidiary of Parent, and (iii)&#160;Shares held by stockholders who have properly exercised and perfected their demands for appraisal
of such Shares in accordance with the DGCL and have neither withdrawn nor lost such rights prior to the effective time of the Merger),
will be entitled to one CVR for each Share outstanding (A)&#160;that Purchaser accepts for payment from such holder pursuant to the Offer
or (B)&#160;owned by or issued to such holder as of immediately prior to the effective time of the Merger and converted into the right
to receive the Merger Consideration from Purchaser pursuant to the Merger Agreement. Each holder of Company Options (as defined in the
Merger Agreement) and Company RSUs (as defined in the Merger Agreement) will be entitled to one CVR for each Share subject to such Company
Option or Company RSU immediately prior to the effective time of the Merger. The CVRs are contractual rights only and not transferable
except under certain limited circumstances, will not be certificated or evidenced by any instrument and will not be registered with the
U.S. Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) or listed for trading. The CVRs will not have any voting or dividend
rights and will not represent any equity or ownership interest in Parent, Purchaser, the Company or any of their respective affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each CVR will represent a non-tradable contractual
contingent right to receive one contingent cash payment in an amount equal to $5.00 per CVR, in cash, without interest (except deemed
interest for tax purposes, as applicable), payable if, after the closing of the Merger, the cumulative worldwide Sales (as defined in
the CVR Agreement) of Arcellx&#8217;s anitocabtagene autoleucel (anito-cel) product exceed $6,000,000,000 on or prior to December&#160;31,
2029 (the &#8220;<span style="text-decoration: underline">Milestone Expiration Date</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any potential payouts of the CVR are subject to
various risks and uncertainties related to the development of anito-cel, regulatory approvals related to commercialization of anito-cel,
commercialization of anito-cel, and third-party patent claims as more fully described in the Company&#8217;s periodic reports filed with
the SEC. The Milestone may not be achieved prior to the Milestone Expiration Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the form of CVR Agreement
does not purport to be complete and is qualified in its entirety by reference to the form of CVR Agreement, a copy of which is included
as Annex III to the Merger Agreement filed as Exhibit&#160;2.1 to this report and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Tender and Support Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February&#160;22, 2026, in connection with
the execution and delivery of the Merger Agreement, Parent entered into tender and support agreements (collectively, the
&#8220;<span style="text-decoration: underline">Support Agreements</span>&#8221;) with each of the directors and executive officers
of the Company and certain other members of the Company's management team, solely in their respective capacities as stockholders of the Company, entities affiliated with New Enterprise
Associates, and entities affiliated with SR One Capital Fund I Aggregator, L.P., who collectively own or control an aggregate of
approximately 10.3% of the outstanding Shares as of February&#160;19, 2026. The Support Agreements provide that, among other things,
each of the stockholders has agreed to (i)&#160;tender all of its, his or her Shares, (ii)&#160;vote against other proposals to
acquire the Company and for any proposal for the Merger and (iii)&#160;certain other restrictions on its, his or her respective
ability to take actions with respect to the Company and its or his or her Shares. Each of the Support Agreements provides that it
will terminate upon the first to occur of (a)&#8239;the valid termination of the Merger Agreement in accordance with its terms,
(b)&#8239;the Effective Time, (c)&#8239;the termination thereof by written notice from Parent to the Support Stockholders or
(d)&#8239;any amendment or change to the Merger Agreement or the Offer that is effected without the Stockholder&#8217;s consent that
decreases the amount, or changes the form, of consideration payable to all stockholders of the Company pursuant to the terms of the
Merger Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Support Agreements
is qualified in all respects by reference to the form of Tender and Support Agreement, which is attached as Exhibit&#160;10.1 hereto and
incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01.</b></span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February&#160;23, 2026, Parent and the Company
issued a joint press release announcing (i)&#160;their entry into the Merger Agreement and (ii)&#160;the acceptance by the U.S. Food and
Drug Administration of the Biologic License Application for anito-cel, the Company&#8217;s BCMA-targeting ddCAR product candidate being
evaluated in patients with relapsed or refractory multiple myeloma, a copy of which is attached as Exhibit&#160;99.1 to this Current Report
on Form&#160;8-K and incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in Item 7.01 of this Current Report
on Form&#160;8-K, including the information incorporated by reference from Exhibit&#160;99.1 hereto, is furnished pursuant to Item 7.01
of Form&#160;8-K and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report
on Form&#160;8-K, including the information incorporated by reference from Exhibit&#160;99.1 hereto this report, shall not be deemed to
be incorporated by reference in the filings of the Company under the Securities Act of 1933.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Forward-Looking Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Current Report on Form&#160;8-K contains forward-looking
statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties and other factors.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all
statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management
teams. In some cases, forward-looking statements can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or the negative of these terms or other similar expressions, although
not all forward-looking statements contain these words. Forward-looking statements include, without limitation, statements regarding the
transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies&#8217;
businesses, including, without limitation, the timing of the expected commercial launch of anito-cel and Gilead&#8217;s ability to streamline
preparation and accelerate adoption and access to anito-cel if the transaction is consummated; the potential for anito-cel to become a
foundational treatment, including for earlier lines of therapy; regulatory applications and related timelines, including the Prescription
Drug User Fee Act date for anito-cel&#8217;s BLA; filings and approvals relating to the transaction&#894; the expected timing of the completion
of the transaction&#894; the ability to satisfy the various closing conditions and complete the transaction&#894; the expectation that
the transaction will be accretive to Gilead following FDA approval in the future&#894; and any assumptions underlying any of the foregoing.
Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties
and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently
anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations
contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger&#894; uncertainties
as to how many of Arcellx&#8217;s stockholders will tender their stock in the offer&#894; the possibility that competing offers will be
made&#894; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental
entity may prohibit, delay or refuse to grant approval for the consummation of the transaction&#894; the effects of the transaction on
relationships with employees, other business partners or governmental entities&#894; the difficulty of predicting the timing or outcome
of regulatory approvals or actions, if any; the risk that, if the transaction is consummated, the businesses will not be integrated successfully
and that other anticipated benefits from the transaction will not be realized; any negative effects on the existing collaboration between
Arcellx and Gilead that may result from the announcement of a transaction, or the failure to complete the transaction; the risk that the
milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof; the impact
of competitive products and pricing&#894; other business effects, including the effects of industry, economic or political conditions
outside of the companies&#8217; control&#894; transaction costs&#894; actual or contingent liabilities; and other risks and uncertainties
detailed from time to time in the companies&#8217; periodic reports filed with the SEC, including current reports on Form&#160;8-K, quarterly
reports on Form&#160;10-Q and annual reports on Form&#160;10-K, as well as the Schedule 14D-9 to be filed by Arcellx and the Schedule
TO and related tender offer documents to be filed by Gilead and Purchaser. All forward-looking statements are based on information currently
available to Gilead and Arcellx, and Gilead and Arcellx assume no obligation and disclaim any intent to update any such forward-looking
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Additional Information and Where to Find It</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The tender offer described in this Current Report
Form&#160;8-K has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a
solicitation of an offer to sell securities of Arcellx, nor is it a substitute for any tender offer materials that Gilead, Purchaser
or Arcellx will file with the SEC. A solicitation and an offer to buy securities of Arcellx will be made only pursuant to an offer to
purchase and related materials that Gilead intends to file with the SEC. At the time the tender offer is commenced, Gilead will file
a Tender Offer Statement on Schedule TO with the SEC, and Arcellx will file a Solicitation/Recommendation Statement on Schedule 14D-9
with the SEC with respect to the tender offer. ARCELLX&#8217;S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS
(INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION
STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE
WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related letter of transmittal and certain other tender offer documents,
as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of Arcellx at no expense to
them. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents
will be made available for free at the SEC&#8217;s web site at <span style="text-decoration: underline">www.sec.gov</span>. Additional copies may be obtained for free by contacting
Gilead or Arcellx. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead
Sciences,&#160;Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000,
or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement
on Schedule TO. Investors and security holders of Arcellx may also obtain, free of charge, the Solicitation/Recommendation Statement
on Schedule 14D-9 and other related documents that Arcellx has filed with or furnished to the SEC under the &#8220;Financials&#8221;
section of Arcellx&#8217;s website at <span style="text-decoration: underline">https://ir<span style="color: blue">.</span></span>arcellx<span style="color: blue"><span style="text-decoration: underline">.</span></span><span style="text-decoration: underline">com/financials/sec-filings/default.aspx<span style="color: blue">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In addition to the Offer to Purchase, the
related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead
and Arcellx file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead&#8217;s and
Arcellx&#8217;s filings with the SEC are also available for free to the public from commercial document-retrieval services and at
the website maintained by the SEC at <span style="text-decoration: underline">www.sec.gov</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="padding-left: 20.4pt; text-align: justify; text-indent: -20.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibit 99.1 is furnished pursuant to this Item 9.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 8%">Exhibit<br/>
 Number</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm267044d1_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><a href="tm267044d1_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated February&#160;22, 2026, among Arcellx,&#160;Inc., Gilead Sciences,&#160;Inc. and Ravens Sub,&#160;Inc.</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="tm267044d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm267044d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Tender and Support Agreement.</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="tm267044d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm267044d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Press Release, dated February&#160;23, 2026.</span></a></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Schedules omitted pursuant to Item 601(a)(5)&#160;of Regulation S-K.
Gilead agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GILEAD SCIENCES,&#160;INC.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Andrew Dickinson</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Dickinson</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February&#160;23, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OVKXQvCtpCKyCInodckplnRHZjezT+ovW5VoGBiGe8+9QkzEhta6QobLssjhhHVTKYdQ4A0ZzRW9I9vuUvC3wLu2jpVxw/sDM/IMemY+lfLqhcHaaotlClESxkkoZxDLdJbAYi+CXs/I3HSJxmlVgTIlHJka1ugUv8eEk+rIUP0eqs7IVpNJIZ5Go/wBGcUSDtSqF/HDQp5nIpgME4gN07PxrlXn0PQkrCqsfZ0d6f8GXwR1Sog= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm267044d1_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;AGREEMENT AND PLAN OF MERGER<BR>
<BR>
among:<BR>
<BR>
ARCELLX, INC.,<BR>
<BR>
a Delaware corporation;<BR>
<BR>
GILEAD SCIENCES, INC.,<BR>
<BR>
a Delaware corporation; and<BR>
<BR>
RAVENS SUB, INC.,<BR>
<BR>
a Delaware corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated as of February 22, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 1 THE OFFER</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right">2</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.01.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offer</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.02.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Actions</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 2 MERGER TRANSACTION</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right">6</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.01.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger of Purchaser into the Company</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.02.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of the Merger</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.03.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing; Effective Time</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.04.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws; Directors and Officers</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.05.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion of Shares</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.06.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Matters; Stock Transfer Books</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.07.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenters&rsquo; Rights</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.08.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of Equity Awards and Company ESPP</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.09.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Action</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 3 REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right">13</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.01.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due Organization</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.02.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Documents</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.03.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization, Etc</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.04.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority; Binding Nature of Agreement</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.05.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Filings; Financial Statements</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.06.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Changes; No Material Adverse Effect</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.07.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title to Assets</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.08.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real Property</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.09.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.10.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Privacy</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.11.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contracts</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.12.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.13.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Legal Requirements</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.14.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Matters</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.15.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Business Practices</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.16.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental Authorizations</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.17.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Matters</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.18.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Matters; Benefit Plans</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.19.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; padding-top: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; width: 15%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.20.</FONT></TD>
    <TD STYLE="padding-top: 2pt; width: 80%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; width: 5%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.21.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings; Orders</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.22.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Takeover Laws</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.23.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Contravention; Consents</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.24.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Financial Advisor</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.25.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers and Other Advisors</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.26.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acknowledgement by the Company</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 4 REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt">37</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.01.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due Organization</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.02.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.03.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority; Binding Nature of Agreement</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.04.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Contravention; Consents</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.05.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.06.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Litigation</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.07.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funds</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.08.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DGCL Section 203(c)</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.09.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acknowledgement by Parent and Purchaser</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.10.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers and Other Advisors</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 5 CERTAIN COVENANTS OF THE COMPANY</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt">41</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.01.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access and Investigation</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.02.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation of the Company&rsquo;s Business</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.03.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Solicitation</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 6 ADDITIONAL COVENANTS OF THE PARTIES</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt">49</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.01.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board Recommendation</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.02.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filings, Consents and Approvals</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.03.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Benefits</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.04.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification of Officers and Directors</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.05.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder Litigation</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.06.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Agreements</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.07.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.08.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Takeover Laws</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.09.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 16 Matters</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.10.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule 14d-10 Matters</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.11.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Exchange Delisting; Deregistration</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; width: 15%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.12.</FONT></TD>
    <TD STYLE="padding-top: 2pt; width: 80%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVR Agreement</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; width: 5%; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.13.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.14.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO Non-Compete Agreement</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 7 CONDITIONS PRECEDENT TO THE MERGER</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt">60</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.01.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Restraints</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.02.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consummation of Offer</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 8 TERMINATION</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt">61</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.01.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.02.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Termination</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.03.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses; Termination Fees</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article 9 MISCELLANEOUS PROVISIONS</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt">64</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.01.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.02.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.03.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Survival of Representations and Warranties</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.04.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire Agreement; Counterparts</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.05.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.06.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignability</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.07.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Third Party Beneficiaries</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.08.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Taxes</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.09.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.10.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.11.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligation of Parent</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-left: 0.5in; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.12.</FONT></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction</FONT></TD>
    <TD STYLE="padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit A: Certain Definitions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annex I: Conditions to the Offer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annex II: Amended and Restated Certificate of Incorporation of Arcellx,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annex III: CVR Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AGREEMENT AND PLAN
OF MERGER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THIS AGREEMENT AND PLAN OF MERGER </B>(&ldquo;<B>Agreement</B>&rdquo;)
is made and entered into as of February 22, 2026 by and among: Gilead Sciences, Inc., a Delaware corporation (&ldquo;<B>Parent</B>&rdquo;);
Ravens Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (&ldquo;<B>Purchaser</B>&rdquo;); and Arcellx, Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;). Certain capitalized terms used in this Agreement are defined in <U>Exhibit
A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(A) Parent has agreed to cause Purchaser to commence
a cash tender offer (as it may be amended from time to time as permitted under this Agreement, the &ldquo;<B>Offer</B>&rdquo;) to acquire
all of the outstanding shares of Company Common Stock (the &ldquo;<B>Shares</B>&rdquo;), other than Shares to be cancelled pursuant to
Sections 2.05(a)(i) and 2.05(a)(ii), for (x) $115.00 per share (the &ldquo;<B>Closing Amount</B>&rdquo;), net to the seller in cash, without
interest, subject to any withholding of Tax in accordance with Section 2.06(e), and (y) one (1) contractual contingent value right (a
&ldquo;<B>CVR</B>&rdquo;), which shall represent the right to receive the Milestone Payment (as such term is defined in the CVR Agreement)
subject to the terms and conditions set forth in the CVR Agreement (the Closing Amount plus one (1) CVR, together, the &ldquo;<B>Offer
Price</B>&rdquo;), upon the terms and subject to the conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(B) As soon as practicable following the consummation
of the Offer, Purchaser will be merged with and into the Company (the &ldquo;<B>Merger</B>&rdquo;), with the Company continuing as the
surviving corporation in the Merger (the &ldquo;<B>Surviving Corporation</B>&rdquo;), on the terms and subject to the conditions set forth
in this Agreement, whereby (i) each issued and outstanding Share not owned by Parent, Purchaser or the Company as of the Effective Time
(other than Shares to be cancelled pursuant to Sections 2.05(a)(i), 2.05(a)(ii), 2.05(a)(iii) and any Dissenting Shares) shall be converted
into the right to receive the Merger Consideration, and (ii) the Company shall become a wholly owned Subsidiary of Parent as a result
of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(C) The board of directors of the Company (the
&ldquo;<B>Board of Directors</B>&rdquo;) has unanimously (i) determined that this Agreement and the CVR Agreement and the Transactions,
including the Offer and the Merger, are advisable and fair to, and in the best interest of, the Company and its stockholders, (ii) declared
it advisable to enter into this Agreement, (iii) adopted resolutions approving and declaring the advisability of the execution, delivery
and performance by the Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (iv) resolved
that the Merger shall be effected under Section 251(h) of the DGCL, and (v) adopted resolutions recommending that the stockholders of
the Company accept the Offer and tender their Shares to Purchaser pursuant to the Offer (the preceding clauses (i) through (v), the &ldquo;<B>Company
Board Recommendation</B>&rdquo;), in each case, on the terms and subject to the conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(D) The board of directors of each of Parent and
Purchaser have approved this Agreement and declared it advisable for Parent and Purchaser, respectively, to enter into this Agreement
and to consummate the Transactions, and the board of directors of Parent has approved the CVR Agreement and declared it advisable for
Parent to enter into the CVR Agreement and to consummate the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(E) Concurrently with the execution and delivery
of this Agreement, and as a condition and inducement to the willingness of Parent and Purchaser to enter into this Agreement, certain
stockholders of the Company (collectively, the &ldquo;<B>Supporting Stockholders</B>&rdquo;) are entering into a tender and support agreement
with Parent and Purchaser, pursuant to which, among other things, each Supporting Stockholder has agreed to tender all of its Shares to
Purchaser in the Offer and (if applicable) vote all of its Shares in favor of the Merger, in each case on the terms and subject to the
conditions set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(F) At or prior to the Offer Acceptance Time, Parent
and the Rights Agent will enter into the CVR Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(G) Parent, Purchaser and the Company acknowledge
and agree that the Merger shall be effected pursuant to Section 251(h) of the DGCL and shall, subject to the satisfaction of the conditions
set forth in this Agreement, be consummated as soon as practicable following the consummation of the Offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Parties, intending to be legally bound, agree
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
1<BR>
THE OFFER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>The Offer</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Commencement of the Offer</B>. Provided that this Agreement shall not have been terminated in accordance with Article 8, as
promptly as practicable after the date of this Agreement but in no event more than 10 business days after the date of this Agreement (subject
to the Company having timely provided any information required to be provided by it pursuant to Sections 1.01(e) and 1.02(b)), Purchaser
shall (and Parent shall cause Purchaser to) commence (within the meaning of Rule 14d-2 under the Exchange Act) the Offer to purchase all
of the outstanding Shares (other than Shares to be cancelled pursuant to Sections 2.05(a)(i) and 2.05(a)(ii)), at a price per Share equal
to the Offer Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Terms and Conditions of the Offer</B>. The obligations of Purchaser to (and of Parent to cause Purchaser to) accept for payment,
and (prior to the Offer Acceptance Time) pay for, any Shares validly tendered (and not validly withdrawn) pursuant to the Offer shall
be subject to the satisfaction or waiver (to the extent permitted under applicable Legal Requirements) of the conditions set forth in
Annex I (collectively, the &ldquo;<B>Offer Conditions</B>&rdquo;), and no other conditions. The Offer shall be made by means of an offer
to purchase (the &ldquo;<B>Offer to Purchase</B>&rdquo;) that contains the terms set forth in this Agreement, the Minimum Condition, the
Termination Condition and the other Offer Conditions. Purchaser expressly reserves the right to (i) increase the Offer Price, (ii) waive
any Offer Condition (to the extent permitted under applicable Legal Requirements) and (iii) make any other changes in the terms and conditions
of the Offer not inconsistent with the terms of this Agreement; <I>provided</I>, <I>however</I>, notwithstanding anything to the contrary
contained in this Agreement, without the prior written consent of the Company, Parent and Purchaser shall not (A) decrease the Closing
Amount or amend the terms of the CVR or the CVR Agreement, (B) change the form of consideration payable in the Offer (<I>provided</I>,
<I>however</I>, that nothing herein shall limit the ability of Parent and Purchaser to increase the cash consideration payable in the
Offer), (C) decrease the maximum number of Shares sought to be purchased in the Offer, (D) impose conditions or requirements to the Offer
in addition to the Offer Conditions, (E) amend, modify or waive the Minimum Condition, Termination Condition or the conditions set forth
in clause (e) or (g) of Annex I, (F) otherwise amend or modify any of the other terms of the Offer in a manner that adversely affects
in any material respect, or would reasonably be expected to adversely affect in any material respect, any holder of Shares in its capacity
as such, (G) terminate the Offer or accelerate, extend or otherwise change the Expiration Date, in each case, except as provided in Sections
1.01(c) or 1.01(d), or (H) provide any &ldquo;subsequent offering period&rdquo; (or any extension thereof) within the meaning of Rule
14d-11 promulgated under the Exchange Act. The Offer may not be withdrawn prior to the Expiration Date (or any rescheduled Expiration
Date) of the Offer, unless this Agreement is terminated in accordance with Article 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Expiration and Extension of the Offer</B>. The Offer shall initially be scheduled to expire at one minute after 11:59 p.m. Eastern
Time on the date that is 20 business days (determined as set forth in Rule 14d-1(g)(3) and Rule 14e-1(a) under the Exchange Act) following
the Offer Commencement Date (unless otherwise agreed to in writing by Parent and the Company) (the &ldquo;<B>Initial Expiration Date</B>&rdquo;,
and such date or such subsequent date to which the Initial Expiration Date of the Offer is extended in accordance with the terms of this
Agreement, the &ldquo;<B>Expiration Date</B>&rdquo;). Notwithstanding anything to the contrary contained in this Agreement, but subject
to the Parties&rsquo; respective termination rights under Article 8: (i) if, as of the then-scheduled Expiration Date, any Offer Condition
is not satisfied (unless such condition is waivable by Purchaser or Parent and has been waived), Purchaser shall, and Parent shall cause
Purchaser to, extend the Offer for additional periods of up to 10 business days per extension (with each such period to end one minute
after 11:59 p.m. Eastern Time on the last business day of such period) (or such other duration as may be agreed in writing by Parent and
the Company), to permit such Offer Condition to be satisfied; <I>provided</I>, <I>however</I>, that if at any then-scheduled Expiration
Date all of the Offer Conditions other than the Minimum Condition and any other conditions that by their nature are to be satisfied at
the Offer Acceptance Time have been satisfied or waived and the Minimum Condition has not been satisfied Purchaser shall not be required
to, and Parent shall not be required to cause Purchaser to, extend the Offer pursuant to this clause (i) on more than two occasions in
consecutive periods of 10 business days each; and (ii) Purchaser shall, and Parent shall cause Purchaser to, extend the Offer from time
to time for any period required by any Legal Requirement, any interpretation or position of the SEC, the staff thereof, Nasdaq or the
staff thereof applicable to the Offer; <I>provided</I>, <I>however</I>, that in no event shall Purchaser (A) be required to extend the
Offer beyond the earlier to occur of (x) the valid termination of this Agreement in accordance with Article 8 and (y) the End Date (such
earlier occurrence, the &ldquo;<B>Extension Deadline</B>&rdquo;) or (B) extend the Offer beyond the Extension Deadline without the prior
written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Termination of Offer</B>. Nothing in this Section 1.01 shall be deemed to impair, limit or otherwise restrict in any manner
the right of the Company, Parent or Purchaser to terminate this Agreement pursuant to Article 8. In the event that this Agreement is validly
terminated pursuant to Article 8, Purchaser shall (and Parent shall cause Purchaser to) promptly, irrevocably and unconditionally terminate
the Offer and shall not acquire any Shares pursuant to the Offer. If the Offer is terminated or withdrawn by Purchaser in accordance with
the terms of this Agreement, Purchaser shall immediately return, and shall cause any depository acting on behalf of Purchaser to return,
in accordance with applicable Legal Requirements, all tendered Shares to the registered holders thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Offer Documents</B>. As promptly as practicable on the Offer Commencement Date, Parent and Purchaser shall (i) file with the
SEC a tender offer statement on Schedule TO with respect to the Offer (together with any exhibits, amendments or supplements thereto,
the &ldquo;<B>Offer Documents</B>&rdquo;) that will contain or incorporate by reference the Offer to Purchase, form of the related letter
of transmittal, and summary advertisement, (ii) make all deliveries, mailings and telephonic notices required by Rule 14d-3 under the
Exchange Act and (iii) cause the Offer to Purchase and related documents to be disseminated to holders of Shares as and to the extent
required by applicable Legal Requirements. Parent and Purchaser agree that they shall cause the Offer Documents filed by either Parent
or Purchaser with the SEC to (x) comply in all material respects with the Exchange Act and other applicable Legal Requirements and (y)
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>,
that no covenant is made by Parent or Purchaser with respect to information supplied by or on behalf of the Company for inclusion or incorporation
by reference in the Offer Documents. Each of Parent, Purchaser and the Company agrees to respond promptly to any comments (including oral
comments) of the SEC or its staff and to promptly correct any information provided by it for use in the Offer Documents if and to the
extent that such information shall have become false or misleading in any material respect, and to correct any material omissions therefrom,
and Parent and Purchaser further agree to take all steps necessary to promptly cause the Offer Documents as so corrected to be filed with
the SEC and to be disseminated to holders of Shares, in each case as and to the extent required by applicable Legal Requirements. The
Company hereby consents to the inclusion of the Company Board Recommendation in the Offer Documents, unless a Company Adverse Change Recommendation
has occurred and has been communicated to Parent in writing prior to the filing of such Offer Documents with the SEC. The Company shall
promptly furnish or otherwise make available to Parent and Purchaser or Parent&rsquo;s legal counsel all information concerning the Acquired
Companies and the Company&rsquo;s stockholders that may be required or reasonably requested in connection with any action contemplated
by this Section 1.01(e). The Company and its counsel shall be given reasonable opportunity to review and comment on the Offer Documents
(including any response to any comments (including oral comments) of the SEC or its staff with respect thereto) prior to the filing thereof
with the SEC, and Parent and Purchaser shall give reasonable consideration to any such comments made by the Company or its counsel. Parent
and Purchaser agree to provide the Company and its counsel with any comments (including oral comments) Parent, Purchaser or their counsel
may receive from the SEC or its staff with respect to the Offer Documents promptly after receipt of those comments (including oral comments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Funds</B>. Without limiting the generality of Section 9.11, Parent shall cause to be provided to Purchaser, on a timely basis,
all of the funds necessary to purchase all Shares that Purchaser becomes obligated to purchase pursuant to the Offer, and shall cause
Purchaser to perform, on a timely basis, all of Purchaser&rsquo;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Adjustments</B>. If, between the date of this Agreement and the Offer Acceptance Time, the outstanding Shares are changed into
a different number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split,
consolidation of shares, reclassification, recapitalization or other similar transaction, then the Offer Price shall be appropriately
adjusted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Acceptance</B>. Subject only to the satisfaction or, to the extent waivable by Purchaser or Parent, waiver by Purchaser or Parent
of each of the Offer Conditions, Purchaser shall (and Parent shall cause Purchaser to) (i) immediately after the Expiration Date irrevocably
accept for payment all Shares tendered (and not validly withdrawn) pursuant to the Offer (the time of such acceptance, the &ldquo;<B>Offer
Acceptance Time</B>&rdquo;) and (ii) as promptly as practicable after the Offer Acceptance Time (and in any event within three business
days) pay for such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Company Actions</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Schedule 14D-9</B>. Subject to Section 6.01(b), as promptly as practicable on the Offer Commencement Date, following the filing
of the Offer Documents, the Company shall (i) file with the SEC a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9
(together with any exhibits, amendments or supplements thereto, the &ldquo;<B>Schedule 14D-9</B>&rdquo;) that shall reflect the Company
Board Recommendation, unless a Company Adverse Change Recommendation has occurred and has been communicated to Parent in writing prior
to the filing of such Offer Documents with the SEC, and include the fairness opinion of the Company&rsquo;s financial advisor referenced
in Section 3.24 and the notice and other information required by Section 262(d)(2) of the DGCL and (ii) cause the Schedule 14D-9 and related
documents to be disseminated to holders of Shares as and to the extent required by applicable Legal Requirements, including by setting
the Stockholder List Date as the record date for purposes of receiving the notice required by Section 262(d)(2) of the DGCL. The Company
agrees that it shall cause the Schedule 14D-9 to (x) comply in all material respects with the Exchange Act and other applicable Legal
Requirements and (y) not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; <I>provided</I>,
<I>however</I>, that no covenant is made by the Company with respect to information supplied by or on behalf of Parent or Purchaser for
inclusion or incorporation by reference in the Schedule 14D-9. Each of Parent, Purchaser and the Company agrees to respond promptly to
any comments (including oral comments) of the SEC or its staff and to promptly correct any information provided by it for use in the Schedule
14D-9 if and to the extent that such information shall have become false or misleading in any material respect, and the Company further
agrees to take all steps necessary to promptly cause the Schedule 14D-9 as so corrected to be filed with the SEC and to be disseminated
to holders of Shares, in each case as and to the extent required by applicable Legal Requirements. Parent and Purchaser shall promptly
furnish or otherwise make available to the Company or the Company&rsquo;s legal counsel all information concerning Parent or Purchaser
that may be required or reasonably requested in connection with any action contemplated by this Section 1.02(a). Parent and its counsel
shall be given reasonable opportunity to review and comment on the Schedule 14D-9 (including any response to any comments (including oral
comments) of the SEC or its staff with respect thereto) prior to the filing thereof with the SEC, and the Company shall give reasonable
consideration to any such comments made by Parent or its counsel. The Company agrees to provide Parent and its counsel with any comments
(including oral comments) the Company or its counsel may receive from the SEC or its staff with respect to the Schedule 14D-9 promptly
after receipt of those comments (including oral comments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Stockholder Lists</B>. The Company shall promptly after the date hereof furnish Parent, and if requested by Parent, furnish
the Paying Agent and the Depository Agent, with a list of its stockholders, mailing labels and any available listing or computer file
containing the names and addresses of all record holders of Shares and lists of securities positions of Shares held in stock depositories,
in each case accurate and complete as of the most recent practicable date, and shall provide to Parent, and if requested by Parent, provide
to the Paying Agent and the Depository Agent, such additional information (including updated lists of stockholders, mailing labels and
lists of securities positions) and such other assistance as Parent may reasonably request in connection with the Offer and the Merger
(the date of the list used to determine the Persons to whom the Offer Documents and the Schedule 14D-9 are first disseminated, which date
shall not be more than ten (10) business days prior to the date the Offer Documents and the Schedule 14D-9 are first disseminated, the
&ldquo;<B>Stockholder List Date</B>&rdquo;). Subject to applicable Legal Requirements, and except for such steps as are necessary to disseminate
the Offer Documents and any other documents necessary to consummate the Transactions, Parent and Purchaser and their agents shall hold
in confidence in accordance with the Confidentiality Agreement the information contained in any such labels, listings and files.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><B>Share Registry</B>. The Company shall register (and shall instruct its transfer agent to register) the transfer of the Shares
accepted for payment by Purchaser effective immediately after the Offer Acceptance Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
2<BR>
MERGER TRANSACTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Merger of Purchaser into
the Company</I></FONT>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with Section 251(h)
of the DGCL, at the Effective Time, the Company and Parent shall consummate the Merger, whereby Purchaser shall be merged with and into
the Company, the separate existence of Purchaser shall cease, and the Company will continue as the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Effect of the Merger</I></FONT>.
The Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. Without limiting the generality
of the foregoing, at the Effective Time, all of the property, rights, privileges, immunities, powers and franchises of the Company and
Purchaser shall vest in the Surviving Corporation, and all of the debts, liabilities and duties of the Company and Purchaser shall become
the debts, liabilities and duties of the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Closing; Effective Time</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Unless this Agreement shall have been terminated pursuant to Article 8, and unless otherwise mutually agreed in writing between
the Company, Parent and Purchaser, the consummation of the Merger (the &ldquo;<B>Closing</B>&rdquo;) shall take place at the offices of
Ropes &amp; Gray LLP, 525 University Avenue, Palo Alto, CA 94301 or remotely by exchange of documents and signatures (or their electronic
counterparts), as soon as practicable following (but in any event on the same date as) the Offer Acceptance Time except if the conditions
set forth in Section 7.01 shall not be satisfied or, to the extent permitted by applicable Legal Requirements, waived as of such date,
in which case the Closing shall take place on the first business day on which all conditions set forth in Section 7.01 are satisfied or,
to the extent permitted by applicable Legal Requirements, waived, unless another date or place is agreed to in writing by the Company
and Parent prior to the Offer Acceptance Time. The date on which the Closing occurs is referred to in this Agreement as the &ldquo;<B>Closing
Date</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the provisions of this Agreement, as soon as practicable on the Closing Date, the Company and Purchaser shall file or
cause to be filed a certificate of merger with the Secretary of State of the State of Delaware with respect to the Merger, in such form
as required by, and executed and acknowledged in accordance with, the relevant provisions of the DGCL, and the Parties shall take all
such further actions as may be required by applicable Legal Requirements to make the Merger effective. The Merger shall become effective
upon the date and time of the filing of that certificate of merger with the Secretary of State of the State of Delaware or such later
date and time as is agreed upon in writing by the Parties and specified in the certificate of merger (such date and time, the &ldquo;<B>Effective
Time</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Certificate of Incorporation
and Bylaws; Directors and Officers</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the Effective Time, the certificate of incorporation of the Company shall, by virtue of the Merger and without any further
action, be amended and restated to read in its entirety as set forth on Annex II and, as so amended and restated, shall be the certificate
of incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or by applicable Legal Requirements,
subject to Section 6.04(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the Effective Time, the bylaws of the Surviving Corporation shall be amended and restated to conform to the bylaws of Purchaser
as in effect immediately prior to the Effective Time, until thereafter changed or amended as provided therein or by applicable Legal Requirements,
subject to Section 6.04(a), except that references to the name of Purchaser shall be replaced by references to the name of the Surviving
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the Effective Time, the directors and officers of the Surviving Corporation shall be the respective individuals who served
as the directors and officers of Purchaser as of immediately prior to the Effective Time, until their respective successors are duly elected
and qualified, or their earlier death, resignation or removal. Prior to the Closing, each director of the Company and, if so requested
by Parent, each officer of the Company, shall execute and deliver a letter effectuating his or her resignation as a member of the Board
of Directors and an officer of the Company (but, for the avoidance of doubt, not as an employee of the Company), respectively, to be effective
as of the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Conversion of Shares</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Purchaser, the Company or
any stockholder of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Shares owned immediately prior to the Effective Time by the Company (including those held in the Company&rsquo;s treasury)
shall be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Shares owned both as of the Offer Commencement Date and immediately prior to the Effective Time by Parent, Purchaser or any
other direct or indirect wholly owned Subsidiary of Parent shall be cancelled and retired and shall cease to exist, and no consideration
shall be delivered in exchange therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Shares irrevocably accepted for purchase pursuant to the Offer shall be cancelled and retired and shall cease to exist, and
no consideration shall be delivered in exchange therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>except as provided in clauses (i), (ii) and (iii) above and subject to Section 2.05(b), each Share outstanding immediately prior
to the Effective Time (other than any Dissenting Shares, which shall have only those rights set forth in Section 2.07) shall be converted
into the right to receive (A) the Closing Amount in cash, in each case without any interest thereon, subject to any withholding of Taxes
in accordance with Section 2.06(e), <I>plus</I> (B) one (1) CVR (clauses (A) and (B), collectively, the &ldquo;<B>Merger Consideration</B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each share of the common stock, $0.001 par value per share, of Purchaser then outstanding shall be converted into one share of
common stock of the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From and after the Effective Time, subject to this
Section 2.05(a), all Shares shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and each applicable
holder of such Shares shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration therefor
upon the surrender of such Shares in accordance with Section 2.06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If, between the date of this Agreement and the Effective Time, the outstanding Shares are changed into a different number or class
of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares,
reclassification, recapitalization or other similar transaction, then the Merger Consideration shall be appropriately adjusted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Exchange Matters; Stock
Transfer Books</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Prior to the Offer Acceptance Time, Parent shall designate a bank or trust company reasonably acceptable to the Company to act
as agent (the &ldquo;<B>Depository Agent</B>&rdquo;) for the holders of Shares to receive the aggregate Closing Amount (payable in respect
of the Merger Consideration) to which holders of such Shares shall become entitled pursuant to Section 1.01(b), and to act as agent (the
&ldquo;<B>Paying Agent</B>&rdquo;) for the holders of Shares to receive the aggregate Closing Amount (payable in respect of the Merger
Consideration) to which holders of such Shares shall become entitled pursuant to Section 2.05. Promptly after (and in any event no later
than the first business day after) the Offer Acceptance Time, Parent shall deposit, or shall cause to be deposited, with the Depository
Agent cash sufficient to make the payment of the aggregate Closing Amount (payable in respect of the Merger Consideration) payable pursuant
to Section 1.01(h). On or prior to the Closing Date, Parent shall deposit, or shall cause to be deposited, with the Paying Agent cash
sufficient to pay the aggregate Closing Amount (payable in respect of the Merger Consideration) payable pursuant to Section 2.05 (together
with the amount deposited pursuant to the immediately preceding sentence, the &ldquo;<B>Payment Fund</B>&rdquo;). The Payment Fund shall
not be used for any purpose other than to pay the aggregate Offer Price in the Offer and the aggregate Merger Consideration to holders
of Shares in the Merger. To the extent Parent becomes aware that (i) there are any losses with respect to any such investments or (ii)
the Payment Fund has diminished for any reason below the level required for the Paying Agent to make promptly all cash payments pursuant
to Section 1.01(h) and Section 2.05, Parent shall, or shall cause the Surviving Corporation to, promptly replace or restore the cash in
the Payment Fund so as to ensure that the Payment Fund is, at all times during the duration of the Payment Fund, maintained at a level
sufficient for the Paying Agent to make all such payments pursuant to Section 1.01(h) and Section 2.05. Parent shall not be required to
deposit any funds related to any CVR with the Rights Agent unless and until such deposit is required pursuant to the CVR Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as provided in this Section 2.06(b), at the Effective Time, holders of Shares shall not be required to take any action with
respect to the exchange of their Shares for the Merger Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any holder of Shares held in direct registry form through the Company&rsquo;s transfer agent, Computershare Trust Company, N.A.
(the &ldquo;<B>Company Transfer Agent</B>&rdquo;) shall, subject to compliance with customary procedures of the Paying Agent and the Company
Transfer Agent, automatically upon the Effective Time, be entitled to receive, and Parent shall cause the Paying Agent to pay and deliver
as promptly as possible after the Effective Time, the Merger Consideration to which such holder shall become entitled pursuant to Section
2.05(a)(iv), and the Shares so exchanged shall be forthwith canceled. Payment of the applicable Merger Consideration with respect to such
Shares shall be made only to the Person in whose name such Shares are registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>With respect to Shares held, directly or indirectly, through the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;), Parent and
the Company shall cooperate to establish procedures with the Paying Agent, DTC, DTC&rsquo;s nominees and such other necessary third-party
intermediaries to ensure that the Paying Agent will transmit to DTC or its nominees as promptly as practicable after the Effective Time,
upon surrender of Shares held of record by DTC or its nominees in accordance with DTC&rsquo;s customary surrender procedures and such
other procedures as agreed by Parent, the Company, the Paying Agent, DTC, DTC&rsquo;s nominees and such other necessary third-party intermediaries,
the aggregate Merger Consideration to which the beneficial owners of such Shares held, directly or indirectly through DTC shall become
entitled pursuant to Section 2.05(a)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No interest shall accrue or be paid on the Merger Consideration payable to holders of Shares in accordance with this Section 2.06(b)
for the benefit of the holder thereof. Until exchanged as contemplated by this Section 2.06(b), each Share shall be deemed at any time
after the Effective Time to represent only the right to receive the applicable Merger Consideration as contemplated by Section 2.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>At any time following twelve (12) months after the Effective Time, Parent shall be entitled to require the Paying Agent to deliver
to it any funds (with respect to the aggregate Closing Amount to which holders of Shares shall become entitled pursuant to Section 2.05)
which had been made available to the Paying Agent and not disbursed to holders of Shares (including all interest and other income received
by the Paying Agent in respect of all funds made available to it), and, thereafter, such holders shall be entitled to look to the Surviving
Corporation (subject to abandoned property, escheat and other similar Legal Requirements) only as general creditors thereof with respect
to the Merger Consideration to which such holders shall become entitled pursuant to Section 2.05. Notwithstanding the foregoing, neither
the Surviving Corporation nor the Paying Agent shall be liable to any holder of Shares for the Merger Consideration to which such holder
shall become entitled pursuant to Section 2.05, delivered in respect of such Shares to a public official pursuant to any abandoned property,
escheat or other similar Legal Requirements. Any amounts remaining unclaimed by such holders at such time at which such amounts would
otherwise escheat to or become property of any Governmental Body shall become, to the extent permitted by applicable Legal Requirements,
the property of the Surviving Corporation or its designee, free and clear of all claims or interest of any Person previously entitled
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>At the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the Shares shall
be closed and thereafter there shall be no further registration of transfers of Shares on the records of the Company. From and after the
Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time shall cease to have any rights with respect
to such Shares except as otherwise provided herein or by applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each of the Company, the Surviving Corporation, Parent and Purchaser, and their Affiliates, the Paying Agent, the Depository Agent
or the Rights Agent, as the case may be, shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts
otherwise payable pursuant to this Agreement or the CVR Agreement, such amounts as are required to be deducted and withheld under any
Legal Requirement with respect to Taxes. Any amounts so deducted and withheld and paid over to the applicable Governmental Body in accordance
with applicable Legal Requirements shall be treated for all purposes of this Agreement or the CVR Agreement as having been paid to the
Person in respect of which such deduction or withholding was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Dissenters&rsquo; Rights</I></FONT>.
Notwithstanding anything in this Agreement to the contrary, Shares outstanding immediately prior to the Effective Time and held by holders
who are entitled to appraisal rights under Section 262 of the DGCL and have properly exercised and perfected their respective demands
for appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and, as of the Effective Time, have neither effectively
withdrawn nor lost their rights to such appraisal and payment under the DGCL (the &ldquo;<B>Dissenting Shares</B>&rdquo;), shall not be
converted into the right to receive Merger Consideration, but shall, by virtue of the Merger, be automatically cancelled and no longer
outstanding, shall cease to exist and the holder thereof shall be entitled to only such consideration as shall be determined pursuant
to Section 262 of the DGCL in respect of such Shares; <I>provided</I>, <I>however</I>, that if any such holder shall have failed to perfect
or shall have effectively withdrawn or lost such holder&rsquo;s right to appraisal and payment under the DGCL, such holder&rsquo;s Shares
shall be deemed to have been converted as of the Effective Time into the right to receive the Merger Consideration (less any amounts entitled
to be deducted or withheld pursuant to Section 2.06(e)), and such Shares shall not be deemed to be Dissenting Shares. The Company shall
give prompt notice to Parent and Purchaser of any demands received by the Company for appraisal of any Dissenting Shares, withdrawals
of such demands and any other instruments served pursuant to Section 262 of the DGCL, in each case prior to the Effective Time, and, at
or prior to the Effective Time, the Company shall provide the Paying Agent with a list of the names and addresses of the holders of Dissenting
Shares, if any, and such other information regarding the Dissenting Shares as the Paying Agent reasonably requests. Parent and Purchaser
shall have the right to direct and participate in all negotiations and proceedings with respect to such demands, and the Company shall
not, without the prior written consent of Parent and Purchaser, settle or offer to settle, or make any payment with respect to, any such
demands, approve any withdrawal of any such demands or agree or commit to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.08.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Treatment of Equity Awards
and Company ESPP</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>At the Effective Time, and without any action on the part of Parent, Purchaser, the Company, or any other Person, each Company
Option that is then outstanding and unexercised, whether or not vested, and which has a per Share exercise price that is less than the
Closing Amount, shall be cancelled and converted into the right of the holder to receive (i) (subject to any applicable withholding Taxes)
(i) a lump-sum cash payment equal to (x) the excess (if any) of (A) the Closing Amount over (B) the per Share exercise price subject to
such Company Option, multiplied by (y) the total number of Shares subject to such Company Option immediately prior to the Effective Time
and (ii) one (1) CVR for each Share subject to such Company Option immediately prior to the Effective Time. For the avoidance of doubt,
at the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per Share exercise
price that is equal to or greater than the Closing Amount, shall be cancelled with no consideration payable therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>At the Effective Time, and without any action on the part of Parent, Purchaser, the Company, or any other Person, each Company
RSU that is then outstanding, whether or not vested, shall be cancelled and converted into the right of the holder to receive (i) (subject
to any applicable withholding Taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of Shares
subject to such Company RSU immediately prior to the Effective Time (with the number of Shares underlying any Company RSUs that are subject
to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined
by the Board of Directors or a committee thereof) and (ii) one (1) CVR for each Share subject to such Company RSU immediately prior to
the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the following sentence, as soon as reasonably practicable after the Effective Time (but in no event later than the second
(2<SUP>nd</SUP>) regular payroll date that follows the Effective Time or at such later date required to avoid the imposition of Taxes
under Section 409A of the Code), Parent shall cause the Surviving Corporation to, and the Surviving Corporation shall, pay, or cause to
be paid, the consideration payable pursuant to Section 2.08(a) and Section 2.08(b), without interest and net of any applicable withholding
Taxes, to the holders of Company Options and Company RSUs through, to the extent applicable, the Surviving Corporation&rsquo;s payroll
or the Company&rsquo;s normal payroll procedures. Notwithstanding the foregoing, all payments of the CVRs in respect of Company Options
or Company RSUs pursuant this&nbsp;<U>Section&nbsp;2.08</U>&nbsp;shall be made by Parent or its applicable affiliate as set forth in the
CVR Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As soon as practicable following the date hereof, the Company shall take all actions that are necessary or advisable with respect
to the Company ESPP to provide that (i) with respect to the offering period under the Company ESPP in effect as of the date hereof, if
any (the &ldquo;<B>ESPP Offering Period</B>&rdquo;), no individual who was not a participant in the Company ESPP as of the date hereof
may enroll in the Company ESPP with respect to such ESPP Offering Period and no participant may increase the percentage amount of his
or her payroll deduction election from that in effect on the date hereof for such ESPP Offering Period, (ii) no new offering period shall
be commenced under the Company ESPP on or after the date hereof, and (iii) if the applicable purchase date with respect to the ESPP Offering
Period would otherwise occur on or after the Offer Acceptance Time, then the ESPP Offering Period will be shortened and the applicable
purchase date with respect to such ESPP Offering Period will occur on the day that is no later than five business days prior to the date
on which the Offer Acceptance Time occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Prior to the Offer Acceptance Time, the Company shall take all actions that are necessary or advisable (under the Company Equity
Plans, the award agreements pursuant to which Company Options and Company RSUs are outstanding or otherwise and the Company ESPP) to effect
the transactions described in this Section 2.08 and terminate the Company Equity Plans and the Company ESPP as of immediately prior to
the Effective Time, in each case, without liability to the Company, Parent, the Surviving Corporation, or any of their respective Affiliates
or Subsidiaries, other than the obligation to make the payments described in this Section 2.08. Parent shall have a reasonable opportunity
to review and comment on all resolutions, notices and other documentation effectuating the provisions set forth in this Section 2.08 and
the Company shall incorporate all reasonable comments made by Parent to such resolutions, notices, and other documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.09.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Further Action</I></FONT>.
The Parties agree to take all necessary action to cause the Merger to become effective in accordance with this Article 2 as soon as practicable
following the consummation of the Offer without a meeting of the Company&rsquo;s stockholders, as provided in Section 251(h) of the DGCL.
If, at any time after the Effective Time, any further action is reasonably determined by Parent to be necessary or desirable to carry
out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and
property of Purchaser and the Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in
the name of Purchaser, in the name of the Company and otherwise) to take such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
3<BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby represents and warrants to Parent
and Purchaser as follows (it being understood that each representation and warranty contained in this Article 3 is subject to (a) exceptions
and disclosures set forth in the section or subsection of the Company Disclosure Letter corresponding to the particular Section or subsection
in this Article 3; (b) any exception or disclosure set forth in any other section or subsection of the Company Disclosure Letter to the
extent it is reasonably apparent on the face of such disclosure that such exception or disclosure is applicable to qualify such representation
and warranty; and (c) disclosure in the Company SEC Documents, and publicly available prior to the date of this Agreement (other than
any general cautionary or forward-looking statements contained in the &ldquo;Risk Factors&rdquo; or &ldquo;Forward-Looking Statements&rdquo;
sections of such Company SEC Documents); <I>provided</I>, <I>however</I>, that this clause (c) shall not be applicable to Section 3.03
and Section 3.04):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Due Organization</I></FONT>.
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and the Company&rsquo;s
only Subsidiaries are set forth in Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31,
2024. Each Subsidiary of the Company is duly organized, validly existing and in good standing (with respect to jurisdictions that recognize
such concept) under the laws of its jurisdiction of organization. Each Acquired Company has all necessary power and authority: (i) to
conduct its business in the manner in which its business is currently being conducted and (ii) to own and use its assets in the manner
in which its assets are currently owned and used, in each case, except as has not had, individually or in the aggregate, a Material Adverse
Effect. Each Acquired Company is qualified or licensed to do business as a foreign corporation or other entity, and is in good standing
(with respect to jurisdictions that recognize such concept), in each jurisdiction where the nature of its business requires such qualification
or licensing, except as has not had, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Organizational Documents</I></FONT>.
The Company has delivered or made available to Parent accurate and complete copies of the certificate of incorporation, bylaws, and other
organizational or governing documents of the Company and each of its Subsidiaries, including all amendments thereto, as in effect on the
date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Capitalization, Etc</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The authorized capital stock of the Company consists of: (i) 1,000,000,000 Shares, of which 58,464,222 had been issued and outstanding
as of the close of business on February 19, 2026 (the &ldquo;<B>Capitalization Date</B>&rdquo;) and (ii) 200,000,000 shares of Company
Preferred Stock, of which no shares were outstanding as of the Capitalization Date. From the Capitalization Date to the execution of this
Agreement, the Company has not issued any Shares except pursuant to the exercise of Company Options or the vesting or settlement of Company
RSUs, in each case outstanding as of the Capitalization Date in accordance with their terms as in effect on the Capitalization Date and,
from the Capitalization Date to the execution of this Agreement, the Company has not issued any warrants to acquire Shares or any Company
Options, Company RSUs or other equity or equity-based awards. All of the outstanding equity interests of the Acquired Companies have been
duly authorized and validly issued, and are fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company owns all of the authorized and outstanding capital stock and other equity interests of each of the Company&rsquo;s
Subsidiaries. The outstanding capital stock and other equity interests of the Company&rsquo;s Subsidiaries owned by the Company are owned
free and clear of all Encumbrances and transfer restrictions, except for Encumbrances or transfer restrictions of general applicability
as may be provided under the Securities Act or applicable securities laws. The Company does not own, directly or indirectly, any capital
stock or other equity interests in, or subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire,
or other securities convertible into or exchangeable or exercisable for, any capital stock or other equity interests of any other Entity.
All of the Shares are held either directly or indirectly through DTC or in direct registry form through the Company Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) None of the outstanding equity interests of any Acquired Company are entitled or subject to any preemptive right, right of
repurchase or forfeiture, right of participation, right of maintenance or any similar right; (ii) there are no outstanding bonds, debentures,
notes or other indebtedness of any Acquired Company having a right to vote on any matters on which the holders of the outstanding equity
interests of such Acquired Company have a right to vote; (iii) there is no Contract to which any Acquired Company is bound relating to
the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting
any option or similar right with respect to), any equity interests of such Acquired Company; and (iv) as of the date of this Agreement,
there are no outstanding subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to repurchase or redeem
any shares of the capital stock, restricted stock unit, performance stock unit, stock appreciation rights, incentive award measured based
on the Shares, stock-based performance unit or any other right that is linked to, or the value of which is in any way based on or derived
from the value of any shares of capital stock or other securities of any Acquired Company, in each case other than derivative securities
not issued by any Acquired Company. The Shares constitute the only outstanding securities of the Company registered under the Securities
Act. No Subsidiary of the Company owns any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the Capitalization Date: (i) 16,241,558 Shares were reserved and available for issuance pursuant to the Company Equity Plans,
of which amount (A) 6,730,586 Shares were subject to issuance pursuant to Company Options granted and outstanding under the Company Equity
Plans; (B) 4,124,047 Shares were subject to issuance pursuant to Company RSUs granted and outstanding under the Company Equity Plans (assuming,
with respect to Company RSUs that are subject to performance-based vesting conditions, that such conditions are satisfied at maximum levels);
(C) 3,809,812 Shares were subject to issuance pursuant to Company RSUs granted and outstanding under the Company Equity Plans (assuming,
with respect to Company RSUs that are subject to performance-based vesting conditions, that such conditions are satisfied at target levels);
(D) 15,260 Shares were subject to outstanding purchase rights under the Company ESPP (assuming a purchase price equal to the fair market
value of a Share on the first day of the ESPP Offering Period); and (E) 3,921,273 Shares were reserved for issuance under the Company
Equity Plans for awards not yet granted; and (ii) 1,465,652 Shares were reserved and available for issuance pursuant to outstanding purchase
rights under the Company ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as set forth in Section 3.03(a) and except for the Company Options, Company RSUs and purchase rights under the Company ESPP
outstanding as of the date of this Agreement (and Shares issuable upon the exercise or settlement thereof), as of the date of this Agreement,
there are no: (i) outstanding shares of capital stock or other securities of the Company; (ii) outstanding subscriptions, options, calls,
warrants or rights (whether or not currently exercisable) to acquire, any shares of the capital stock, restricted stock unit, performance
stock unit, stock appreciation rights, incentive award measured based on the Shares, stock-based performance unit or any other right that
is linked to, or the value of which is in any way based on or derived from the value of any shares of capital stock or other securities
of any Acquired Company, in each case other than derivative securities not issued by any Acquired Company; (iii) outstanding securities,
instruments, bonds, debentures, notes or obligations that are or may become convertible into or exchangeable for any shares of the capital
stock or other securities of any Acquired Company; (iv) stockholder rights plans (or similar plans commonly referred to as a &ldquo;poison
pill&rdquo;) or Contracts under which any Acquired Company is or may become obligated to sell or otherwise issue any shares of its capital
stock or any other securities; or (v) voting trusts or other Contract to which any Acquired Company is a party with respect to the voting
of capital stock of any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Section 3.03(f) of the Company Disclosure Letter sets forth a listing of all awards of the Company Options and Company RSUs that
are outstanding as of the close of business on the Capitalization Date, indicating, with respect to each such outstanding Company Option
and Company RSU, (i) the name of the holder, (ii) the type of award (e.g., nonqualified stock option, incentive stock option or Company
RSU), (iii) the Company Equity Plan under which the Company Option or Company RSU was granted, (iv) the grant date, (v) the number of
Shares subject thereto (at target and maximum performance, if applicable), (vi) the vesting schedule, (vii) with respect to each award
of Company Options, the per Share exercise price, and (viii) with respect to each award of Company Options, the expiration date. Other
than as set forth on such schedule, the equity based awards in the ungranted equity pool under the Company Equity Plans, or purchase rights
under the Company ESPP, as of the Capitalization Date, there are no issued, reserved for issuance, outstanding or authorized stock options,
restricted stock units, performance stock units, subscriptions, options, warrants, calls, rights, stock appreciation rights, incentive
awards measured based on the Shares, phantom stock, profit participation, or similar equity or equity based awards with respect to any
Acquired Company. Each Company Option and Company RSU was granted and has at all times been administered in compliance with all applicable
Legal Requirements and the terms and conditions of the Company Equity Plan and agreement under which it was granted. Each Company Option
has a per share exercise price equal to or greater than the fair market value of a Share on the date of grant as determined in accordance
with Section 409A and Section 422 of the Code, as applicable. Each Company Option that is intended to qualify as an &ldquo;incentive stock
option&rdquo; satisfies the requirements of Section 422 of the Code. Each Company Option and Company RSU is exempt from Section 409A of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Authority; Binding Nature
of Agreement</I></FONT>. The Company has the corporate power and authority to execute and deliver and to perform its obligations under
this Agreement and to consummate the Transactions. The Board of Directors has (a) determined that this Agreement, and the Transactions,
including the Offer and the Merger, are advisable and fair to, and in the best interest of, the Company and its stockholders, (b) declared
it advisable to enter into this Agreement, (c) approved the execution, delivery and performance by the Company of this Agreement and the
consummation of the Transactions, including the Offer and the Merger, (d) resolved that the Merger shall be effected under Section 251(h)
of the DGCL and (e) resolved to recommend that the stockholders of the Company accept the Offer and tender their Shares to Purchaser pursuant
to the Offer, which resolutions, subject to Section 6.01, have not been subsequently withdrawn or modified in a manner adverse to Parent
as of the date of this Agreement. This Agreement has been duly executed and delivered by the Company, and assuming due authorization,
execution and delivery by Parent and Purchaser, this Agreement constitutes the legal, valid and binding obligation of the Company and
is enforceable against the Company in accordance with its terms, except as such enforcement may be subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&rsquo;
rights, and by general equitable principles. If the Merger is consummated in accordance with Section 251(h) of the DGCL as contemplated
hereby, no vote of the Company&rsquo;s stockholders or any holder of Shares is necessary to authorize or adopt this Agreement or to consummate
the Transactions, assuming the accuracy of the representations set forth in Section 4.08.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>SEC Filings; Financial Statements</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, the Company has filed or furnished on a timely basis all reports, schedules, forms, statements and other
documents (including exhibits and all other information incorporated therein) required to be filed or furnished by the Company with the
SEC (as supplemented, modified or amended since the time of filing, the &ldquo;<B>Company SEC Documents</B>&rdquo;). As of their respective
filing dates, or, if amended prior to the date of this Agreement, as of the date of (and giving effect to) the last such amendment (and,
in the case of registration statements and proxy statements, on the date of effectiveness and the dates of the relevant meetings, respectively),
the Company SEC Documents complied in all material respects with the requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley
Act of 2001, as amended (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;), as the case may be, and the rules and regulations of the SEC promulgated
thereunder applicable to those Company SEC Documents, and, except to the extent that information contained in such Company SEC Document
has been revised, amended, modified or superseded (prior to the date of this Agreement) by a later filed Company SEC Document, none of
the Company SEC Documents when filed or furnished contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The financial statements (including any related notes and schedules) contained or incorporated by reference in the Company SEC
Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)
were prepared in accordance with United States generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;) applied on a consistent
basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited
interim financial statements, as may be permitted by the SEC on Form 10-Q, 8-K or any successor form under the Exchange Act); and (iii)
fairly presented, in all material respects, the financial position of the Acquired Companies as of the respective dates thereof and the
results of operations and cash flows of the Acquired Companies for the periods covered thereby (subject, in the case of the unaudited
financial statements, to the absence of notes and to normal and recurring year-end adjustments that are not, individually or in the aggregate,
material).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company maintains a system of &ldquo;internal control over financial reporting&rdquo; (as defined in Rule 13a-15 under the
Exchange Act), which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (i) pertain to
the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of
the Acquired Companies; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management
and the Board of Directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the assets of the Acquired Companies that could have a material effect on its financial statements. The Company&rsquo;s
management has completed an assessment of the effectiveness of the Company&rsquo;s system of internal control over financial reporting
in compliance with the requirements of Section 404 of the Sarbanes-Oxley Act for the fiscal year ended December 31, 2024, and, except
as set forth in the Company SEC Documents filed prior to the date of this Agreement, that assessment concluded that those controls were
effective. To the knowledge of the Company, since January 1, 2025, neither the Company nor the Company&rsquo;s independent registered
accountant has identified or been made aware of: (1) any significant deficiency or material weakness in the design or operation of the
internal control over financial reporting utilized by the Company, which is reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; or (2) any fraud, whether or not material, that involves the management
or other employees of the Company who have a significant role in the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company maintains disclosure controls and procedures as defined in and required by Rule 13a-15 or 15d-15 under the Exchange
Act that are reasonably designed to ensure that all information required to be disclosed in the Company&rsquo;s reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms
of the SEC and that all such information is accumulated and communicated to the Company&rsquo;s management as appropriate to allow timely
decisions regarding required disclosure and to enable the principal executive officer of the Company and the principal financial officer
of the Company to make the certifications required under the Exchange Act with respect to such reports. The Company is in compliance in
all material respects with all current listing and corporate governance requirements of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company is a party to, nor does it have any obligation or other commitment to become a party to, &ldquo;off-balance
sheet arrangements&rdquo; (as defined in Item 303(a) of Regulation S-K under the Exchange Act) where the result, purpose or intended effect
of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Acquired Companies in the
Company SEC Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with
respect to the Company SEC Documents. To the knowledge of the Company, none of the Company SEC Documents is the subject of ongoing SEC
review and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened in writing, in each
case regarding any accounting practices of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each document required to be filed by the Company with the SEC in connection with the Offer, including the Schedule 14D-9 (the
&ldquo;<B>Company Disclosure Documents</B>&rdquo;), and any amendments or supplements thereto, when filed, distributed or otherwise disseminated
to the Company&rsquo;s stockholders, as applicable, will comply as to form in all material respects with the applicable requirements of
the Exchange Act. The Company Disclosure Documents, at the time of the filing of such Company Disclosure Documents or any supplement or
amendment thereto with the SEC and at the time such Company Disclosure Documents or any supplements or amendments thereto are first distributed
or otherwise disseminated to the Company&rsquo;s stockholders, will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The information with respect to the Acquired Companies that the Company furnishes to Parent or Purchaser specifically for use in
the Offer Documents, at the time of the filing of, at any time such document is amended or supplemented and at the time of any distribution
or dissemination of the Offer Documents, will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made,
not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding the foregoing, the Company makes no representation with respect to statements made or incorporated by reference
therein based on information supplied by or on behalf of Parent, Purchaser and their respective Representatives specifically for inclusion
or incorporation by reference in the Company Disclosure Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Absence of Changes; No Material
Adverse Effect</I></FONT>. Except as expressly contemplated by this Agreement, from January 1, 2025, through the date of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) except for the execution and performance of this Agreement, and the discussions, negotiations and transactions related hereto,
each Acquired Company has operated in all material respects in the ordinary course of business consistent with past practice, and (ii)
no Acquired Company has taken any action or failed to take any action that would have constituted a breach of (A) Sections 5.02(b)(i),
5.02(b)(ii), 5.02(b)(iv), 5.02(b)(v), 5.02(b)(vi), 5.02(b)(vii), 5.02(b)(viii), 5.02(b)(ix), 5.02(b)(x), 5.02(b)(xii), 5.02(b)(xiv), 5.02(b)(xv),
5.02(b)(xvi), 5.02(b)(xvii), 5.02(b)(xviii), 5.02(b)(xix), 5.02(b)(xx) or 5.02(b)(xxii) or (B) Section 5.02(b)(xxiii), solely with respect
to the foregoing clause (A), in each case, had such action been taken after the execution of this Agreement without the prior consent
of Parent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there has not occurred any Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Title to Assets</I></FONT><I>.
</I>The Acquired Companies have good and valid title to all assets (excluding Intellectual Property Rights and Personal Data) owned by
the Acquired Companies as of the date of this Agreement, and all of such assets are owned by the Acquired Companies free and clear of
any Encumbrances (other than Permitted Encumbrances), in each case, except as has not had, individually or in the aggregate, a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.08.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Real Property</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company owns any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each Acquired Company holds valid and existing leasehold interests in the Leased Real Property that is leased or subleased by such
Acquired Company from another Person, free and clear of all Encumbrances other than Permitted Encumbrances, in each case, except as has
not had, individually or in the aggregate, a Material Adverse Effect. Since January 1, 2024, no Acquired Company has received any notice
regarding (i) any material violation or breach or default under any Real Property Lease that has not since been cured, (ii) any pending
or threatened in writing condemnation of any portion of the Leased Real Property or (iii) building, fire or zoning code violations with
respect to the Leased Real Property, in each case in clauses (i) through (iii), that is material to the Acquired Companies, taken as a
whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.09.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Intellectual Property</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Section 3.09(a) of the Company Disclosure Letter sets forth a list of all Owned Registered IP and Licensed Registered IP (including
issued Patents and Patent applications, Trademark registrations and applications, and Copyright registrations and applications). All Registered
IP material to any of the businesses of any of the Acquired Companies is, to the knowledge of the Company, (i) subsisting, (ii) other
than any pending applications therefor, not invalid or unenforceable, and (iii) not subject to any outstanding order, judgment or decree
adversely affecting any Acquired Company&rsquo;s use thereof or rights thereto. The Acquired Companies are the sole and exclusive beneficial
owners (and in the case of Registered IP, record owners) of all Company IP material to any of the businesses of any of the Acquired Companies.
The Acquired Companies have complied with all Legal Requirements regarding the duty of disclosure, candor and good faith in connection
with each Patent that is owned by, or purported to be owned by, or prosecuted by, or purported to be prosecuted by any of the Acquired
Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No interference, opposition, reissue, reexamination proceeding, cancellation proceeding, investigation or other Legal Proceeding
(other than routine examination proceedings with respect to pending applications) is or has been pending, or threatened in writing against,
any Acquired Company in which the claim construction, validity, enforceability, priority, inventorship or ownership of any Owned Registered
IP or, to the knowledge of the Company, Licensed Registered IP is being or has been contested or challenged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Acquired Companies (i) own and possess all rights, title and interest in and to all Company IP and (ii) have the valid right
to use (A) the Company IP and (B) pursuant to a valid and enforceable written agreement, the Company Licensed IP, in each case (i) and
(ii), in the operation of the business of the Acquired Companies as currently conducted, free and clear of all Encumbrances other than
Permitted Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Acquired Companies have used commercially reasonable efforts to maintain the confidentiality of (i) Trade Secrets owned, purported
to be owned, or materially used by any Acquired Company and (ii) other confidential information, in each case (i) and (ii), material to
the business of any Acquired Company, including requiring all Persons to whom such Trade Secrets or confidential information have been
disclosed by any Acquired Company to be bound by written obligations of confidentiality, except with respect to disclosures of Trade Secrets
or information made in the ordinary course of business consistent with past practice, including in connection with an industry publication
or presentation approved by an Acquired Company or as embodied in a new patent application filed by an Acquired Company. Except as has
not been, and would not reasonably be expected to be, material to the operation of the business of any Acquired Company, to the knowledge
of the Company, no Trade Secret or information that is the subject of this Section 3.09(d) has been disclosed improperly by any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) To the knowledge of the Company, the operation of the Acquired Companies&rsquo; respective businesses as conducted since January
1, 2020, does not (and will not upon the commercialization of any Product Candidates, as such Product Candidates currently exist) infringe,
misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned
by any other Person, and (ii) since January 1, 2020 through the date of this Agreement, there has been no Legal Proceeding pending or
threatened in any written notice or other written communication directed to any Acquired Company relating to any allegations of the foregoing
against any Acquired Company, which includes any such allegations (including in the form of an invitation to enter into a license) against
any Acquired Company and to the knowledge of the Company, no facts or circumstances exist that would reasonably be expected to provide
the basis for any such allegations as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2020 through the date of this Agreement, to the knowledge of the Company, (i) no Person is infringing, misappropriating
or otherwise violating, or has infringed, misappropriated or otherwise violated, any Company IP or Company Licensed IP and (ii) there
has been no Legal Proceeding pending or threatened in writing relating to any allegations of the foregoing made by any Acquired Company,
any of their respective licensors, or, to the knowledge of the Company, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>None of the Company IP, or to the knowledge of the Company, Company Licensed IP is subject to any outstanding injunction, order,
decree, charge, consent, judgment, covenant not to sue, settlement, ruling or other disposition of dispute, in each case, that restricts
the use, transfer, registration or licensing of any Company IP or Company Licensed IP by any Acquired Company, or otherwise adversely
affects the ownership, validity, scope, use, registrability, or enforceability of any such Company IP or Company Licensed IP. None of
the Acquired Companies or, to the knowledge of the Company, any of their respective licensors have received any written notice that any
Company Licensed IP is subject to any outstanding injunction, order, decree, charge, consent, judgment, settlement, ruling or other disposition
of dispute, in each case, that adversely restricts the use, transfer, registration or licensing of any such Company Licensed IP by any
Acquired Company or otherwise adversely affects the ownership, validity, scope, use, registrability or enforceability of any such Company
Licensed IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each individual who is or was involved in the creation or development of any material Company IP is or was, at the time of creation
or development, subject to a valid and enforceable agreement containing a present assignment of such Intellectual Property Rights to the
applicable Acquired Company and is subject to valid and enforceable confidentiality provisions protecting such Intellectual Property Rights,
and, to the knowledge of the Company, no individual who is or was involved in the creation or development of any material Company Licensed
IP has failed to sign such an agreement. To the knowledge of the Company, there is no material breach under any such agreement. To the
knowledge of the Company, no individual retains any material right or interest in any such Intellectual Property Right, including any
entitlement to compensation due pursuant to any Legal Requirement in relation to such Intellectual Property Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No material Company IP or, to the knowledge of the Company, material Company Licensed IP was developed with any funding, facilities,
personnel, or other material support or resources from any Governmental Body, any foundation, nonprofit, charity, non-governmental organization,
or any public or private university, college, or other educational institution or research center, in a manner that would give any such
entities an ownership interest in any such material Company IP or material Company Licensed IP. No Acquired Companies or, to the knowledge
of the Company, any of their respective licensors has failed to comply in any material respect with any invention disclosure, election
of title or patent reporting requirements with respect to any material Company IP or material Company Licensed IP developed with funding,
facilities, personnel or other material support or resources from any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as has not had, individually or in the aggregate, a Material Adverse Effect, (i) the Company IT Assets operate in accordance
with their specifications and related documentation and perform in a manner that permits the Acquired Companies to conduct their respective
business as currently conducted, (ii) the Acquired Companies have taken commercially reasonable actions, consistent with current industry
standards and Privacy Requirements, sufficient to protect the confidentiality, integrity and security of the Company IT Assets (and all
data and other information and transactions stored or contained therein or processed or transmitted thereby) and Sensitive Data against
any unauthorized use, access, interruption, modification or corruption, including (x) the implementation of commercially reasonable data
backup, disaster avoidance and recovery procedures and business continuity procedures and (y) the implementation and maintenance of a
written information security program comprising administrative, technical, and physical safeguards, and (iii) since January 1, 2020, there
has been no actual, reasonably suspected, or alleged Security Breach or unauthorized use, access, interruption, modification, loss or
corruption of any of the Company IT Assets (or any data stored or contained therein or processed or transmitted thereby).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The consummation of the Transactions will not result in (i) the loss or impairment of, (ii) except for payments to patent offices
to record the Transactions in the ordinary course of business consistent with past practice, payment of any additional amounts with respect
to, or (iii) require the consent of any other Person in respect of, in each case of clauses (i)-(iii), any Acquired Company&rsquo;s right
to own or use any of the material Company IP or material Intellectual Property Rights licensed to any Acquired Company, in each case,
in the same manner as owned or used immediately preceding the consummation of the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Data Privacy</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></FONT>The Acquired Companies are, and have been, at all times since January 1, 2024 in compliance in all material respects with
all Privacy Requirements. The Acquired Companies have implemented controls, including policies and procedures, reasonably designed to
ensure compliance with the Privacy Requirements and have adopted and published privacy notices and policies that accurately describe their
privacy practices in all material respects. The execution, delivery, performance and consummation by the Acquired Companies of the Transactions
contemplated hereby (including the Processing of Personal Data by the Acquired Companies in connection therewith) will not violate in
any material respect any applicable Privacy Requirements. The Acquired Companies have not provided any Person or any Covered Person access
to or the ability to access Sensitive Personal Information in material violation of the DOJ Final Rule, the PADFAA, or the NIH Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></FONT>Since January 1, 2024, all Personal Data collected from all Acquired Companies&rsquo; websites, digital properties, and
otherwise by the Acquired Companies has been collected, maintained, used or otherwise Processed by the Acquired Companies in material
compliance with obligations under the Privacy Requirements, except in each case with respect to the foregoing, as would not, individually
or in the aggregate, have a Material Adverse Effect. The Acquired Companies do not use or deploy third-party cookies, pixels or other
online tracking technologies to collect Personal Data from, or target for, recruitment or advertising purposes actual or potential customers
or trial participants except in compliance in all material respects with applicable Privacy Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, the Acquired Companies have not given, and have not been obligated by applicable Legal Requirement, Governmental
Body, or other Privacy Requirement to give, notice to any Person of any such Security Breach. Since January 1, 2024, the Acquired Companies
have not received any notice of any material Legal Proceedings, claims, investigations (including investigations by a Governmental Body),
or alleged violations of Privacy Requirements with respect to Personal Data Processed by the Acquired Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Contracts</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Section 3.11(a) of the Company Disclosure Letter identifies each Contract to which any Acquired Company is a party, or by which
it is bound, that constitutes a Material Contract as of the date of this Agreement and identifies each such Material Contract under the
applicable clause of Section 3.11(a) to which it applies. For purposes of this Agreement, each of the following to which any Acquired
Company is a party or by which it is bound as of the date of this Agreement (other than nondisclosure agreements entered into (x) in the
ordinary course of business consistent with past practice or (y) in connection with discussions, negotiations and transactions related
to this Agreement or other potential strategic transactions) constitutes a &ldquo;<B>Material Contract</B>&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract that is a settlement, conciliation or similar agreement with or approved by any Governmental Body and pursuant to
which (A) any Acquired Company will be required after the date of this Agreement to pay any monetary obligations or (B) that contains
material obligations or limitations on any Acquired Company&rsquo;s conduct;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract (A) limiting the freedom or right of any Acquired Company to engage in any line of business or to compete with any
other Person in any location or line of business, (B) containing any &ldquo;most favored nations&rdquo; terms and conditions (including
with respect to pricing) granted by any Acquired Company, or (C) containing exclusivity obligations or otherwise materially limiting the
freedom or right of any Acquired Company to sell, distribute or manufacture any products or services for any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract that requires by its terms, or is reasonably expected to require, the payment or delivery of cash or other consideration
to or by any Acquired Company in an aggregate amount having a value in excess of $5,000,000 in the fiscal year ended December 31, 2025
or ending December 31, 2026, and in each case (A) that could not or, if still in effect, cannot be cancelled by such Acquired Company
without penalty or further payment without more than sixty (60) days&rsquo; notice and (B) excluding commercially available off-the-shelf
software licenses and Software-as-a-Service offerings, material transfer agreements and non-exclusive outbound license agreements (in
each case, entered into in the ordinary course of business consistent with past practice);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any distribution, wholesale, third-party logistics, pharmacy benefit manager or payer Contract, in each case that requires by its
terms, or is reasonably expected to require, the payment or delivery of cash to or by any Acquired Company in an aggregate amount having
a value in excess of $5,000,000 in the fiscal year ended December 31, 2025 or ending December 31, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract relating to Indebtedness in excess of $500,000 (whether incurred, assumed, guaranteed or secured by any asset) of
any Acquired Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract with any Person constituting, or relating to the formation, creation, operation, management or control of, a joint
venture, collaboration, partnership, limited liability company, strategic alliance, joint development, joint commercialization, research
or development project, or similar arrangement, in each case that is material to the business of an Acquired Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any supply Contract or Contract with a contract manufacturing organization, contract manufacturing and development organization
or a contract research organization that requires by its terms, or is reasonably expected to require, the payment or delivery of cash
by any Acquired Company in an aggregate amount having a value in excess of $2,000,000 in the fiscal year ended December 31, 2025 or ending
December 31, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract with a health care professional involving the issuance or transfer to such health care professional of any equity,
investment, ownership, or similar interest in any Acquired Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract that by its express terms requires any Acquired Company, or any successor to, or acquirer of, any Acquired Company,
to make any payment to another Person as a result of a change of control of any Acquired Company (a &ldquo;<B>Change of Control Payment</B>&rdquo;)
or gives another Person a right to receive or elect to receive a Change of Control Payment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any collective bargaining agreement or any other labor-related Contract, agreement, understanding, or arrangement with any labor
union, other labor organization or employee representative body representing any of the Company&rsquo;s employees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract that prohibits the declaration or payment of dividends or distributions in respect of the capital stock of any Acquired
Company, the pledging of the capital stock or other equity interest of any Acquired Company or the issuance of any guaranty by any Acquired
Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any material (A) In-bound License and (B) Out-bound License (provided, that any exclusive Out-bound License shall be deemed material);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract pursuant to which any Acquired Company has continuing obligations or interests involving (A) &ldquo;milestone&rdquo;
or other similar contingent payments, including upon the achievement of research, development, regulatory or commercial milestones or
(B) payment of royalties or other amounts calculated based upon any revenues or income of any Acquired Company, in each case of clauses
(A) and (B) that cannot be terminated by such Acquired Company without penalty without more than sixty (60) days&rsquo; notice and requires
by its terms, or is reasonably expected to require, the payment or delivery of cash by any Acquired Company in an aggregate amount having
a value in excess of $5,000,000 in the fiscal year ended December 31, 2025 or ending December 31, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each Contract for the acquisition or divestiture of a business or of material assets that contains continuing representations,
covenants, indemnities or other obligations (including &ldquo;earn out&rdquo; or other contingent payment obligations), but excluding
any material transfer agreements, agreements for acquisition of supplies or equipment, clinical trial agreements and non-exclusive license
agreements, in each case, that were entered into in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract that relates to any swap, forward, futures or other similar derivative transaction with a notional value in excess
of $150,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract that contains a put, call, right of first refusal, right of first negotiation or similar right pursuant to which any
Acquired Company could be required to purchase or sell, or offer for purchase or sale, or exclusively license, as applicable, any (A)
equity interests of any Person or (B) material assets (excluding ordinary course commitments to purchase goods, products and off-the-shelf
software) or businesses, in each case (A) and (B) for an amount in excess of $1,000,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract with a sole source supplier material to the conduct of the business of an Acquired Company as currently conducted
and in which a reasonable alternative supplier is not available;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract, the primary purpose of which is to provide for indemnification or guarantee of the obligations of any other Person
that would be material to an Acquired Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract between any Acquired Company and any Governmental Body, academic institution or research center;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Real Property Lease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any other Contract that is currently in effect and has been filed (or is required to be filed) by the Company as an exhibit pursuant
to Item 601(b)(10) of Regulation S-K under the Securities Act or that would be required to be disclosed under Item 404 of Regulation S-K
under the Securities Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any Contract (A) with any Affiliate, director, executive officer (as such term is defined in the Exchange Act), Person holding
5% or more of the Shares, or, to the knowledge of the Company, any Affiliate (other than the Company) or immediate family member of any
of the foregoing or (B) in which any of the foregoing Persons has a direct or indirect material financial interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has made available to Parent an accurate and complete copy of each Material Contract or has publicly filed each Material
Contract (without redactions or omissions) in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC. No Acquired
Company nor, to the knowledge of the Company, any other party is in material breach of, or material default under, any Material Contract
and no Acquired Company nor to the knowledge of the Company, any other party to a Material Contract has taken or failed to take any action
that with or without notice, lapse of time or both would constitute a material breach of or material default under any Material Contract.
Each Material Contract is, with respect to the Acquired Companies party thereto and, to the knowledge of the Company, each other party
thereto, a valid and binding agreement in full force and effect, enforceable in accordance with its terms, except as such enforcement
may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability
relating to or affecting creditors&rsquo; rights, and by general equitable principles. Since January 1, 2024 through the date of this
Agreement, no Acquired Company has received or delivered any written notice or, to the knowledge of the Company, oral notice, regarding
any violation or breach or default under any Material Contract that has not since been cured. None of the Acquired Companies has waived
in writing any rights under any Material Contract, the waiver of which would reasonably be expected to be material to the Acquired Companies,
taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Liabilities</I></FONT>.
The Acquired Companies do not have any liabilities or obligations of any nature (whether accrued, absolute, contingent or otherwise),
which would be required to be reflected or reserved against on a consolidated balance sheet of the Company prepared in accordance with
GAAP or the notes thereto, except for: (a) liabilities reflected or reserved against in the financial statements or notes thereto included
in the Company SEC Documents filed prior to the date of this Agreement; (b) liabilities or obligations incurred pursuant to the terms
of this Agreement; (c) liabilities for performance of obligations under Contracts binding upon the Acquired Companies (other than resulting
from any breach or acceleration thereof); (d) liabilities incurred in the ordinary course of business consistent with past practice since
January 1, 2025 (it being understood that breaches of Legal Requirements shall not be deemed to be liabilities incurred in the ordinary
course of business consistent with past practice); and (e) liabilities that are not, and would not reasonably be expected to be, material
to the Acquired Companies, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Compliance with Legal Requirements</I></FONT>.
Each Acquired Company is, and since January 1, 2024, has been, in compliance in all material respects with all applicable Legal Requirements.
Since January 1, 2024, through the date of this Agreement, no Acquired Company has been given written notice of, or, to the knowledge
of the Company or to the knowledge of any other Acquired Company, been charged with, any violation of, any applicable Legal Requirement,
except as would not be material to the Acquired Companies, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Regulatory Matters</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, except as would not be material to the Acquired Companies, taken as a whole, each Acquired Company has filed,
maintained or furnished with the applicable regulatory authorities (including the FDA, European Medicines Agency (&ldquo;<B>EMA</B>&rdquo;)
or any other Governmental Body performing functions similar to those performed by the FDA, EMA or otherwise having jurisdiction over the
pricing, reimbursement, safety, efficacy, approval, development, testing, labeling, manufacture, storage, distribution or commercialization,
of pharmaceutical or biological products (such other Governmental Bodies, collectively, the &ldquo;<B>Specified Governmental Bodies</B>&rdquo;))
all required filings, declarations, listings, registrations, reports, submissions, applications, supplements, amendments, modifications,
notices and other documents, including but not limited to adverse event reports. All such filings, declarations, listings, registrations,
reports, submissions, applications, supplements, amendments, modifications, notices and other documents filed or submitted after January
1, 2024 (i) have been made available to Parent, and (ii) except as would not be material to the Acquired Companies, taken as a whole,
were in compliance with applicable Legal Requirements, including all applicable Health Care Laws, in all respects when filed, maintained
or furnished, and no material deficiencies have been asserted by any applicable Governmental Body with respect to any such filings, declarations,
listing, registrations, reports, submissions, applications, supplements, amendments, modifications, notices and other documents. Since
January 1, 2024, any updates, changes, corrections or modifications to such materials required under applicable Legal Requirements, including
all applicable Health Care Laws, have been submitted to FDA, EMA and other Specified Governmental Bodies in compliance with such Legal
Requirements in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as would not be material to the Acquired Companies, taken as a whole, all nonclinical studies and clinical trials sponsored
or conducted by or on behalf of any Acquired Company or, to the knowledge of the Company, by any Acquired Company&rsquo;s research, development,
collaboration or similar partners with respect to any Product Candidates of any Acquired Company while acting in such capacity (each such
party, other than Parent or any Affiliate of Parent, a &ldquo;<B>Collaboration Partner</B>&rdquo;), have been since January 1, 2024, and
are being, conducted in compliance with all applicable Legal Requirements, rules, regulations and binding guidances, including Good Laboratory
Practices, Good Manufacturing Practices, and Good Clinical Practices requirements, other Health Care Laws, applicable research protocols
and federal, ex-U.S. and state laws, rules, regulations and binding guidances, including those related to human subject protection. Since
January 1, 2024, no clinical trial sponsored or conducted by or on behalf of any Acquired Company has been terminated, delayed or suspended
prior to completion for safety or other non-business reasons, and neither the FDA, the EMA nor any other Specified Governmental Body,
clinical investigator or contract research organization that has participated or is participating in, data safety monitoring board, institutional
review board or similar entity that has or has had jurisdiction over, a clinical trial conducted or sponsored by or on behalf of any Acquired
Company has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a partial or full clinical hold
order on, or otherwise terminate, materially delay or suspend, any proposed or ongoing clinical trial conducted or proposed to be conducted
by or on behalf of any Acquired Company, or alleged any material violation of any Health Care Law in connection with any such clinical
trial. The Acquired Companies or an agent on their behalf periodically reviews clinical trial sites participating in any Acquired Company-sponsored
trial for compliance with all applicable Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, no Acquired Company nor, to the knowledge of the Company, any Company Associate, employee, agent, or clinical
investigator has (i) made an untrue statement of a material fact or fraudulent statement to the FDA, EMA or any other Specified Governmental
Body, (ii) failed to disclose a material fact required to be disclosed to the FDA, EMA, Centers for Medicare and Medicaid Services or
any other Specified Governmental Body or (iii) committed any other act, made any statement or failed to make any statement, that (in any
such case) establishes a reasonable basis for the FDA to invoke its policy respecting &ldquo;Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities&rdquo; as set forth in 56 Fed. Reg. 43191 (September 10, 1991) or for the EMA or any other Specified Governmental
Body to invoke any similar policy. No Acquired Company is the subject of any pending or, to the knowledge of the Company, threatened in
writing investigation or other action by the FDA pursuant to its &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
Gratuities&rdquo; Policy or by the EMA or any other Governmental Body in any similar investigation or other action. No Acquired Company
nor any Company Associate or clinical investigator of any Product Candidates or, to the knowledge of the Company, any Collaboration Partner
(1) has been suspended, debarred, excluded or convicted of any crime or engaged in any conduct that would reasonably be expected to result
in (A) debarment under 21 U.S.C. Section 335a or any similar Legal Requirement, (B) exclusion under any federal or individual state program
including but not limited to Federal Health Care Programs (as defined in 42 U.S.C. Section 1320a-7(b)(f)) or any similar Legal Requirement,
or (C) disqualification from serving as an investigator under 21 C.F.R. Parts 312 or 812, (2) are currently subject to or, to the knowledge
of the Company, have been threatened with, an investigation or proceeding that could reasonably be expected to result in such debarment,
exclusion or suspension, (3) have been assessed, or threatened in writing, with assessment of civil monetary penalties pursuant to 42
C.F.R. Part 1003, (4) are, or have been listed on the list of parties excluded from federal procurement programs and non-procurement programs
as maintained in the Government Services Administration&rsquo;s System for Award Management or other federal agencies, or (5) charged
with, convicted of, or entered a plea of guilty or nolo contendere to a crime or any criminal or civil offense relating to the delivery
of any item or service under any U.S. federal or state health care programs, including Federal Health Care Programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each Acquired Company is, and since January 1, 2024, has been, in compliance in all material respects with all applicable Health
Care Laws. The Product Candidates are being, and since January 1, 2024, have been, developed, processed, tested, labeled, manufactured,
imported, exported, stored, and distributed, as applicable, in all material respects with all Health Care Laws, including Good Manufacturing
Practices and Good Tissue Practices. Since January 1, 2024, (i) no Acquired Company is or has been subject to any enforcement, regulatory,
administrative or other Legal Proceedings against or affecting any Acquired Company or any Product Candidate relating to or arising under
any Health Care Law or other applicable Legal Requirement, or contractual requirement, and no such enforcement, regulatory, administrative
or other Legal Proceeding has been threatened in writing, (ii) no Acquired Company has received written notice of any pending or threatened
claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other Legal Proceeding against or affecting any Acquired
Company or any Product Candidate relating to or arising under any Health Care Law, and to the knowledge of the Company, there is not pending
any allegation that any operation or activity of any Acquired Company relating to any Acquired Company&rsquo;s business or any Product
Candidate is in violation of any Health Care Law, (iii) as of the date of this Agreement, no Acquired Company, nor, to the knowledge of
the Company, any of the Company&rsquo;s vendors, has received any Form FDA-483 or other Specified Governmental Body notices of violations,
inspectional observations, warning letters, untitled letters or other similar written administrative, regulatory or enforcement notice,
and (iv) no Acquired Company is subject to a deferred prosecution agreement, non-prosecution agreement, corporate integrity agreement,
consent decree, monitoring agreement, settlement agreement or other similar agreement mandating or prohibiting future or past activities.
No Person has filed against an Acquired Company an action relating to the Acquired Company under any federal or state whistleblower statute,
including under the False Claims Act of 1863 (31 U.S.C. &sect; 3729 et seq.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, (i) no investigational new drug application, new drug application, or similar document filed by or on behalf
of any Acquired Company with the FDA, EMA or any other Specified Governmental Body has, to the knowledge of the Company, been withdrawn,
terminated or suspended, and (ii) no Acquired Company nor, to the knowledge of the Company, any Collaboration Partner, has received any
written notice from a Governmental Body that any Product Candidate cannot be researched, developed, tested, labeled, manufactured, imported,
exported, stored, or distributed substantially in the manner presently performed or contemplated by any Acquired Company or any Collaboration
Partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, each Acquired Company and, to the knowledge of the Company, its Collaboration Partners have prepared, submitted
and implemented timely responses and, as applicable, any corrective action plans required to be prepared and submitted in response to
all (i) internal or third-party audits, inspections, investigations or examinations related to the Product Candidates and each Acquired
Company&rsquo;s business; (ii) adverse event reports relating to the Product Candidates; (iii) Form FDA-483s, warning letters, untitled
letters or other similar documents outlining actual or potential deficiencies or violations of law; (iv) material patient complaints relating
to the Product Candidates; (v) medical incident reports relating to the Product Candidates; and (vi) material corrective and preventive
actions relating to the Product Candidates and each Acquired Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>There have been no allegations or investigations into research misconduct or data integrity misconduct (i.e., falsification or
fabrication of data or plagiarism) with respect to any nonclinical studies or clinical trials sponsored or conducted by or on behalf of
any Acquired Company or, to the knowledge of the Company, by any Collaboration Partner with respect to any Product Candidates of any Acquired
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, no Acquired Company has either voluntarily or involuntarily initiated, conducted, or issued, any recall,
safety alert, report, warning, &ldquo;dear doctor&rdquo; letter, investigator notice, or other notice or action, in each case relating
to an alleged lack of safety, efficacy, or regulatory compliance of any Product Candidate, and as of the date here of, neither the FDA,
EMA, or any other Specified Governmental Body has ordered, commenced, or threatened to initiate any action to cause the same, and to the
Company&rsquo;s knowledge, there are no circumstances that would be reasonably likely to result in any such notice or action or any termination
or suspension of distribution or development of any Product Candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Acquired Companies have implemented and maintain a compliance program that addresses compliance with Health Care Laws that
conforms in all material respects to industry standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The compensation that the Acquired Companies pay, and have paid to licensed health care professionals complies with all applicable
Health Care Laws in all material respects and, (i) is for bona fide purposes, (ii) is for commercially reasonable services required by
the Acquired Company for its respective business or operations, and (iii) contemplates compensation consistent with fair market value
for such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company (i) is, or has been, a &ldquo;Covered Entity&rdquo; or a &ldquo;Business Associate,&rdquo; as those terms are
defined by HIPAA, and (ii) has entered into a &ldquo;Business Associate Agreement&rdquo; with any &ldquo;Covered Entity,&rdquo; as such
terms are defined by HIPAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Certain Business Practices</I></FONT>.
No Acquired Company nor, to the knowledge of the Company, any of its Representatives (in each case, acting in the capacity of a Representative,
and for the benefit, of the Acquired Companies) has (a) used any funds (whether of the Acquired Companies or otherwise) for contributions,
gifts, entertainment or other expenses relating to political activity in violation of applicable Legal Requirements, (b) made any payment
to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns in violation of applicable
Legal Requirements or (c) violated any provision of any Anti-Corruption Laws or any rules or regulations promulgated thereunder, anti-money
laundering laws, export control laws, or sanctions or any rules or regulations promulgated thereunder or any other applicable Legal Requirement
of similar effect, in each case of (a), (b) and (c), except as has not had, and would not have, individually or in the aggregate, a Material
Adverse Effect. Since January 1, 2023 through the date of this Agreement, no Acquired Company has received any written communication from
a Governmental Body that alleges any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Governmental Authorizations</I></FONT>.
The Acquired Companies hold all material Governmental Authorizations, including those required under Health Care Laws, necessary for the
Acquired Companies to conduct their respective businesses as presently conducted. The Governmental Authorizations held by the Acquired
Companies are valid and in full force and effect, and each Acquired Company is in material compliance with the terms and requirements
of such Governmental Authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Tax Matters</I></FONT>.
Except as would not be material to the Acquired Companies, individually or in the aggregate,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All Tax Returns required to be filed by each Acquired Company with any Governmental Body (the &ldquo;<B>Company Returns</B>&rdquo;)
have been filed, and such Tax Returns (taking into account any amendments thereto) are complete and accurate in all respects. All Taxes
required to have been paid by each Acquired Company (whether or not shown on the Company Returns) have been paid to the relevant Governmental
Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each Acquired Company has complied with all applicable Legal Requirements relating to the payment, collection, withholding and
remittance of Taxes (including information reporting requirements) with respect to payments made to any employee, creditor, stockholder,
customer or other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) There is no audit, examination or Legal Proceeding that is ongoing, pending or has been threatened in writing against or
with respect to any Acquired Company in respect of any Taxes or with regard to any Company Return and (ii) no written claim has been
received by any Acquired Company from any Governmental Body in any jurisdiction where such Acquired Company does not file Tax Returns
or pay Taxes that such Acquired Company is or may be required to file a Tax Return or be subject to Tax in that jurisdiction. No tolling,
extension or waiver of the statute of limitation period applicable to any of the Company Returns has been granted and is currently in
effect (other than pursuant to customary extensions of the due date for filing a Tax Return).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No deficiency of any amount of Taxes has been asserted in writing as a result of any audit, examination or Legal Proceeding by
any Governmental Body that has not been paid, accrued for or been contested in good faith and in accordance with applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company (i) has ever been a member of an affiliated group (within the meaning of Section 1504(a) of the Code) filing
a consolidated federal income Tax Return (other than a group the common parent of which is or was the Company) or (ii) has liability for
the Taxes of any other Person under Section 1.1502-6 of the Treasury Regulations (or any corresponding or similar provision of any state,
local or non-U.S. Tax law), or as a transferee or successor or otherwise by operation of Legal Requirements (other than pursuant to agreements
not primarily related to Taxes and entered into in the ordinary course of business consistent with past practice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>During the two (2)-year period ending on the date hereof, none of the Acquired Companies has been either a &ldquo;distributing
corporation&rdquo; or a &ldquo;controlled corporation&rdquo; in a distribution of stock intended to qualify for tax-free treatment under
Section 355 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company has participated in any &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulations Section
1.6011-4(b)(2) in any tax year for which the statute of limitations has not expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company is a party to, bound by, or has any obligation under any Tax sharing, Tax allocation or Tax indemnity agreement
or similar Contract or arrangement relating to the apportionment, sharing, assignment, indemnification or allocation of any Tax or Tax
asset (other than customary gross-up or indemnification provisions in credit agreements, derivatives, leases, employment agreements and
similar agreements entered into in the ordinary course of business consistent with past practice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>There are no Encumbrances with respect to Taxes upon any of the assets or properties of any Acquired Company, other than Permitted
Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Employee Matters; Benefit
Plans</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has provided to Parent a census (the &ldquo;<B>Census</B>&rdquo;) that contains a true, correct, and complete list,
as of a recent practicable date, of, for (i) each employee of an Acquired Company (including any individual who has been hired by an Acquired
Company but has not yet begun active service), the name or unique employee identification number, current annual base salary or current
hourly wages, as applicable, last annual bonus received, current target annual bonus opportunity, title, hire date, whether full-time
or part-time, and status as being exempt or non-exempt from the application of state and federal wage and hour laws. Within ten (10) days
following the date of this Agreement, the Company shall furnish or otherwise make available to Parent a schedule (i) with respect to each
employee of an Acquired Company, employee visa type (including date of expiration), if any, and status if on leave and (ii) each independent
contractor or other individual non-employee service provider engaged by any Acquired Company, together with the name or unique identifier,
general description of duties, and rate of compensation for each such contractor or service provider. Except as required by applicable
Legal Requirements or as would not be material to the Acquired Companies, taken as a whole, the employment of each of the Acquired Companies&rsquo;
employees is terminable by the applicable Acquired Company at-will, subject to any severance rights contained in any applicable Employee
Plan made available to Parent, and except as would not be material to the Acquired Companies, taken as a whole, each of the Acquired Companies&rsquo;
independent contractors or other individual non-employee service providers is terminable at any time upon thirty (30) days&rsquo; notice
or less, without any liability to the Acquired Companies (other than with respect to the obligation to provide notice). No later than
the Effective Time, the Company shall provide to Parent updated Censuses, setting forth the information provided for in this Section 3.18(a)
as of immediately prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company is a party to, or bound by, any collective bargaining agreement or any other labor-related Contract, agreement,
understanding or arrangement with any labor union, other labor organization or employee representative body representing any of its employees,
and no employees of any Acquired Company are represented by any labor union, other labor organization or other employee representative
body with respect to their employment with any Acquired Company. Since January 1, 2024, there has not been any unfair labor practice charge,
grievance, arbitration, strike, lockout, slowdown, interruption of work, petition or demand for recognition by or on behalf of any labor
union, or group of employees, or other union organizing activity or dispute, or, to the knowledge of the Company, any threat thereof,
by any employees of any Acquired Company with respect to their employment with the Acquired Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as would not be material to the Acquired Companies, taken as a whole, since January 1, 2024, each Acquired Company has been
in compliance with all applicable Legal Requirements related to employment and employment practices, including all laws respecting terms
and conditions of employment, health and safety, wages and hours, overtime, meals and rest breaks, employee and independent contractor
classification, child labor, immigration and work authorization, employment discrimination, harassment, health and safety, disability
rights or benefits, equal opportunity, plant closures and layoffs, civil rights, affirmative action, workers&rsquo; compensation, labor
relations, continuation coverage under group health plans, wage payment, employee leave issues and unemployment insurance (collectively,
&ldquo;<B>Employment Laws</B>&rdquo;). The Acquired Companies are, and have been since January 1, 2024, in material compliance with the
WARN Act and have no liabilities or other obligations thereunder. All employees, independent contractors, contingent workers, and other
service providers have been properly classified under applicable Legal Requirements as employees or independent contractors and as exempt
or non-exempt from minimum wage and overtime requirements (in each case, within the meaning of or pursuant to the Fair Labor Standards
Act and similar applicable Legal Requirements), except as would not be material to the Acquired Companies, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Since January 1, 2024, no allegations of sexual harassment or misconduct or workplace discrimination or harassment (including based
on race, ethnicity, gender or any other class protected by applicable Legal Requirements) have been made against any current or former
officer, director or supervisory-level Company Associate and none of the Acquired Companies nor any Company Associate has entered into
any settlement agreement related to his or her employment or service with any Acquired Company related to any such allegations by any
such Person. No material Legal Proceeding by or on behalf of any current or former employee, officer, director, independent contractor,
contingent worker or other service provider or applicant has been brought or, to the knowledge of the Company, threatened against the
Acquired Companies relating to Legal Requirements, including but not limited to, those respecting employment and employment practices,
including Employment Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as would not be material to the Acquired Companies, taken as a whole, to the knowledge of the Company, no current or former
employee, officer, independent contractor or other service provider of any Acquired Company is in violation of any term of any employment
agreement, nondisclosure agreement, common law nondisclosure obligation, non-competition agreement or restrictive covenant obligation:
(i) with or to any Acquired Company or (ii) with or to a former employer of any such individual relating to the right of any such individual
to provide services to any Acquired Company or the knowledge or use of Trade Secrets or other proprietary or confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No employee of any Acquired Company at the level of vice president or higher has given notice of termination of employment or,
to the knowledge of the Company, has a present intention to terminate employment with the Acquired Companies prior to the one (1)-year
anniversary of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Section 3.18(g) of the Company Disclosure Letter sets forth a list of each material Employee Plan (other than agreements and instruments
that do not materially deviate from the forms delivered or made available to Parent prior to the execution of this Agreement, <I>provided</I>
that such forms have been disclosed in Section 3.18(g) of the Company Disclosure Letter). The Company has, prior to the execution of this
Agreement, either delivered or made available to Parent with respect to each material Employee Plan copies of, to the extent applicable:
(i) all plan documents (or, if not reduced to writing, a written summary of all material plan terms) and all amendments thereto, and all
related trust or other funding documents, (ii) the current summary plan description and any material modifications thereto, if any, (iii)
the most recent annual actuarial valuation, if any, and the most recent annual report (Form Series 5500 and all schedules and financial
statements attached thereto), (iv) all material correspondence to or from the IRS, the United States Department of Labor or any other
Governmental Body with respect to an Employee Plan, (v) the most recent determination, advisory, or opinion letter received from the IRS
with respect to the Employee Plan, (vi) results of non-discrimination testing for the last three (3) years, with details of any related
corrections, and (vii) copies of Forms 1094-C and sample Forms 1095-C filed by an Acquired Company that served as an &ldquo;applicable
large employer&rdquo; or member of an &ldquo;applicable large employer group&rdquo; within the meaning of the Patient Protection and Affordable
Care Act for 2019 through 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Acquired Company or any of its respective ERISA Affiliates sponsors, maintains, administers or contributes to (or has any obligation
to contribute to), or has during the past six (6) years, sponsored, maintained, administered or contributed to (or been required to contribute
to), or has or is reasonably expected to have any direct or indirect liability with respect to, (i) any plan that is or was subject to
Title IV of ERISA or Code Sections 412 or 430, or is otherwise a &ldquo;defined benefit plan&rdquo; within the meaning of Section 3(35)
of ERISA, (ii) any &ldquo;multiemployer plan&rdquo; within the meaning of Section 3(37) of ERISA, (iii) any &ldquo;multiple employer welfare
arrangement,&rdquo; as defined in Section&nbsp;3(40) of ERISA or (iv) any &ldquo;multiple employer plan,&rdquo; as described in Code Section&nbsp;413(c)
or Section 210 of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each of the Employee Plans that is intended to be qualified under Section 401(a) of the Code has obtained a favorable determination
letter (or opinion letter, if applicable) as to its qualified status under the Code, and, to the knowledge of the Company, there are no
existing circumstances or any events that have occurred that would reasonably be expected to affect adversely the qualified status of
any such Employee Plan or result in material liability, contingent or otherwise, to any Acquired Company. Each of the Employee Plans was
established and has been operated, funded, and administered in material compliance with its terms and all applicable Legal Requirements,
including ERISA and the Code. To the knowledge of the Company, no Acquired Company is or could reasonably be expected to be subject to
a liability pursuant to Section 502 of ERISA or a Tax or penalty imposed pursuant to Section 4975 or 4976 of the Code, except as would
not be material to such Acquired Company. There are no pending, or, to the knowledge of the Company, threatened or anticipated material
claims, actions, suits or Legal Proceedings by, on behalf of or with respect to any Employee Plan, by any current or former employee or
other service provider of any Acquired Company or beneficiary covered under any such plan, or otherwise involving any such Employee Plan
(other than routine claims for benefits). Except as would not be material to the Acquired Companies, taken as a whole, (i) there are no,
and for the last six (6) years there have not been, any audits or investigations by any Governmental Body involving any Employee Plan
or the assets thereof and (ii) no Employee Plan is, or within the last six (6) years has been, the subject of an application or filing
under, or a participant in, a government-sponsored amnesty, voluntary compliance, self-correction or similar program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except to the extent required under Section 601 et seq. of ERISA or 4980B of the Code (or any other similar state or local Legal
Requirement) where the full cost of such benefit is borne entirely by the applicable individual (or his or her eligible dependents or
beneficiaries), no Acquired Company nor any Employee Plan has any present or future obligation to provide post-retirement, post-employment
or post-service medical, dental, disability, hospitalization, life or similar health or welfare benefits to or make any payment to, or
with respect to, any present or former employee, officer, director or independent contractor of any Acquired Company, including pursuant
to any retiree medical benefit plan or other retiree welfare plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as otherwise provided for in Section 2.08 of this Agreement, neither the execution of this Agreement nor the consummation
of the Transactions could (either alone or in combination with other events or circumstances) (i) entitle any current or former employee,
director, officer, independent contractor or other service provider of any Acquired Company to severance pay, unemployment compensation
or any other payment or benefit or increase thereof, (ii) accelerate the time of payment or vesting, or increase the amount of, compensation
or benefits due to any current or former employee, director, officer, independent contractor or other service provider of any Acquired
Company, (iii) directly or indirectly cause any Acquired Company to transfer or set aside any assets to fund any payments or benefits
under any Employee Plan, or (iv) limit or restrict the right of the Company to amend, modify, or terminate any Employee Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> (i) The consummation of the Transactions will not (either alone or in combination with other events or circumstances) result in
any &ldquo;excess parachute payment&rdquo; within the meaning of Section 280G of the Code, (ii) no Employee Plan is a &ldquo;nonqualified
deferred compensation plan&rdquo; within the meaning of Section 409A of the Code, and (iii) none of the Acquired Companies has any obligation
to gross-up, indemnify or otherwise reimburse any current or former employee, officer, director or independent contractor or other service
provider of any Acquired Company for any Tax incurred by such Person, including under Section 409A or 4999 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Environmental Matters</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each Acquired Company is and, since January 1, 2023, has been in compliance with all applicable Environmental Laws, which compliance
includes obtaining, maintaining and complying with all Governmental Authorizations required under Environmental Laws for the operation
of its business, except as has not had, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except for matters that have been resolved without ongoing obligations or have not had, and would not have, individually or in
the aggregate, a Material Adverse Effect, no Acquired Company has received in writing any notice, report or other information of or entered
into any legally binding agreement, order, settlement, judgment, injunction or decree involving uncompleted, outstanding or unresolved
material violations, liabilities or requirements on the part of any Acquired Company relating to or arising under Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as has not had, individually or in the aggregate, a Material Adverse Effect, to the knowledge of the Company, no Releases
of Hazardous Materials have occurred on, at, under or from any property or facility currently or formerly owned, leased, operated or used
by any Acquired Company, including the Leased Real Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Insurance</I></FONT>. The
Company has delivered or made available to Parent a copy of all material insurance policies relating to the business, assets and operations
of the Acquired Companies. Except as has not had, individually or in the aggregate, a Material Adverse Effect, the Acquired Companies
maintain insurance coverage in such amounts and covering such risks as are in accordance with normal industry practice for companies in
the biotechnology industry of similar size and stage of development. To the knowledge of the Company, all such insurance policies are
in full force and effect, no notice of cancellation or material modification has been received (other than a notice in connection with
ordinary renewals), and there is no existing default or event which, with the giving of notice or lapse of time or both, would constitute
a default, by any insured thereunder except for such defaults as have not had, individually or in the aggregate, a Material Adverse Effect.
There is no claim pending under any of the Acquired Companies&rsquo; insurance policies as to which coverage has been questioned, denied
or disputed by the underwriters of such policies except for such claims as have not had, individually or in the aggregate, a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Legal Proceedings; Orders</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the date of this Agreement, there are no, and have not been since January 1, 2024, any, material Legal Proceedings pending
and served (or, to the knowledge of the Company, pending and not served or threatened in writing) against any Acquired Company or, to
the knowledge of the Company, against any present or former officer, director or employee of any Acquired Company in such individual&rsquo;s
capacity as such, or that and would not or would not reasonably be expected to materially impair, prevent or materially delay the Company&rsquo;s
ability to consummate the Transactions prior to the End Date on the terms set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As of the date of this Agreement, there is no order, writ, injunction, ruling, stipulation, settlement, award, finding, determination,
decree or judgment to which any Acquired Company is subject that is material to the Acquired Companies, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To the knowledge of the Company, as of the date of this Agreement, no investigation or review by any Governmental Body with respect
to any Acquired Company is pending or is being threatened in writing that is or would reasonably be expected to be material to the Acquired
Companies, taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Takeover Laws</I></FONT>.
Assuming the accuracy of the representations and warranties of Parent and Purchaser set forth in Section 4.08, the Board of Directors
has taken all actions necessary or appropriate, and will take after the date hereof, all actions that may be necessary or appropriate,
so that the restrictions applicable to business combinations contained in Section 203 of the DGCL and any other Takeover Law are, and
will be, to the extent such restrictions can be rendered inapplicable by action of the Board of Directors under Legal Requirements, inapplicable
to the execution, delivery and performance of this Agreement, the CVR Agreement and to the consummation of the Offer, the Merger and the
other Transactions. To the knowledge of the Company, assuming the accuracy of the representations of Parent and Purchaser in Section 4.08,
no other Takeover Law applies or will apply to this Agreement, the CVR Agreement or to the consummation of the Offer, the Merger and the
other Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.23.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Non-Contravention; Consents</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Assuming compliance with the applicable provisions of the DGCL, the HSR Act, any applicable filing, notification or approval in
any foreign jurisdiction required by Antitrust Laws (if any) or Foreign Investment Laws, Takeover Laws and the rules and regulations of
the SEC and Nasdaq, the execution and delivery of this Agreement by the Company and the consummation of the Transactions will not: (i)
cause a violation of any of the provisions of the certificate of incorporation or bylaws of (or any other organizational or governing
document) of any Acquired Company; (ii) cause a violation by any Acquired Company of any Legal Requirement or order applicable to any
Acquired Company, or to which any Acquired Company is subject; (iii) require any consent under, conflict with, result in breach of, or
constitute a default under (or an event that with notice or lapse of time or both would become a default), or give rise to any right of
purchase, termination, amendment, cancellation, acceleration adverse to any Acquired Company or other adverse change of any right or obligation
or the loss of any benefit to which any Acquired Company is entitled, under any provision of any Material Contract; or (iv) result in
an Encumbrance (other than a Permitted Encumbrance) on any of the property or assets of any Acquired Company, in the case of each of clauses
(ii), (iii) and (iv) except as would not have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required by
the Exchange Act (including the filing with the SEC of the Schedule 14D-9 and such reports under the Exchange Act as may be required in
connection with this Agreement and the Transactions), the DGCL, Takeover Laws, the HSR Act, any applicable filing, notification or approval
in any foreign jurisdiction required by Antitrust Laws (if any) or Foreign Investment Laws, and the applicable rules and regulations of
the SEC and any national securities exchange, no Acquired Company is required to give notice to, make any filing with, or obtain any Consent
from any Governmental Body in connection with the execution and delivery of this Agreement by the Company, or the consummation by the
Company of the Merger or the other Transactions, except those that the failure to make or obtain would not have, individually or in the
aggregate, a Material Adverse Effect and would not, or would reasonably not be expected to, materially impair, prevent or materially delay
the Company&rsquo;s ability to consummate the Transactions prior to the End Date on the terms set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.24.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Opinion of Financial Advisor</I></FONT>.
Centerview Partners LLC (the &ldquo;<B>Financial Advisor</B>&rdquo;) has rendered to the Board of Directors its oral opinion, to be confirmed
by delivery of a written opinion, that, as of the date of such opinion, and based upon and subject to the various assumptions made, procedures
followed, matters considered, and qualifications and limitations set forth therein, each of the Offer Price or Merger Consideration to
be paid to holders of Shares (other than Shares to be canceled pursuant to Sections 2.05(a)(i), 2.05(a)(ii), 2.05(a)(iii) or any Dissenting
Shares or any Shares held by any Affiliate of the Company or Parent) pursuant to this Agreement is fair, from a financial point of view,
to such holders. The Company will make available to Parent solely for informational purposes and on a non-reliance basis, a signed copy
of such opinion promptly after receipt thereof by or on behalf of the Company, it being expressly understood and agreed that such opinion
is for the benefit of the Board of Directors and may not be relied upon by Parent or Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.25.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Brokers and Other Advisors</I></FONT>.
Except for the Financial Advisor, no broker, finder, investment banker, financial advisor or other Person is entitled to any brokerage,
finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission, or the reimbursement of expenses in connection therewith,
in connection with the Transactions based upon arrangements made by or on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.26.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Acknowledgement by the Company</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company is not relying, and the Company has not relied, on any representations or warranties regarding the subject matter of
this Agreement or the CVR Agreement, express or implied, except for the representations and warranties in Article 4. Such representations
and warranties by Parent and Purchaser in Article 4 constitute the sole and exclusive representations and warranties of Parent and Purchaser
in connection with the Transactions and the Company understands, acknowledges and agrees that all other representations and warranties
of any kind or nature whether express, implied or statutory (including as to accuracy or completeness of any information) are specifically
disclaimed by Parent and Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In connection with the due diligence investigation of Parent and Purchaser by the Company and its respective Affiliates or Representatives,
the Company and its respective Affiliates and Representatives have received and may continue to receive after the date hereof from Parent,
Purchaser and their Affiliates, stockholders and Representatives certain estimates, projections, forecasts and other forward-looking information,
as well as certain business and strategic plan information, regarding Parent, Purchaser, their respective Affiliates and their businesses
and operations. The Company acknowledges that there are uncertainties inherent in attempting to make such estimates, projections, forecasts
and other forward-looking statements, as well as in such business and strategic plans, and that the Company will have no claim against
Parent, Purchaser, or any of its Affiliates, stockholders or Representatives, or any other Person with respect to any of the foregoing.
Accordingly, the Company hereby acknowledges and agrees that neither Parent or Purchaser nor any of their respective Affiliates, shareholders
or Representatives, nor any other Person, has made or is making any express or implied representation or warranty with respect to such
estimates, projections, forecasts, forward-looking statements or business plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
4<BR>
REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Parent and Purchaser represent and warrant to the
Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Due Organization</I></FONT>.
Each of Parent and Purchaser is a corporation or other Entity duly organized, validly existing and in good standing under the laws of
its jurisdiction of organization. Each of Parent and Purchaser has all necessary power and authority: (a) to conduct its business in the
manner in which its business is currently being conducted; and (b) to own and use its assets in the manner in which its assets are currently
owned and used, except where the failure has not had, individually or in the aggregate, a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Purchaser</I></FONT>. Purchaser
was formed solely for the purpose of engaging in a strategic transaction and activities incidental thereto and has not engaged, and prior
to the Effective Time will not engage, in any business activities other than in connection with the Transactions and those incident to
Purchaser&rsquo;s formation. Either Parent or a wholly owned Subsidiary of Parent owns beneficially and of record all of the outstanding
capital stock of Purchaser, free and clear of all Encumbrances and transfer restrictions, except for Encumbrances or transfer restrictions
of general applicability as may be provided under the Securities Act or applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Authority; Binding Nature
of Agreement</I></FONT>. Parent and Purchaser each have the corporate power and authority to execute and deliver and to perform their
respective obligations under this Agreement and the CVR Agreement, as applicable, and to consummate the Transactions. The board of directors
of each of Parent and Purchaser have approved this Agreement and the CVR Agreement, as applicable, and declared it advisable for Parent
and Purchaser, respectively, to enter into this Agreement and approved the execution, delivery and performance by Parent and Purchaser
of this Agreement and the CVR Agreement, as applicable, and the consummation of the Transactions, including the Offer and the Merger.
This Agreement and the CVR Agreement, as applicable, have been duly executed and delivered by Parent and Purchaser, and assuming due authorization,
execution and delivery by the Company, this Agreement and the CVR Agreement, as applicable, constitute the legal, valid and binding obligation
of Parent and Purchaser and is enforceable against Parent and Purchaser in accordance with its terms, except as such enforcement may be
subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating
to or affecting creditors&rsquo; rights, and by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Non-Contravention; Consents</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Assuming compliance with the applicable provisions of the DGCL, the HSR Act, any applicable filing, notification or approval in
any foreign jurisdiction required by Antitrust Laws (if any) or Foreign Investment Laws, and the applicable rules and regulations of the
SEC and any national securities exchange, the execution and delivery of this Agreement by Parent and Purchaser and of the CVR Agreement
by Parent, and the consummation of the Transactions, will not: (i) cause a violation of any of the provisions of the certificate of incorporation
or bylaws (or any other organizational or governing document) of Parent or Purchaser; (ii) cause a violation by Parent or Purchaser of
any Legal Requirement or order applicable to Parent or Purchaser, or to which Parent or Purchaser are subject; or (iii) require any consent
under, conflict with, result in breach of, or constitute a default under (or an event that with notice or lapse of time or both would
become a default), or give rise to any right of purchase, termination, amendment, cancellation, acceleration or other change of any right
or obligation or the loss of any benefit to which Parent or Purchaser is entitled, under any provision of any material Contract except
in the case of clauses (ii) and (iii), as would not have, individually or in the aggregate, a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required by
the Exchange Act (including the filing with the SEC of the Offer Documents), Takeover Laws, the DGCL, the HSR Act, any applicable filing,
notification or approval in any foreign jurisdiction required by Antitrust Laws (if any) or Foreign Investment Laws, and the applicable
rules and regulations of the SEC and any national securities exchange, neither Parent nor Purchaser, nor any of Parent&rsquo;s other Affiliates,
is required to give notice to, make any filing with or obtain any Consent from any Governmental Body in connection with the execution
and delivery of this Agreement or the CVR Agreement by Parent or Purchaser, as applicable, or the consummation by Parent or Purchaser
of the Offer, the Merger or the other Transactions, except those that the failure to make or obtain as would not, individually or in the
aggregate, have a Parent Material Adverse Effect. No vote of Parent&rsquo;s or Purchaser&rsquo;s stockholders is necessary to approve
this Agreement, the CVR Agreement or any of the Transactions (except in the case of Purchaser as has been obtained prior to the execution
hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Disclosure</I></FONT>. None
of the Offer Documents will contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. None of
the information with respect to Parent or Purchaser supplied or to be supplied by or on behalf of Parent or Purchaser or any of their
Subsidiaries, specifically for inclusion or incorporation by reference in the Schedule 14D-9 will, (a) at the time such document is filed
with the SEC, (b) at any time such document is amended or supplemented or (c) at the time such document is first published, sent or given
to the Company&rsquo;s stockholders, contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
For clarity, the representations and warranties in this Section 4.05 will not apply to, and neither Parent nor Purchaser makes any representation
with respect to, statements or omissions included or incorporated by reference in the Offer Documents or the Schedule 14D-9 based upon
information supplied to Parent by the Company or any of its Representatives on behalf of the Company specifically for inclusion therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Absence of Litigation</I></FONT>.
As of the date of this Agreement, there is no Legal Proceeding pending and served or, to the knowledge of Parent, pending and not served,
against Parent or Purchaser, except as would not, individually or in the aggregate, have a Parent Material Adverse Effect. As of the date
of this Agreement, neither Parent nor Purchaser is subject to any continuing order of, consent decree, settlement agreement or similar
written agreement with, or continuing investigation by, any Governmental Body, or any order, writ, judgment, injunction, decree, determination
or award of any Governmental Body, except as would not, individually or in the aggregate, have a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Funds</I></FONT>. As of
the Offer Acceptance Time, Parent will have available funds in an amount sufficient to consummate the Transactions by payment in cash
of the aggregate Closing Amount due at the Offer Acceptance Time, the portion of the aggregate Merger Consideration payable in cash due
at the Effective Time and the aggregate amounts payable in cash to holders of Company Options and Company RSUs following the Effective
Time pursuant to Section 2.08(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.08.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>DGCL Section 203</I>(c)</FONT>.
Neither Parent nor Purchaser is, nor for the past three (3) years has been, an &ldquo;interested stockholder&rdquo; of the Company under
Section 203(c) of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.09.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Acknowledgement by Parent
and Purchaser</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither Parent nor Purchaser is relying, and neither Parent nor Purchaser has relied, on any representations or warranties regarding
the subject matter of this Agreement, express or implied, except for the representations and warranties in Article 3, including the Company
Disclosure Letter. Such representations and warranties by the Company in Article 3 constitute the sole and exclusive representations and
warranties of the Acquired Companies in connection with the Transactions and each of Parent and Purchaser understands, acknowledges and
agrees that all other representations and warranties of any kind or nature whether express, implied or statutory (including as to accuracy
or completeness of any information) are specifically disclaimed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In connection with the due diligence investigation of the Acquired Companies by Parent and Purchaser and their respective Affiliates
or Representatives, Parent and Purchaser and their respective Affiliates and Representatives have received and may continue to receive
after the date hereof from the Company and its Affiliates, stockholders and Representatives certain estimates, projections, forecasts
and other forward-looking information, as well as certain business and strategic plan information, regarding the Acquired Companies and
their businesses and operations. Parent and Purchaser acknowledge (each for itself and on behalf of its controlled Affiliates) that (i)
there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as
well as in such business and strategic plans, (ii) Parent and Purchaser (each for itself and on behalf of its controlled Affiliates) are
taking full responsibility for making their own evaluation of the adequacy and accuracy of all estimates, projections, forecasts and other
forward-looking information, as well as such business and strategic plans, so furnished to them (including the reasonableness of the assumptions
underlying such estimates, projections, forecasts, forward-looking information or business and strategic plans) except to the extent such
information is expressly included in a representation or warranty contained in Article 3 of this Agreement and (iii) none of Parent, Purchaser,
or their respective Affiliates will have any claim against the Company, or any of its Affiliates, stockholders or Representatives, or
any other Person with respect to any of the foregoing unless any such information is expressly included in a representation or warranty
contained in Article 3 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Brokers and Other Advisors</I></FONT>.
Except for Persons, if any, whose fees and expenses shall be paid by Parent or Purchaser, no broker, finder, investment banker, financial
advisor or other Person is entitled to any brokerage, finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission, or
the reimbursement of expenses in connection therewith, in connection with the Transactions based upon arrangements made by or on behalf
of Parent, Purchaser, or any of their respective Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
5<BR>
CERTAIN COVENANTS OF THE COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Access and Investigation</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>During the period from the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement
pursuant to Article 8 (the &ldquo;<B>Pre-Closing Period</B>&rdquo;), upon reasonable advance notice to the Company, the Company shall,
and shall cause its Subsidiaries and their respective Representatives to, provide Parent and Parent&rsquo;s Representatives with reasonable
access during normal business hours of the Company to the Company and its Subsidiaries and their respective Representatives, designated
personnel and assets and to all existing books, records, documents and information relating to the Acquired Companies, and promptly provide
Parent and Parent&rsquo;s Representatives with all reasonably requested information regarding the business of the Acquired Companies and
such additional financial, operating and other data and information regarding the Acquired Companies, as Parent may reasonably request
(other than any books, records, documents and information relating to the negotiation and execution of this Agreement, or, except as expressly
provided in Section 5.03 and Section 6.01, any Acquisition Proposal or relating to any deliberation of the Board of Directors or any duly
authorized committee thereof regarding any Acquisition Proposal or Company Adverse Change Recommendation), in each case for any reasonable
purpose related to the consummation of the Transactions or for integration planning; <I>provided</I>, <I>however</I>, that any such access
shall be conducted at a reasonable time, under the supervision of appropriate personnel of the Acquired Companies and in such a manner
as not to unreasonably interfere with the normal operation of the business of the Acquired Companies. Any such access shall be subject
to the Company&rsquo;s reasonable security measures and insurance requirements and the requirements of the applicable Real Property Lease
and shall not include invasive testing. Nothing herein shall require the Company to disclose any information to Parent if such disclosure
would, in its reasonable discretion and after notice to Parent (i) jeopardize any attorney-client or other legal privilege (so long as
the Company has reasonably cooperated with Parent to permit such inspection of or to disclose such information on a basis that does not
waive such privilege with respect thereto), or (ii) contravene any applicable Legal Requirement or Contract (so long as the Company has
reasonably cooperated with Parent to permit disclosure to the extent permitted by such Legal Requirement or party to such Contract); <I>provided</I>,
<I>however</I>, in the case of clause (ii), that the Parties shall cooperate in seeking to find a way to allow disclosure of such information
to the extent doing so could reasonably (in the good faith belief of the Company (after consultation with outside counsel)) be managed
through the use of customary &ldquo;clean room&rdquo; arrangements pursuant to which non-employee Representatives of Parent could be provided
access to such information. With respect to the information disclosed pursuant to this Section 5.01, Parent shall comply with, and shall
instruct Parent&rsquo;s Representatives to comply with, all of its obligations under the mutual confidentiality agreement, effective as
of February 18, 2026, between the Company and Parent (the &ldquo;<B>Confidentiality Agreement</B>&rdquo;). Notwithstanding anything to
the contrary herein, the Company may satisfy its obligations set forth above by electronic means if physical access is not reasonably
feasible or would not be permitted under the applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) Subject to applicable Legal Requirements, each of the Company and Parent shall promptly notify the other of (A) any notice
or other communication received by such Party from any Governmental Body in connection with this Agreement, the Offer, the Merger or the
other Transactions, or from any Person alleging that the consent of such Person is or may be required in connection with the Offer, the
Merger or the other Transactions; or (B) any Legal Proceeding commenced or, to any Party&rsquo;s knowledge, threatened in writing against,
such Party or any of its Subsidiaries or otherwise relating to, involving or affecting such Party or any of its Subsidiaries, in each
case in connection with, arising from or otherwise relating to the Offer, the Merger or any other Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(A) The Company shall give prompt notice to Parent of any change, circumstance, condition, development, effect, event, occurrence
or state of facts that has had, individually or in the aggregate, a Material Adverse Effect, or would reasonably be expected to make the
satisfaction of any of the Offer Conditions impossible or unlikely, and (1) Parent shall give prompt notice to the Company of any change,
circumstance, condition, development, effect, event, occurrence or state of facts that has had, individually or in the aggregate, a Parent
Material Adverse Effect, or would reasonably be expected to make the satisfaction of any of the Offer Conditions impossible or unlikely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>For the avoidance of doubt, the delivery of any notice pursuant to this Section 5.01(b) shall not cure any breach of any representation
or warranty requiring disclosure of such matter prior to the date of this Agreement or otherwise limit or affect the remedies available
hereunder to any Party. The failure to deliver any such notice shall not cause any Offer Condition or any of the conditions set forth
in Article 7 to fail to be satisfied or give rise to any right to terminate under Article 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Operation of the Company&rsquo;s
Business</I></FONT>. During the Pre-Closing Period, except (x) as expressly required by this Agreement or as required by applicable Legal
Requirements or to the extent necessary to comply with any obligation under any Contracts made available to Parent prior to the date of
this Agreement, (y) with the prior written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed),
or (z) as set forth in Section 5.02 of the Company Disclosure Letter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Company shall, and shall cause each of its Subsidiaries to, (i) conduct its business in the ordinary course of business consistent
with past practice and (ii) use commercially reasonable efforts to preserve intact its material assets, properties, Contracts, licenses
and business organization, keep available the services of its current officers, employees and consultants (other than terminations for
cause) and preserve satisfactory business relationships with licensors, (sub)licensees, lessors, Governmental Bodies and others having
material business dealings with the Acquired Companies (<I>provided</I>, <I>however</I>, that no action by the Company or its Subsidiaries
with respect to matters specifically addressed by any provision of Section 5.02(b) shall be deemed a breach of this Section 5.02(a) unless
such action would constitute a breach of such other provision); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Company shall not (and shall cause its Subsidiaries not to):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A) establish a record date for, declare, accrue, set aside or pay any dividend or make any other distribution in respect of any
shares of its capital stock (including the Shares) or other equity or voting interests, or (B) repurchase, redeem or otherwise reacquire
any of its equity interests, or any rights, warrants or options to acquire any of its equity interests or any restricted stock units,
other than: (1) cancellation of Company Options or Company RSUs (or Shares issued upon the exercise or vesting and settlement thereof)
outstanding as of the date of this Agreement or issued in compliance with Section 5.02(b)(iii) pursuant to the terms of any such Company
Option or Company RSU between the Company and a Company Associate or member of the Board of Directors upon termination of such Person&rsquo;s
employment or engagement by the Company (in the case of Company Options or Company RSUs, outstanding on the date of this Agreement pursuant
to their terms as in effect on the date of this Agreement or issued in compliance with Section 5.02(b)(iii)), (2) in connection with withholding
to satisfy the exercise price and/or Tax obligations with respect to Company Options or Company RSUs in accordance with the terms of such
Company Option or Company RSU or (3) in connection with the issuance of Shares pursuant to the Company ESPP as in effect on the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>split, combine, subdivide or reclassify any shares of its capital stock (including the Shares) or other equity interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>sell, issue, grant, deliver, pledge, transfer, encumber, dispose of or authorize the sale, issuance, grant, delivery, pledge, transfer
or encumbrance of (A) any capital stock, equity interest or other security, (B) any option, call, warrant, restricted securities, restricted
stock unit, stock appreciation rights, incentive award measured based on the Shares or similar equity or equity-based awards with respect
to any Acquired Company or right to acquire any capital stock, voting securities, equity interest or other security, including any Company
Options and Company RSUs or (C) any instrument convertible into, exchangeable for or settled in any capital stock, voting securities,
equity interest or other security (except that the Company may issue Shares as required to be issued upon (x) the exercise of Company
Options outstanding as of the date of this Agreement in accordance with their terms as in effect on the date of this Agreement or issued
in compliance with this Section 5.02(b)(iii) in accordance with their terms or (y) the vesting or settlement of Company RSUs outstanding
as of the date of this Agreement in accordance with their terms as in effect on the date of this Agreement or issued in compliance with
this Section 5.02(b)(iii) in accordance with their terms);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>except as set forth in Section 2.08, as required by applicable Legal Requirements, or as required pursuant to an Employee Plan
as in effect on the date of this Agreement, (A) establish, adopt, enter into, terminate, or amend any Employee Plan (or any plan, program,
scheme, arrangement, practice, policy or agreement that would be an Employee Plan if it were in existence on the date hereof) or any collective
bargaining agreement or other labor agreement, (B) amend or waive any of its material rights under, or accelerate the payment or vesting,
exercisability or funding of compensation or benefits under, any provision of any of the Employee Plans (or any plan, program, scheme,
arrangement, practice, policy or agreement that would be an Employee Plan if it were in existence on the date of this Agreement) or (C)
grant or promise or commit to grant to any current or former employee or other service provider any increase in compensation or benefits,
change of control payments or benefits, deferred compensation, equity or equity-based awards, bonuses or severance, retention or other
payments or benefits;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other than due to offers of employment or engagement made by any Acquired Company prior to the date of this Agreement and set forth
on Section 5.02(b)(v) of the Company Disclosure Letter, hire, engage, or terminate (other than a termination for cause) any employee or
retain any consultant or non-employee service provider or promote any employee (other than non-executive employees whose total annual
base compensation opportunity does not exceed $250,000);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(A) commence, alone or with any third party, any clinical trial in respect of any Product Candidate, or (B) unless mandated by
a Specified Governmental Body, discontinue, terminate or suspend any ongoing clinical or preclinical study with respect to any Product
Candidate that is being performed by or on behalf of, or is otherwise controlled by, any Acquired Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>terminate, allow to lapse or expire, suspend, modify or otherwise take any step to limit the effectiveness or validity of, or fail
to maintain as valid and in full force and effect, any applicable material Governmental Authorization owned or controlled by any Acquired
Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>qualify any new site for manufacturing of any Product Candidate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>amend or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational
or governing documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>form any Subsidiary, acquire any equity or voting interest in any other Entity or enter into any joint venture or clinical or commercial
collaboration agreement or any other material collaboration, license, development, partnership, limited liability company, strategic alliance,
material research, commercialization or similar material arrangement or trigger or exercise any right of first negotiation or right of
first refusal under any collaboration, license or development agreement or similar arrangement, excluding the Company&rsquo;s exercise
of any rights in the ordinary course of business under the Collaboration and License Agreement, by and between the Company and Kite Pharma,
Inc., dated December 8, 2022, as amended from time-to-time by the parties thereto (the &ldquo;<B>Collaboration Agreement</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>make or authorize any capital expenditure (except that the Acquired Companies may make capital expenditures in the ordinary course
of business consistent with past practice that do not exceed $200,000 individually or $500,000 in the aggregate);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>acquire, lease, license, sublicense, pledge, sell or otherwise dispose of, divest or spin-off, abandon, waive, covenant not to
assert, relinquish or permit to lapse (other than any Patent expiring at the end of its statutory term and not capable of being extended),
transfer or assign, guarantee, exchange or swap, mortgage or otherwise encumber (including pursuant to a sale-leaseback transaction or
securitization) or subject to any material Encumbrance (other than Permitted Encumbrances) any material right or other material asset
or property (except (A) non-exclusive licenses or sublicenses of Intellectual Property Rights in the ordinary course of business consistent
with past practice, (B) entering into clinical trial agreements with respect to clinical trials that are ongoing as of the date of this
Agreement in the ordinary course of business consistent with past practice, and material transfer agreements in the ordinary course of
business consistent with past practice, in each case (A) and (B), pursuant to which an Acquired Company solely and exclusively owns any
and all Intellectual Property Rights conceived, developed or reduced to practice thereunder, in amounts not exceeding $300,000 individually
or $750,000 in the aggregate, (C) pursuant to dispositions of obsolete, surplus or worn out assets or properties that are no longer useful
in the conduct of the business of the Acquired Companies in amounts not exceeding $300,000 in the aggregate or (D) expirations of Real
Property Leases in accordance with the terms thereof);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>except pursuant to an Acceptable Confidentiality Agreement, disclose any Trade Secrets or other confidential information relating
to any of the Product Candidates and that could materially adversely effect the commercialization of any Product Candidate, and with respect
to any such Trade Secrets, except with protections sufficient to protect and maintain such Trade Secret as a Trade Secret under applicable
Legal Requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>lend money or make capital contributions or advances to or make investments in, any Person, or incur, assume or guarantee or otherwise
become contractually liable for any Indebtedness in excess of $500,000 (except for advances to employees and consultants for travel and
other business related expenses in the ordinary course of business consistent with past practice and in compliance with the Company&rsquo;s
policies related thereto) or enter into any swap or hedging transaction or other derivative agreements other than in the ordinary course
of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A) other than in the ordinary course of business consistent with past practice, amend or modify in any material respect, or waive
or release any material rights under or voluntarily terminate, replace or release, settle or compromise any material claim, liability
or obligation under any Material Contract, or (B) enter into any contract that would constitute a Material Contract if it were in effect
on the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>except, in each case, as required by applicable Legal Requirements, (A) adopt or make any material change to any accounting method
or material accounting period used for Tax purposes; (B) make, change or revoke any material Tax election; (C) file a material amended
Tax Return; (D) enter into a &ldquo;closing agreement&rdquo; within the meaning of Section 7121 of the Code (or any corresponding or similar
provision of any state, local or non-U.S. Tax law) with any Governmental Body regarding any material Tax liability or assessment; (E)
request any letter ruling from the IRS (or any comparable ruling from any other taxing authority); (F) settle or compromise any audit,
examination or Legal Proceeding relating to material Taxes or surrender a right to a material Tax refund; (G) waive or extend the statute
of limitations with respect to any material Tax or material Tax Return (other than pursuant to customary extensions of the due date for
filing a Tax Return); or (H) enter into any Tax allocation, indemnity or sharing agreement (other than customary gross-up or indemnification
provisions in credit agreements, derivatives, leases, employment agreements and similar agreements entered into in the ordinary course
of business consistent with past practice);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>commence any Legal Proceeding or settle, release, waive or compromise any Legal Proceeding or other claim (or threatened Legal
Proceeding or other claim), other than any settlement, release, waiver or compromise that (1) results solely in monetary obligations involving
only the payment of monies by the Acquired Companies of not more than $500,000 in the aggregate (excluding monetary obligations that are
funded by an insurance policy of the Acquired Companies), and (2) results in no material non-monetary obligation of the Acquired Companies;
<I>provided</I>, <I>however</I>, that the settlement, release, waiver or compromise of any Legal Proceeding or claim brought by the stockholders
of any Acquired Company against any Acquired Company and/or its directors relating to the Transactions or a breach of this Agreement or
any other agreements contemplated hereby shall be subject to Section 2.07 or Section 6.05, as applicable, and <I>provided</I>, <I>further</I>,
that the foregoing shall not permit any Acquired Company to settle, release, waive or compromise any Legal Proceeding or claim (x) that
provides for the grant to any third party of a license or other grant by any Acquired Company of rights to any material Company IP or
material Company Licensed IP or (y) that would impose any material restrictions or changes on the business or operations of, or the admission
of wrongdoing by, any Acquired Company, or commence any material Legal Proceeding, other than in the ordinary course of business consistent
with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>enter into, negotiate, amend or extend any collective bargaining agreement or other agreement with any labor organization (except
to the extent required by applicable Legal Requirements);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>take any action that would constitute a &ldquo;mass layoff&rdquo; or &ldquo;plant closing&rdquo; (as defined by the WARN Act) or
require notice to employees, or trigger any other obligations or liabilities under the WARN Act or any similar state, local or foreign
Legal Requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>adopt or implement any stockholder rights plan (or similar plans or arrangements);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xxi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(A) commence any clinical trial or initiate commercialization or reimbursement activities (including promotional and marketing
activities) relating to any Product Candidate of which Parent has not been informed prior to the date of this Agreement, (B)&#8239;unless
mandated by any Governmental Body, discontinue, terminate, suspend or materially modify any ongoing clinical trial, IND-enabling preclinical
studies or other material preclinical development activities, manufacturing or commercialization or reimbursement activities (including
promotional and marketing activities) relating to any Product Candidate, in each case, without first consulting with Parent in good faith,
or (C)&#8239;accelerate or delay public disclosure of the results of any ongoing clinical trial from any release dates publicly announced
prior to the date hereof without first consulting with Parent in good faith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xxii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>adopt a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation, restructuring, recapitalization
or other reorganization of any Acquired Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xxiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>authorize any of, or agree or commit to take, any of the actions described in the foregoing clauses (i) through (xxii) of this
Section 5.02(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, nothing contained
herein shall give to Parent or Purchaser, directly or indirectly, rights to control or direct the operations of the Acquired Companies
prior to the Offer Acceptance Time. Prior to the Effective Time, each of Parent and the Company shall exercise, consistent with the terms
and conditions hereof, complete control and supervision of its and its Subsidiaries&rsquo; respective operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>No Solicitation</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall not, and shall cause its Subsidiaries
and its and their officers and directors not to, and shall use reasonable best efforts to cause their other Representatives not to, directly
or indirectly, (i) continue any solicitation, knowing encouragement, discussions or negotiations with any Persons that may be ongoing
with respect to an Acquisition Proposal; (ii) (A) solicit, initiate or knowingly facilitate or encourage (including by way of furnishing
non-public information) any inquiries regarding, or the making of any proposal or offer that constitutes, or would reasonably be expected
to lead to, an Acquisition Proposal (other than discussions solely to clarify the terms and conditions of such proposal or offer), (B)
engage in, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any other Person any non-public
information in connection with, or for the purpose of soliciting or knowingly encouraging or facilitating, an Acquisition Proposal or
any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal (other than to state that the terms of this
provision prohibit such discussion), (C) approve, adopt, endorse or recommend or enter into any letter of intent, acquisition agreement,
agreement in principle or similar agreement with respect to an Acquisition Proposal or any proposal or offer that would reasonably be
expected to lead to an Acquisition Proposal (other than an Acceptable Confidentiality Agreement) or (D) take any action to exempt any
Person (other than Parent and its Subsidiaries) from the restrictions on &ldquo;business combinations&rdquo; or any similar provision
contained in applicable Takeover Laws or the Company&rsquo;s organizational and other governing documents; (iii) subject to the fiduciary
duties of the Board of Directors, waive or release any Person from, forebear in the enforcement of, or amend any standstill agreement
or any standstill provisions of any other Contract; or (iv) resolve or agree to do any of the foregoing. On the date hereof, the Company
shall discontinue electronic or physical data room access granted, and request the prompt return or destruction (to the extent provided
for by the applicable confidentiality agreement) of all non-public information or documents previously furnished to any Person (other
than Parent, its Affiliates and their respective Representatives) that has made or has indicated an intention to make an Acquisition Proposal
and all material incorporating such information created by any such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If at any time on or after the date of this Agreement and prior to the Offer Acceptance Time the Company or any of its Representatives
receives a <I>bona fide </I>unsolicited written Acquisition Proposal from any Person or group of Persons, which Acquisition Proposal was
made or renewed on or after the date of this Agreement and did not, directly or indirectly, result from any material breach of this Section
5.03, and the Board of Directors determines in good faith, after consultation with its financial advisor and outside legal counsel, that
such Acquisition Proposal constitutes or would reasonably be expected to result in a Superior Offer and that the failure to take such
action described in clauses (x) and (y) below would be inconsistent with its fiduciary duties under applicable Legal Requirements, then,
notwithstanding anything in Section 5.03(a) to the contrary, the Company and its Representatives may (x) furnish, pursuant to an Acceptable
Confidentiality Agreement, information (including non-public information) with respect to the Acquired Companies to the Person or group
of Persons who has made such Acquisition Proposal, <I>provided</I>, <I>however</I>, that the Company shall as promptly as practicable
(and in any event within 36 hours) provide to Parent any non-public information concerning the Acquired Companies that is provided to
any Person to the extent access to such information was not previously provided to Parent or its Representatives; and (y) engage in or
otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal; <I>provided</I>,
<I>however</I>, that in the case of clauses (x) and (y), that at or prior to the first time that the Company furnishes any information
to or participates in any discussions or negotiations with any Person on or after the date of this Agreement, the Company shall provide
written notice to Parent of such determination in good faith of the Board of Directors as provided for above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>During the Pre-Closing Period, the Company shall (i) promptly (and in any event within 24 hours after knowledge of receipt by an
executive officer or director of the Company) notify Parent orally and in writing if any proposals or offers with respect to, or that
would reasonably be expected to lead to, an Acquisition Proposal are received by the Company or any of its Representatives and provide
to Parent a copy of any written Acquisition Proposal (including any proposed term sheet, letter of intent, acquisition agreement or other
agreement or other supporting materials with respect thereto) and a summary of any material unwritten terms and conditions thereof (and
indicate the identity of such Person), and (ii) keep Parent reasonably informed of any material developments, discussions or negotiations
regarding any Acquisition Proposal (including any material changes to the terms thereof) on a prompt basis (and in any event within 36
hours of any request by Parent for an update as to the status of any such material development, discussion or negotiation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Nothing in this Section 5.03 or elsewhere in this Agreement shall prohibit the Company from disclosing to the stockholders of the
Company any &ldquo;stop, look and listen&rdquo; communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act or from taking
and disclosing such other position or disclosure as is required under Rule 14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated
under the Exchange Act or from taking any action necessary to comply with applicable Legal Requirements; <I>provided</I>, <I>however</I>,
that, the Board of Directors shall not effect a Company Adverse Change Recommendation except in accordance with Section 6.01(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company agrees that in the event any of its Subsidiaries or any Representative of any Acquired Company acting in their authorized
capacities on behalf of the Company takes any action that, if taken by the Company, would constitute a breach of this Section 5.03, the
Company shall be deemed to be in breach of this Section 5.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
6<BR>
ADDITIONAL COVENANTS OF THE PARTIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Company Board Recommendation</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Subject
to Section 6.01(b), the Company hereby consents to the inclusion of a description of the Company Board Recommendation in the Offer
Documents. During the Pre-Closing Period, subject to Section 6.01(b), neither the Board of Directors nor any committee thereof shall
(i) (A) withdraw or withhold (or modify or qualify in a manner adverse to Parent or Purchaser), or publicly propose to withdraw or
withhold (or modify or qualify in a manner adverse to Parent or Purchaser), the Company Board Recommendation, (B) adopt, approve,
recommend or declare advisable, or publicly propose to adopt, approve, recommend or declare advisable, any Acquisition Proposal, (C)
after public announcement of an Acquisition Proposal (other than a tender offer or exchange offer), fail to publicly affirm the
Company Board Recommendation within three (3) business days after a written request by Parent to do so (or, if earlier, by the close
of business on the business day immediately preceding the scheduled date of the Expiration Date), <I>provided</I>, <I>however</I>,
that Parent may only make such request once with respect to any Acquisition Proposal (<I>provided</I>, that each time a
Determination Notice is given Parent shall, subject to the following provision, be entitled to make a new such request); and <I>provided</I>, <I>further</I>,
that the Company shall not be required to provide any such affirmation during the two (2) or three (3) business day periods, as
applicable, following the giving of a Determination Notice, (D) following the commencement of a tender offer or exchange offer
relating to the Shares by a Person unaffiliated with Parent, fail to publicly affirm the Company Board Recommendation and recommend
that the Company&rsquo;s stockholders reject such tender offer or exchange offer within ten (10) business days after the
commencement of such tender offer or exchange offer pursuant to Rule 14d-9(f) promulgated under the Exchange Act (or, if earlier, by
the close of business on the business day immediately preceding the scheduled date of the Expiration Date) or (E) fail to include
the Company Board Recommendation in the Schedule 14D-9 when filed with the SEC or disseminated to the Company&rsquo;s stockholders
(any action described in this clause (i) being referred to as a &ldquo;<B>Company Adverse Change Recommendation</B>&rdquo;) or (ii)
approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or cause or allow the Company to
execute or enter into, any Contract, letter of intent, memorandum of understanding, agreement in principle or term sheet with
respect to, or that is intended to or would reasonably be expected to lead to, any Acquisition Proposal or requiring, or reasonably
expected to cause, the Company to abandon or terminate the Transactions, or otherwise prevent or materially delay the Acquired
Companies from consummating, or materially impair the ability of the Acquired Companies to consummate, the Offer or the Merger (other than an Acceptable Confidentiality Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding anything to the contrary contained in this Agreement, at any time prior to the Offer Acceptance Time, and subject
to compliance with the other provisions of this Section 6.01:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if the Company has received a <I>bona fide </I>unsolicited written Acquisition Proposal, which Acquisition Proposal was made on
or after the date of this Agreement and did not, directly or indirectly, result from a material breach of Section 5.03, from any Person
that has not been withdrawn and after consultation with outside legal counsel and its financial advisor, the Board of Directors shall
have determined, in good faith, that such Acquisition Proposal constitutes a Superior Offer, (x) the Board of Directors may make a Company
Adverse Change Recommendation, or (y) provided that the Company and its Subsidiaries are not in breach of Section 5.03 in any material
respect and in a manner that led to such Acquisition Proposal and subject to the other provisions of Section 8.01(e), the Company may
terminate this Agreement pursuant to Section 8.01(e) to enter into a Specified Agreement with respect to such Superior Offer, in each
case, if and only if: (A) the Board of Directors determines in good faith, after consultation with the Company&rsquo;s outside legal counsel
and its financial advisor, that the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors under applicable
Legal Requirements; (B) the Company shall have given Parent prior written notice of its intention to consider making a Company Adverse
Change Recommendation or terminating this Agreement pursuant to Section 8.01(e) at least three (3) business days prior to making any such
Company Adverse Change Recommendation or termination (a &ldquo;<B>Determination Notice</B>&rdquo;) (which notice, and the delivery thereof,
shall not constitute a Company Adverse Change Recommendation or termination) and, if requested in writing by Parent during such three
(3) business day period, shall have negotiated, and caused its Representatives to negotiate, in good faith with respect to any revisions
to the terms of this Agreement or another proposal to the extent proposed by Parent so that such Acquisition Proposal would cease to constitute
a Superior Offer; and (C) (1) the Company shall have provided to Parent information with respect to such Acquisition Proposal in accordance
with Section 5.03(c), as well as a copy of any acquisition agreement with respect to such Acquisition Proposal and a copy of any financing
commitments relating thereto (or, if not provided in writing to the Company, a written summary of the material terms thereof), (2) the
Company shall have given Parent the three (3) business day period after the Determination Notice to propose revisions to the terms of
this Agreement or make another proposal so that such Acquisition Proposal would cease to constitute a Superior Offer, and (3) after giving
effect to the proposals made by Parent during such period, if any, after consultation with outside legal counsel and its financial advisor,
the Board of Directors shall have determined, in good faith, that such Acquisition Proposal constitutes a Superior Offer and that the
failure to make the Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(e) would be inconsistent
with the fiduciary duties of the Board of Directors under applicable Legal Requirements. Issuance of any &ldquo;stop, look and listen&rdquo;
communication by or on behalf of the Company pursuant to Rule 14d-9(f) promulgated under the Exchange Act, taking and disclosing a position
or otherwise making any disclosure as is required under Rule 14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under
the Exchange Act or otherwise complying with applicable Legal Requirements shall not, in and of itself, be considered a Company Adverse
Change Recommendation and shall not require the giving of a Determination Notice or compliance with the procedures set forth in this Section
6.01. The provisions of this Section 6.01(b)(i) shall also apply to any change to any of the financial terms (including the form, amount
and timing of payment of consideration) or other material amendment to any Acquisition Proposal and require a new Determination Notice
(<I>provided</I>, <I>however</I>, that for the purposes of such subsequent Determination Notice, all references to &ldquo;three (3) business
days&rdquo; shall be deemed to be &ldquo;two (2) business days&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other than in connection with a Superior Offer (which shall be subject to Section 6.01(b)(i)), the Board of Directors may make
a Company Adverse Change Recommendation in response to an Intervening Event if: (A) the Board of Directors determines in good faith, after
consultation with the Company&rsquo;s outside legal counsel and its financial advisor, that the failure to do so would be inconsistent
with the fiduciary duties of the Board of Directors under applicable Legal Requirements; (B) the Company shall have given Parent a Determination
Notice at least three (3) business days prior to making any such Company Adverse Change Recommendation and, if desired by Parent, during
such three (3) business day period shall have negotiated, and caused its Representatives to negotiate, in good faith with respect to any
revisions to the terms of this Agreement or another proposal to the extent proposed by Parent so that a Company Adverse Change Recommendation
would no longer be necessary; and (C) (1) the Company shall have specified in reasonable detail the facts and circumstances that render
a Company Adverse Change Recommendation necessary, (2) the Company shall have given Parent the three (3) business day period after the
Determination Notice to propose revisions to the terms of this Agreement or make another proposal so that a Company Adverse Change Recommendation
would no longer be necessary, and (3) after giving effect to the proposals made by Parent during such period, if any, after consultation
with outside legal counsel and its financial advisor, the Board of Directors shall have determined, in good faith, that the failure to
make the Company Adverse Change Recommendation would be inconsistent with the fiduciary duties of the Board of Directors under applicable
Legal Requirements. The provisions of this Section 6.01(b)(ii) shall also apply to any material change to the facts and circumstances
specified by the Company pursuant to clause (C)(1) above and require a new Determination Notice (<I>provided</I>, <I>however</I>, that
for the purposes of such subsequent Determination Notice, all references to &ldquo;three (3) business days&rdquo; shall be deemed to be
&ldquo;two (2) business days&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Filings, Consents and Approvals</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Parties agree to use their reasonable best efforts to take as promptly as reasonably practicable any and all steps necessary
to avoid or eliminate each and every impediment under the Antitrust Laws and Foreign Investment Laws that may be asserted by any Governmental
Body, in each case with competent jurisdiction, so as to enable the Closing to occur as promptly as practicable, but in no case later
than the End Date, including providing as promptly as reasonably practicable and advisable all non-legally privileged information reasonably
required by any Governmental Body pursuant to its evaluation of the Transactions under the HSR Act. Subject to the terms of this Section
6.02, the Parties shall use their respective reasonable best efforts to obtain from any Governmental Body all consents, approvals, authorizations
or orders required to be obtained under the Antitrust Laws and Foreign Investment Laws or to avoid the entry or enactment of any injunction
or other order or decree relating to any Antitrust Law or Foreign Investment Law that would delay, restrain, prevent, enjoin or otherwise
prohibit consummation of the Transactions. Notwithstanding anything to the contrary in this Agreement, Parent and its Affiliates shall
not be required to, and without the prior written consent of Parent the Company shall not, before or after the Offer Acceptance Time or
the Effective Time, (i)&#8239;undertake or enter into agreements or agree to the entry of an order or decree with any Governmental Body
in connection with obtaining the consents, approvals or authorizations of such Governmental Bodies in connection with this Agreement and
the Transactions, (ii)&#8239;sell, license, divest or dispose of or hold separate (through the establishment of a trust or otherwise),
or commit or agree to sell, license, divest or dispose of or hold separate (through the establishment of a trust or otherwise), or commit
or agree to any other structural, behavioral or conduct remedy with respect to, any entities, businesses, divisions, operations, products
or product lines, assets, Intellectual Property Rights or businesses of Parent, the Company or the Surviving Corporation (or any of their
respective Subsidiaries or other Affiliates) or agree to any restriction on the conduct of such businesses, (iii)&#8239;commit or agree
to terminate, amend or replace any existing relationships or contractual rights and obligations of Parent, the Company or the Surviving
Corporation (or any of their respective Subsidiaries or other Affiliates), or (iv)&#8239;effectuate any other change or restructuring of
Parent, the Company or the Surviving Corporation (or any of their respective Subsidiaries or other Affiliates). Nothing in this Section
6.02 shall require Parent or the Acquired Companies to take or agree to take any action unless the effectiveness of such action is conditioned
upon the Closing. Notwithstanding the foregoing and any other provision of this Agreement to the contrary, in no event shall Parent, Purchaser,
the Company or any of their respective Subsidiaries be obligated to litigate or participate in the litigation of any action, whether judicial
or administrative, brought by any Governmental Body challenging or seeking to restrain, prohibit or place conditions on the consummation
of the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the terms and conditions of this Agreement, each of the Parties shall (and shall cause their respective Affiliates,
if applicable, to): (i) as promptly as reasonably practicable (but, unless the Parties agree otherwise, no later than twenty (20) business
days after the date of this Agreement), make an appropriate filing of all Notification and Report forms as required by the HSR Act, with
respect to the Transactions, (ii) as promptly as reasonably practicable (but, unless the Parties agree otherwise, no later than twenty
(20) business days after the date of this Agreement), initiate the filings listed in Section 6.02(b) of the Company Disclosure Letter
and as promptly as reasonably practicable initiate any other filings and notifications (including, where appropriate, by way of pre-notification)
required under Antitrust Laws or Foreign Investment Laws applicable to the Transactions, and (iii) cooperate fully with each other in
determining whether (and as promptly as reasonably practicable preparing and making if so required) any other filings, notifications or
other consents are required to be made with, or obtained from, any other Governmental Bodies in connection with the Transactions, including
any required under Antitrust Laws or Foreign Investment Laws. Parent shall pay all filing fees required to be paid to a Governmental Body
in connection with the filings and notifications required under Antitrust Laws or Foreign Investment Laws applicable to the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Without limiting the generality of anything contained in this Section 6.02, during the Pre-Closing Period, each of the Parties
shall (i) promptly cooperate in all respects and consult with each other in connection with any necessary, proper or advisable filing
or submission in connection with any investigation or other inquiry, including allowing the other Party to have a reasonable opportunity
to review in advance and comment on drafts of filings and submissions; (ii) give the other Parties prompt notice of the making or commencement
of any request, inquiry, investigation, action or Legal Proceeding brought by a Governmental Body or brought by a third party before any
Governmental Body, in each case, with respect to the Transactions under the Antitrust Laws or Foreign Investment Laws, (iii) keep the
other Parties reasonably informed as to the status of any such application, notice, filing, submission, request, inquiry, investigation,
action or Legal Proceeding, (iv) promptly inform the other Parties of, and wherever practicable give the other Party reasonable advance
notice of, and the opportunity to review in advance and participate in, any substantive communication to or from the FTC, DOJ or any other
Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (v) promptly furnish the other
Party, subject to an appropriate confidentiality agreement to limit disclosure to counsel and outside consultants, with copies of documents
provided to or received from any Governmental Body in connection with any such application, notice, filing, submission, request, inquiry,
investigation, action or Legal Proceeding (except that documents, including &ldquo;Transaction-Related Documents&rdquo; as that term is
used under the HSR Act, that contain valuation information can be redacted), (vi) subject to an appropriate confidentiality agreement
to limit disclosure to counsel and outside consultants, and to the extent reasonably practicable, consult and cooperate with the other
Parties, allow the other Parties to have a reasonable opportunity to review in advance, and consider in good faith the views of the other
Parties in connection with any notice, filing, submission, written analysis, appearance, presentation, memorandum, brief, argument, opinion
or proposal made or submitted in connection with any such request, inquiry, investigation, action or Legal Proceeding, and (vii) except
as may be prohibited by any Governmental Body or by any Legal Requirement, in connection with any such request, inquiry, investigation,
action or Legal Proceeding in respect of the Transactions, give the other Party reasonable prior notice and permit authorized Representatives
of the other Party to be present at each meeting or conference, including by telephone or videoconference, relating to such request, inquiry,
investigation, action or Legal Proceeding and to have access to and be consulted in advance in connection with any argument, opinion or
proposal made or submitted to any Governmental Body in connection with such request, inquiry, investigation, action or Legal Proceeding.
Each Party shall supply as promptly as practicable such information, documentation, other material or testimony that may be requested
by any Governmental Body, including by complying at the earliest reasonably practicable date with any request for additional information,
documents or other materials received by any Party or any of their respective Subsidiaries from any Governmental Body in connection with
the Transactions. Neither Party shall commit to or agree with any Governmental Body to stay, toll or extend any applicable statutory deadline
or waiting period under the HSR Act or any other applicable Antitrust Laws or Foreign Investment Laws, delay the consummation of the Transactions,
withdraw or refile, or cause to be withdrawn or refiled, any notification filed under the HSR Act or any other applicable Antitrust Laws
or Foreign Investment Laws, or provide the applicable Governmental Body with additional time to review any of the Transactions, in each
case, without the prior written consent of the other Party; <I>provided</I>, that, notwithstanding the foregoing, Parent may, without
the consent of the Company, voluntarily withdraw its notification under the HSR Act on one (1) occasion so long as Parent refiles its
HSR Act notification within two (2) business days after withdrawal unless otherwise agreed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>During the Pre-Closing Period, the Company shall to the extent permissible under applicable Legal Requirements and reasonably practicable
and where doing so would not reasonably be expected to impair or adversely affect the Company, any of its plans with respect to the Product
Candidates or its ability to interact with any Governmental Body consistent with companies at similar stages of development in the pharmaceutical
industry (in each case as determined in good faith by the Company) (i) offer Parent the opportunity to consult with the Acquired Companies
prior to any proposed material meeting or other material communication with the FDA, EMA, the Centers for Medicare &amp; Medicaid Services
(&ldquo;<B>CMS</B>&rdquo;) or any other Specified Governmental Body relating to any Product Candidate or material Governmental Authorization
(it being understood that in no event shall the Company be required to delay or modify any of its actions as a result of this Section
6.02(d)), (ii) promptly inform Parent of, and provide Parent with a reasonable opportunity to review, in advance, any material filing
proposed to be made by or on behalf of any Acquired Company, and any material correspondence or other material communication proposed
to be submitted or otherwise transmitted to the FDA, EMA, CMS or any other Specified Governmental Body by or on behalf of any Acquired
Company, in each case relating to any Product Candidate or material Governmental Authorization (it being understood that in no event shall
the Acquired Companies be required to delay any such filings, correspondence or communication), (iii) keep Parent reasonably informed
of any material communication (written or oral) with or from the FDA, EMA, CMS or any other Specified Governmental Body or relating to
any Product Candidate or Governmental Authorization and (iv) promptly inform Parent and provide Parent with a reasonable opportunity (but
no less than two (2) business days, to the extent practicable) to comment, in each case, prior to making any material change to any study
protocol, adding any new trial, making any material change to a manufacturing plan or process, making any material change to a development
timeline or initiating, or making any material change to, commercialization and reimbursement activities or materials (including promotional
and marketing activities and materials) relating to any Product Candidate. The Company shall promptly notify Parent of any significant
data relating to any Product Candidate, including information related to any significant adverse events with respect to any Product Candidate,
in each case which it discovers after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the requirements of Section 6.02(c), Parent shall (i) control the timing and strategy for obtaining any approvals, consents,
registrations, waivers, permits, authorizations, exemptions, clearances, orders and other confirmations from any Governmental Body in
connection with the Transactions, and (ii) coordinate the overall development of the positions to be taken and the regulatory actions
to be requested in any filing or submission with any Governmental Body in connection with the Transactions and in connection with any
investigation or other inquiry or litigation by or before, or any negotiations with, any Governmental Body relating to the Transactions
and of all other regulatory matters incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding any other requirement in this Section 6.02, where a party (a &ldquo;<B>Disclosing Party</B>&rdquo;) is required
under this Section 6.02 to provide information to another Party (a &ldquo;<B>Receiving Party</B>&rdquo;) that the Disclosing Party deems
to be competitively sensitive information or otherwise reasonably determines in respect thereof that disclosure should be restricted,
the Disclosing Party may restrict the provision of such competitively sensitive and other restricted information only to antitrust counsel
of the Receiving Party; <I>provided</I>, that the Disclosing Party also provides to the Receiving Party upon request of the Receiving
Party a redacted version of such information which does not contain any such competitively sensitive or other restricted information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Employee Benefits</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as otherwise set forth in Section 6.03(a) of the Company Disclosure Letters, for a period commencing at the Effective Time
and ending on the last day of the calendar year in which the Closing occurs (or, if earlier, until the date of the termination of employment
of any Continuing Employee (as defined below)) (such period, the &ldquo;<B>Continuation Period</B>&rdquo;), Parent shall provide, or cause
to be provided, to each individual who is employed by any Acquired Company as of immediately prior to the Effective Time and who continues
to be actively employed by the Surviving Corporation (or any Affiliate thereof) during such period (a &ldquo;<B>Continuing Employee</B>&rdquo;),
(i) a target cash opportunity that is no less favorable in the aggregate than that in effect for each such Continuing Employee immediately
prior to the date hereof (<I>provided</I>, that the annual base salary or base wages for any Continuing Employee will not be reduced during
the Continuation Period), and (ii) broad-based employee benefits (other than severance, incentive compensation, equity compensation, transaction,
retention or non-recurring payments or benefits, deferred compensation arrangements, retiree health and welfare benefits and defined benefit
pension plans (the &ldquo;<B>Excluded Benefits</B>&rdquo;)) that are substantially comparable in the aggregate either to those provided
(excluding the Excluded Benefits) to such Continuing Employees by the Acquired Companies immediately prior to the Effective Time or to
those provided (excluding the Excluded Benefits) to similarly situated employees of Parent, as determined by Parent in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>With respect to a benefit plan of Parent or an Affiliate or the Surviving Corporation in which a Continuing Employee will be eligible
to participate following the Effective Time, Parent shall use commercially reasonable efforts to provide that such benefit plan shall
credit Continuing Employees for service prior to the Effective Time with the Acquired Companies and their Affiliates or their respective
predecessors for purposes of severance eligibility, if applicable, service anniversaries and vacation accruals (but not for purposes of
equity award vesting, retirement benefits, non-recurring payments or benefits any other Excluded Benefits or as would otherwise result
in any duplication of benefits), in each case, to the same extent as such service would have been recognized under comparable plans of
the Company or its Subsidiaries; <I>provided</I>, <I>however</I>, that, if any Continuing Employee experiences a break in service from
the Company on or following the Effective Time, and such Continuing Employee commences employment with Parent or one of its Subsidiaries
follows such break in service, then this Section 6.03(b) shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To the extent permitted under applicable Legal Requirements, with respect to any employee benefit plans maintained for the benefit
of the Continuing Employees following the Effective Time, Parent shall, and shall cause the Surviving Corporation, any of its Affiliates
and any successor thereto to use commercially reasonable efforts to (i) cause to be waived any eligibility requirements or pre-existing
condition limitations or waiting period requirements to the same extent waived or satisfied under comparable plans of the Company or its
Subsidiaries, and (ii) give effect, in determining any deductible, co-insurance and maximum out-of-pocket limitations, amounts paid by
such employees during the calendar year in which the Effective Time occurs under similar plans maintained by the Company or its Subsidiaries;
<I>provided</I>, <I>however</I>, that, if any Continuing Employee experiences a break in service from the Company on or following the
Effective Time, and such Continuing Employee commences employment with Parent or one of its Subsidiaries following such break in service,
then this Section 6.03(c) shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As soon as reasonably practicable (and in any event not later than fifteen (15) days) following the date of this Agreement, the
Company shall provide to Parent a detailed set of calculations (together with all relevant backup data) reflecting the estimated potential
impact of Section 280G of the Code with respect to each Person who could be entitled to any payment or benefit in connection with the
Transactions (either alone or in combination with other events or circumstances) which could potentially constitute a &ldquo;parachute
payment&rdquo; under Section 280G of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To the extent requested in writing by Parent at least ten (10) days prior to the Effective Time, the Company shall take all actions
that may be necessary under the Company&rsquo;s 401(k) plan to terminate the Company&rsquo;s 401(k) plan at least one day prior to the
Effective Time but contingent on the occurrence of the Closing. The Company shall provide to Parent for its, reasonable review and comment
no later than ten (10) days prior to the Closing Date drafts of any documentation effectuating such termination. Prior to the Closing,
the Company shall deliver to the Parent satisfactory evidence of the Company&rsquo;s actions with respect to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The provisions of this Section 6.03 are solely for the benefit of the Parties, and no provision of this Section 6.03 is, express
or implied, intended to, or shall, (i) constitute the establishment or adoption of or an amendment to any employee benefit plan or other
agreement, arrangement or Contract, including any Employee Plan, for purposes of ERISA or otherwise, or (ii) limit the ability of the
Company or any of its Affiliates (including, following the Effective Time, the Surviving Corporation and its Subsidiaries) to amend, modify
or terminate in accordance with its terms any Employee Plan or any benefit or compensation plan, program, agreement, contract, policy,
scheme or arrangement at any time assumed, established, sponsored or maintained by any of them. No current or former employee, officer,
director, independent contractor or other service provider or any other individual associated therewith shall be regarded for any purpose
as a third party beneficiary of this Agreement or have the right to enforce the provisions hereof, and, without limiting the generality
of Section 9.07, nothing in this Section 6.03 shall create any right in any current or former employee, officer, director, independent
contractor or other service provider or any other Person to any continued employment or engagement with the Acquired Companies, Parent
or any of their respective Affiliates or compensation or benefits of any nature or kind whatsoever, and each current employee&rsquo;s
and officer&rsquo;s relationship remains at-will.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Parties shall cooperate in good faith with respect to any broad-based communications to any current or former employee, officer,
director, independent contractor or other service provider or any other individual associated therewith regarding the transactions contemplated
hereby. The Company shall provide Parent with a reasonable opportunity to review and comment on any such broad-based communications intended
for any current or former employee, officer, director, independent contractor or other service provider or any other individual associated
therewith that it sends to any current or former employee, officer, director, independent contractor or other service provider or any
other individual associated prior to the Closing Date and the Company shall consider any comments of Parent in good faith and will incorporate
such comments into such communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Indemnification of Officers
and Directors</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>For a period of six (6) years from the Effective Time, Parent agrees that all rights to indemnification, advancement of expenses
and exculpation from liabilities for acts or omissions occurring at or prior to the Effective Time (whether asserted or claimed prior
to, at or after the Effective Time) now existing in favor of the current or former directors or officers of the Acquired Companies under
the certificate of incorporation and bylaws (or other organizational or governing documents) of each of the Acquired Companies, and the
indemnification agreements set forth on Section 6.05 of the Company Disclosure Letter, in each case as in effect on the date of this Agreement,
shall continue in full force and effect in accordance with their terms and shall not be amended, repealed or otherwise modified in any
manner that would adversely affect the rights thereunder of any Indemnified Person (as defined below), and Parent shall cause the Surviving
Corporation to perform its obligations thereunder. Without limiting the foregoing, during the period commencing at the Effective Time
and ending on the sixth (6th) anniversary of the Effective Time, Parent shall cause the Surviving Corporation and its Subsidiaries to,
and the Surviving Corporation agrees that it will, pursuant to and to the extent provided in the certificate of incorporation and bylaws
(or other organizational documents) of each of the Acquired Companies, and the indemnification agreements set forth on Section 6.05 of
the Company Disclosure Letter, in each case as in effect on the date of this Agreement, indemnify and hold harmless each individual who
is as of the date of this Agreement, or who becomes prior to the Effective Time, a director or officer of any Acquired Company or who
is as of the date of this Agreement, or who thereafter commences prior to the Effective Time, serving at the request of any Acquired Company
as a director or officer of another Person (the &ldquo;<B>Indemnified Persons</B>&rdquo;), against all claims, losses, liabilities, damages,
judgments, inquiries, fines and reasonable fees, costs and expenses, including attorneys&rsquo; fees and disbursements, incurred in connection
with any claim, action, suit or proceeding, whether civil, criminal, administrative or investigative (including with respect to matters
existing or occurring at or prior to the Effective Time, including this Agreement and the transactions and actions contemplated hereby),
arising out of or pertaining to the fact that the Indemnified Person is or was a director or officer of any Acquired Company or is or
was serving at the request of any Acquired Company as a director or officer of another Person, whether asserted or claimed prior to, at
or after the Effective Time, to the fullest extent permitted under applicable Legal Requirements. In the event of any such claim, action,
suit or proceeding, (x) each Indemnified Person will be entitled to advancement of expenses incurred in the defense of any such claim,
action, suit or proceeding from Parent, the Surviving Corporation or its Subsidiaries, as applicable, in accordance with the organizational
or governing documents, in each case as in effect on the date of this Agreement; <I>provided</I>, <I>however</I>, that any Indemnified
Person to whom expenses are advanced provides an undertaking, if and only to the extent required by the DGCL or the Surviving Corporation&rsquo;s
or any of its Subsidiaries&rsquo; certificate of incorporation or bylaws (or comparable organizational or governing documents) or any
such indemnification or other similar agreements, as applicable, to repay such advances if it is ultimately determined by final adjudication
that such Indemnified Person is not entitled to indemnification and (y) Parent, the Surviving Corporation and its Subsidiaries, as applicable,
shall reasonably cooperate in the defense of any such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>For a period of six (6) years from and after the Effective Time, Parent and the Surviving Corporation shall either cause to be
maintained in effect the current policies of directors&rsquo; and officers&rsquo; liability insurance maintained by or for the benefit
of the Acquired Companies or provide substitute policies for the Acquired Companies and their current and former directors and officers
who are currently covered by the directors&rsquo; and officers&rsquo; liability insurance coverage currently maintained by or for the
benefit of the Acquired Companies, in either case, of not less than the existing coverage and having other terms not less favorable to
the insured persons than the directors&rsquo; and officers&rsquo; liability insurance coverage currently maintained by or for the benefit
of the Acquired Companies with respect to claims arising from facts or events that occurred at or before the Effective Time (with insurance
carriers having at least an &ldquo;A&rdquo; rating by A.M. Best with respect to directors&rsquo; and officers&rsquo; liability insurance),
except that in no event shall Parent or the Surviving Corporation be required to pay with respect to such insurance policies an annual
premium greater than 300% of the annual premium most recently paid by the Company prior to the date of this Agreement (the &ldquo;<B>Maximum
Amount</B>&rdquo;), and if the Surviving Corporation is unable to obtain the insurance required by this Section 6.04(b) it shall obtain
as much comparable insurance as possible for the years within such six (6) year period for a premium equal to the Maximum Amount. In lieu
of such insurance, prior to the Closing Date, the Company shall use reasonable best efforts to purchase a &ldquo;tail&rdquo; directors&rsquo;
and officers&rsquo; liability insurance policy for the Acquired Companies and their current and former directors and officers who are
currently covered by the directors&rsquo; and officers&rsquo; liability insurance coverage currently maintained by or for the benefit
of the Acquired Companies, such tail to provide coverage in an amount not less than the existing coverage and to have other terms not
less favorable to the insured persons than the directors&rsquo; and officers&rsquo; liability insurance coverage currently maintained
by the Acquired Companies with respect to claims arising from facts or events that occurred at or before the Effective Time; <I>provided</I>,
<I>however</I>, that in no event shall the cost of any such tail policy exceed the Maximum Amount. Parent and the Surviving Corporation
shall maintain such policies in full force and effect, and continue to honor the obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event that any Acquired Company or any of its respective successors or assigns (i) consolidates with or merges into any
other Person and is not the continuing or surviving corporation or Entity of such consolidation or merger or (ii) transfers or conveys
all or substantially all of its properties and assets to any Person, then, and in each such case, such Acquired Company, as applicable,
shall cause proper provision to be made so that the successors and assigns of such Acquired Company assume the obligations set forth in
this Section 6.04.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The provisions of this Section 6.04 (i) shall survive the acceptance of Shares for payment pursuant to the Offer and the consummation
of the Merger and (ii) are intended to be for the benefit of, and will be enforceable by, each indemnified or insured party (including
the Indemnified Persons), his or her heirs, successors, assigns and representatives, and (iii) are in addition to, and not in substitution
for, any other rights to indemnification, advancement of expenses, exculpation or contribution that any such Person may have by contract
or otherwise. Unless required by an applicable Legal Requirement, this Section 6.04 may not be amended, altered or repealed after the
Offer Acceptance Time in such a manner as to adversely affect the rights of any Indemnified Person or any of their successors, assigns
or heirs without the prior written consent of the affected Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Stockholder Litigation</I></FONT>.
In the event that any litigation related to this Agreement, the Offer, the Merger or the other Transactions is brought by any stockholder
or other holder of Acquired Company securities (whether directly or on behalf of the Acquired Companies or otherwise) against any Acquired
Company and/or its directors or officers, the Company shall promptly notify Parent (which notification may be solely by email, notwithstanding
the procedures in Section 9.09) and shall keep Parent reasonably and promptly informed with respect to such litigation. The Company shall
give Parent the (a) opportunity to participate in the defense of any such litigation, (b) right to review and comment on all material
filings or responses to be made by any Acquired Company in connection with such litigation (and shall give due consideration to Parent&rsquo;s
comments and other advice with respect to such litigation) and (c) right to consult on any settlement with respect to such litigation,
and no such settlement shall be agreed to without Parent&rsquo;s prior written consent (such consent not to be unreasonably withheld,
conditioned or delayed); <I>provided</I>, <I>however</I>, that in no event shall Parent be required to consent to any such settlement
that would result in the imposition of any material restriction on, or material diminution in the value of, the business or operations
of the Company or that does not provide for the unconditional release of Parent, its Affiliates and Representatives and all Persons entitled
to indemnification by Parent or the Company, in each case from any liability in connection with such litigation; <I>provided</I>, <I>further</I>,
that the Company shall otherwise control the defense and/or settlement and the disclosure of information in connection therewith shall
be subject to the provisions of Section 5.01, including regarding attorney-client privilege or other applicable legal privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Additional Agreements</I></FONT>.
Subject to the terms, limitations and conditions of this Agreement, including Section 6.02(a), Parent and the Company shall use reasonable
best efforts to take, or cause to be taken, all actions necessary to consummate the Offer and the Merger and make effective the other
Transactions. Without limiting the generality of the foregoing, subject to the terms, limitations and conditions of this Agreement, each
Party to this Agreement shall use commercially reasonable efforts to (a) make all filings (if any) and give all notices (if any) required
to be made and given by such Party pursuant to any Material Contract in connection with the Offer and the Merger and the other Transactions
to the extent requested in writing by Parent, (b) seek each Consent (if any) required to be obtained pursuant to any Material Contract
by such Party in connection with the Transactions to the extent requested in writing by Parent; <I>provided</I>, <I>however</I>, that
each of the Parties acknowledges and agrees that obtaining any such consent or approval shall not, in and of itself, be a condition to
the Offer or the Merger and (c) seek to lift any restraint, injunction or other legal bar to the Offer or the Merger brought by any third
Person against such Party. Notwithstanding anything in this Section 6.06 to the contrary, neither Parent, the Company nor any of their
respective Subsidiaries shall be required to pay any consent or other similar fee, payment or consideration, make any other concession
or provide any additional security (including a guaranty), to obtain any third party consents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Disclosure</I></FONT>. The
initial press release relating to this Agreement shall be a joint press release issued by the Company and Parent, and thereafter Parent
and the Company shall consult with each other before issuing any further press release(s) or otherwise making any public statement or
making any announcement, including in any filings with or submissions to the SEC, with respect to or regarding the Company, the Company&rsquo;s
business, the Offer, the Merger, this Agreement or any of the other Transactions (to the extent not previously issued or made in accordance
with this Agreement), and shall not issue any such press release, public statement or announcement without the other Party&rsquo;s written
consent. Notwithstanding the foregoing: (a) each Party may, without such consultation or consent, make any public statement in response
to questions from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and
make disclosures in Company SEC Documents, so long as such statements are substantially consistent with previous press releases, public
disclosures or public statements made jointly by the Parties (or individually, if approved by the other Party); (b) a Party may, without
the prior consent of the other Party but subject to giving advance notice to the other Party and consulting with the other Party with
respect to the content thereof, issue any such press release or make any such public announcement or statement that, after consultation
with outside legal counsel, is determined to be required by Legal Requirement; (c) the Company need not consult with Parent in connection
with such portion of any press release, public statement or filing to be issued or made pursuant to Section 5.03(d); and (d) neither Party
need consult with the other in connection with such portion of any press release, public statement or filing to be issued with respect
to any Acquisition Proposal or Company Adverse Change Recommendation (but without limiting the Company&rsquo;s obligations under Section
5.03 or Section 6.01).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.08.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Takeover Laws</I></FONT>.
If any Takeover Law may become, or may purport to be, applicable to the Transactions, each of Parent, Purchaser and the Company and the
members of their respective Boards of Directors shall use their respective reasonable best efforts, subject in the case of Parent and
Purchaser to the limitations set forth in Section 6.02, to grant such approvals and take such actions as are necessary so that the Transactions
may be consummated as promptly as practicable on the terms and conditions contemplated hereby and otherwise act to lawfully eliminate
the effect of any Takeover Law on any of the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.09.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Section 16 Matters</I></FONT>.
The Company, and the Board of Directors (or a duly formed committee thereof consisting of non-employee directors (as such term is defined
for the purposes of Rule 16b-3 promulgated under the Exchange Act)), shall, to the extent necessary, take appropriate action, prior to
or as of the Offer Acceptance Time, to approve, for purposes of Section 16(b) of the Exchange Act, the disposition and cancellation or
deemed disposition and cancellation of Shares, Company Options and Company RSUs in the Merger by applicable individuals and to cause such
dispositions and/or cancellations to be exempt under Rule 16b-3 promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Rule 14d-10 Matters</I></FONT>.
Prior to the Offer Acceptance Time and to the extent permitted by applicable Legal Requirements, the compensation committee of the Board
of Directors, at a meeting duly called and held, will approve, as an &ldquo;employment compensation, severance or other employee benefit
arrangement&rdquo; within the meaning of Rule 14d-10(d)(2) under the Exchange Act, each agreement, arrangement or understanding between
Purchaser, any Acquired Company or their respective Affiliates and any of the officers, directors or employees of the Acquired Companies
that are effective as of the date of this Agreement or are entered into after the date of this Agreement and prior to the Offer Acceptance
Time pursuant to which compensation is paid to such officer, director or employee and will take all other action reasonably necessary
to satisfy the requirements of the non-exclusive safe harbor set forth in Rule 14d-10(d)(2) under the Exchange Act. Promptly upon Parent
or any of its Affiliates entering into any such arrangement with any of the officers, directors or employees of the Acquired Companies,
Parent will provide to the Company any and all information concerning such arrangements as may be needed by the Company to comply with
this Section 6.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Stock Exchange Delisting;
Deregistration</I></FONT>. Prior to the Closing Date, the Company shall cooperate with Parent and use its reasonable best efforts to take,
or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under
applicable laws and rules and policies of Nasdaq to enable the delisting by the Surviving Corporation of the Shares from Nasdaq and the
deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time. Parent will use reasonable best
efforts to cause (a) Nasdaq to file with the SEC a Form 25 on the Closing Date and (b) the Surviving Corporation to file with the SEC
a Form 15 on the first business day that is at least ten (10) days after the date the Form 25 is filed (such period between the Form 25
filing date and the Form 15 filing date, the &ldquo;<B>Delisting Period</B>&rdquo;). If the Surviving Corporation is reasonably likely
to be required to file any reports in accordance with the Exchange Act during the Delisting Period, the Company will deliver to Parent
at least five (5) business days prior to the Closing a substantially final draft of any such reports reasonably likely to be required
to be filed during the Delisting Period (&ldquo;<B>Post-Closing SEC Reports</B>&rdquo;). The Post-Closing SEC Reports provided by the
Company in accordance with this Section 6.11 will (i) not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading and (ii) comply in all material respects with the provisions of applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>CVR Agreement</I></FONT>.
At or prior to the Offer Acceptance Time, Parent shall authorize and duly adopt, execute and deliver, and will ensure that a duly qualified
Rights Agent executes and delivers, the CVR Agreement, subject to any reasonable revisions to the CVR Agreement that are requested by
such Rights Agent (provided that such revisions are not, individually or in the aggregate, detrimental or adverse, taken as a whole, to
any holder of a CVR) and agreed to by Parent and the Company (such agreement not to be unreasonably withheld, conditioned or delayed).
Parent and the Company shall cooperate, including by making changes to the form of CVR Agreement, as necessary to ensure that the CVRs
are not subject to registration under the Securities Act, the Exchange Act or any applicable state securities or &ldquo;blue sky&rdquo;
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Sales Agreement</I></FONT>.
Within five (5) business days of the date of this Agreement, the Company shall cause the Sales Agreement to be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>CEO Non-Compete Agreement</I></FONT>.
Prior to the Closing Date, the Company will use commercially reasonable efforts to cause the Company&rsquo;s Chief Executive Officer to
enter into a non-competition agreement with Parent to be effective as of the Closing Date; <I>provided</I>, that any failure to enter
into such agreement will not provide the Company with a right to terminate this Agreement, and the Company&rsquo;s Chief Executive Officer
is not a third-party beneficiary of this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
7<BR>
CONDITIONS PRECEDENT TO THE MERGER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligations of the Parties to effect the Merger
are subject to the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver as of the Closing of each of the
following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>No Restraints</I></FONT>.
There shall not have been issued by any Governmental Body of competent jurisdiction in any jurisdiction in which Parent or the Company
has material business operations, and remain in effect, any temporary restraining order, preliminary or permanent injunction or other
order preventing the consummation of the Merger, nor shall any Legal Requirement have been promulgated, enacted, issued or deemed applicable
to the Merger by any Governmental Body of competent jurisdiction in any jurisdiction in which Parent or the Company has material business
operations which prohibits or makes illegal the consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Consummation of Offer</I></FONT>.
Purchaser (or Parent on Purchaser&rsquo;s behalf) shall have accepted for payment all of the Shares validly tendered pursuant to the Offer
and not validly withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
8<BR>
TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Termination</I></FONT>.
This Agreement may be terminated prior to the Offer Acceptance Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by mutual written consent of Parent and the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by either Parent or the Company, if the Closing shall not have occurred on or prior to one minute after 11:59 p.m. Eastern Time,
on November 22, 2026 (such date and time, the &ldquo;<B>End Date</B>&rdquo;); <I>provided</I>, <I>however</I>, that in the case of this
Section 8.01(b), (i) if on the End Date all of the conditions set forth in Annex I, other than clause (e) or (g) (solely in respect of
any Antitrust Law or Foreign Investment Law) set forth in Annex I shall have been satisfied or waived by Parent or Purchaser, to the extent
waivable by Parent or Purchaser (other than conditions that by their nature are to be satisfied at the Offer Acceptance Time, each of
which is then capable of being satisfied), then the End Date shall automatically be extended to February 22, 2027 (and all references
to the End Date herein and in Annex I shall be as so extended) and (ii) the right to terminate this Agreement pursuant to this Section
8.01(b) shall not be available to any Party whose material breach of this Agreement has caused or resulted in the Offer not being consummated
by such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by either Parent or the Company if a Governmental Body of competent jurisdiction shall have issued an order, injunction, decree
or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the
acceptance for payment of Shares pursuant to the Offer or the Merger or making the consummation of the Offer or the Merger illegal, which
order, decree, ruling or other action shall be final and nonappealable; <I>provided</I>, <I>however</I>, that the right to terminate this
Agreement pursuant to this Section 8.01(c) shall not be available to any Party whose material breach of this Agreement has caused or resulted
in such final and nonappealable order, injunction, decree, ruling or other action or that has failed to comply with its obligations under
Section 6.02 with respect to the removal of such order, injunction, decree, ruling or other action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by Parent, if the Board of Directors shall have effected a Company Adverse Change Recommendation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by the Company, if the Board of Directors has authorized the Company to terminate this Agreement to concurrently with such termination
enter into a binding written definitive acquisition agreement providing for the consummation of a transaction for a Superior Offer (a
&ldquo;<B>Specified Agreement</B>&rdquo;); <I>provided</I>, <I>however</I>, that (i) the Company shall not have violated Section 5.03
in any material respect with respect to such Superior Offer, (ii) the Company and the Board of Directors shall have complied with Section
6.01(b) with respect to such Superior Offer and (iii) the Company shall have paid, or caused to be paid, the Termination Fee immediately
before or simultaneously with and as a condition to such termination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by Parent, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant or obligation
in this Agreement on the part of the Company shall have occurred such that a condition set forth in clause (b) or (c) of Annex I would
not be satisfied and cannot be cured by the Company by the End Date, or if capable of being cured in such time period, shall not have
been cured within forty-five (45) days of the date Parent gives the Company written notice of such breach or failure to perform; <I>provided</I>,
<I>however</I>, that Parent shall not have the right to terminate this Agreement pursuant to this Section 8.01(f) if either Parent or
Purchaser is then in material breach of any representation, warranty, covenant or obligation hereunder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>by the Company, if (i) a breach of any representation or warranty contained in this Agreement or failure to perform any covenant
or obligation in this Agreement on the part of Parent or Purchaser shall have occurred, in each case, if such breach or failure would
reasonably be expected to prevent Parent or Purchaser from consummating the Offer and the Merger by the End Date and such breach or failure
cannot be cured by Parent or Purchaser, as applicable, by the End Date, or, if capable of being cured in such time period, shall not have
been cured within forty-five (45) days of the date the Company gives Parent written notice of such breach or failure to perform; <I>provided</I>,
<I>however</I>, that the Company shall not have the right to terminate this Agreement pursuant to this Section 8.01(g) if the Company
is then in material breach of any representation, warranty, covenant or obligation hereunder or (ii) Purchaser fails to commence the Offer
on or prior to the tenth (10<SUP>th</SUP>) business day following the date of this Agreement or if Purchaser fails to (x) accept for payment
all Shares validly tendered (and not validly withdrawn) pursuant to the Offer within the period specified in Section 1.01(h) following
the expiration of the Offer, (y) purchase all Shares validly tendered (and not validly withdrawn) pursuant to the Offer within the period
specified in Section 1.01(h) following the Offer Acceptance Time, or (z) otherwise consummate the Offer in accordance with the terms of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Effect of Termination</I></FONT>.
In the event of the termination of this Agreement as provided in Section 8.01, written notice thereof shall be given to the other Party
or Parties, specifying the provision hereof pursuant to which such termination is made, and this Agreement shall be of no further force
or effect and there shall be no liability on the part of Parent, Purchaser or the Company or any of their respective former, current or
future officers, directors, partners, stockholders, managers, members or Affiliates following any such termination; <I>provided</I>, <I>however</I>,
that (a) the final sentence of Section 1.02(b), the penultimate sentence of Section 5.01(a), this Section 8.02, Section 8.03 and Article
9 (other than Section 9.05(b)) shall survive the termination of this Agreement and shall remain in full force and effect, (b) the Confidentiality
Agreement shall survive the termination of this Agreement and shall remain in full force and effect in accordance with its terms and (c)
except as set forth in Section 8.03, the termination of this Agreement shall not relieve any Party from any liability for fraud or willful
and material breach of this Agreement prior to termination (which liability the Parties acknowledge and agree shall not be limited to
reimbursement of out-of-pocket fees, costs or expenses incurred in connection with the Transactions, and may include damages based on
loss of the economic benefit of the Transactions to Parent or to the Company and the stockholders of the Company (in each case, taking
into consideration all relevant matters, including other business opportunities or combination opportunities and the time value of money)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Expenses; Termination Fees</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as set forth in Section 6.02(b) and this Section 8.03, all fees and expenses incurred in connection with this Agreement
and the Transactions shall be paid by the Party incurring such expenses, whether or not the Offer and Merger are consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>this Agreement is terminated by the Company pursuant to Section 8.01(e), the Company shall pay (or cause to be paid) to Parent
or its designee the Termination Fee by wire transfer of same day funds prior to or simultaneously with (and as a condition to the effectiveness
of) such termination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>this Agreement is terminated by Parent pursuant to Section 8.01(d), the Company shall pay to Parent or its designee the Termination
Fee by wire transfer of same day funds within one (1) business day after such termination; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(x) this Agreement is terminated by Parent or the Company pursuant to Section 8.01(b) (but in the case of a termination by the
Company, only if at such time Parent would not be prohibited from terminating this Agreement pursuant to the proviso to Section 8.01(b))
or by Parent pursuant to Section 8.01(f) resulting from a willful and material breach of any covenant in this Agreement, (y) any Person
shall have publicly disclosed a <I>bona fide </I>Acquisition Proposal, or such Acquisition Proposal has otherwise been communicated to
the Board of Directors or the Company&rsquo;s stockholders, after the date hereof and prior to such termination, and such Acquisition
Proposal has not been unconditionally withdrawn prior to such termination and (z) within twelve (12) months of such termination, the Board
of Directors shall have approved or recommended any Acquisition Proposal (regardless of when made) or the Company shall have entered into
a definitive agreement with respect to such Acquisition Proposal that is ultimately consummated (<I>provided</I>, <I>however</I>, that
for purposes of this clause (z) the references to &ldquo;20%&rdquo; in the definition of &ldquo;Acquisition Proposal&rdquo; shall be deemed
to be references to &ldquo;50%&rdquo;), the Company shall pay (or cause to be paid) to Parent or its designee the Termination Fee by wire
transfer of same day funds prior to the consummation of such Acquisition Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>It is understood that in no event shall the Company be required to pay the Termination Fee on more than one occasion. As used herein,
&ldquo;<B>Termination Fee</B>&rdquo; shall mean a cash amount equal to $260,000,000. In any circumstance in which the Termination Fee
becomes due and payable and is paid by or on behalf of the Company in accordance with this Section 8.03, the Termination Fee shall be
the sole and exclusive monetary remedy available to Parent and Purchaser in connection with any and all losses or damages suffered or
incurred by Parent, Purchaser, any of their respective Affiliates or any other Person in connection with this Agreement (collectively,
&ldquo;<B>Parent Related Parties</B>&rdquo;) (and the termination hereof), the Transactions (and the abandonment thereof) or any matter
forming the basis for such termination, and none of Parent, Purchaser or any of their respective Affiliates shall be entitled to bring
or maintain any claim, action or proceeding against the Company or any of its Affiliates arising out of or in connection with this Agreement,
any of the Transactions or any matters forming the basis for such termination. For the avoidance of doubt, Parent and Purchaser may seek
specific performance to cause the Company to consummate the Transactions in accordance with Section 9.05 or the payment of the Termination
Fee pursuant to this Section 8.03, but in no event shall Parent or Purchaser be entitled to both (i) specific performance to cause the
Company to consummate the Transactions in accordance with Section 9.05 and (ii) the payment of the Termination Fee pursuant to this Section
8.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent&rsquo;s right to receive payment from the Company of the Termination Fee and any other payments pursuant to this Section
8.03 shall be the sole and exclusive remedy of the Parent Related Parties against the Company and any of their respective former, current
or future officers, directors, partners, stockholders, optionholders, managers, members or Affiliates (collectively, &ldquo;<B>Company
Related Parties</B>&rdquo;) for any loss suffered as a result of the failure of the Offer or the Merger to be consummated or for a breach
or failure to perform hereunder or otherwise, and upon payment of such amount(s), none of the Company Related Parties shall have any further
liability or obligation relating to or arising out of this Agreement or the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Parties acknowledge (i) that the agreements contained in this Section 8.03 are an integral part of the Transactions, (ii) that
the Termination Fee is not a penalty, but a reasonable amount that will compensate Parent and Purchaser in the circumstances in which
such payment is payable for the efforts and resources expended and opportunities foregone while negotiating this Agreement and in reliance
on this Agreement and on the expectation of the consummation of the Transactions and (iii) that, without these agreements, the Parties
would not enter into this Agreement; accordingly, if the Company fails to timely pay any amount due pursuant to Section 8.03(b), and,
in order to obtain the payment, Parent commences a Legal Proceeding which results in a judgment against the Company, the Company shall
pay Parent its reasonable and documented out-of-pocket costs and expenses (including reasonable and documented out-of-pocket attorneys&rsquo;
fees) in connection with such suit, together with interest on such amount at the prime rate as published in the Wall Street Journal in
effect on the date such payment was required to be made through the date such payment was actually received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
9<BR>
MISCELLANEOUS PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Amendment</I></FONT>. Prior
to the Offer Acceptance Time, this Agreement may be amended by a written instrument signed by the Company (with the approval of the Board
of Directors), Parent and Purchaser; <I>provided </I>that, following the consummation of the Offer, this Agreement may not be amended
in any manner that causes the Merger Consideration to differ from the Offer Price. This Agreement may not be amended except by an instrument
in writing signed on behalf of each of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Waiver</I></FONT>. No failure
on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party
in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or
remedy. No single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof
or of any other power, right, privilege or remedy. No Party shall be deemed to have waived any claim arising out of this Agreement, or
any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly
set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver or failure to insist on strict
compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent
or other failure. At any time prior to the Offer Acceptance Time, Parent and Purchaser, on the one hand, and the Company, on the other
hand, may (a) extend the time for the performance of any of the obligations or other acts of the other, (b) waive any breach of the representations
and warranties of the other contained herein or in any document delivered pursuant hereto or (c) waive compliance by the other with any
of the agreements or covenants contained herein. Any such extension or waiver shall be valid only if is expressly set forth in a written
instrument duly executed and delivered on behalf of the Party or Parties to be bound thereby, but such extension or waiver or failure
to insist on strict compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with
respect to, any subsequent or other failure. The rights and remedies provided herein shall be cumulative and not exclusive of any rights
or remedies provided by any Legal Requirement except to the extent set forth in Section 8.03(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>No Survival of Representations
and Warranties</I></FONT>. None of the representations and warranties contained in this Agreement, the Company Disclosure Letter or in
any certificate or schedule or other document delivered by any Person pursuant to this Agreement shall survive the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Entire Agreement; Counterparts</I></FONT>.
This Agreement (including its Exhibits, Annexes and the Company Disclosure Letter), the CVR Agreement (including any annexes, schedules
and exhibits thereto) and the Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings,
both written and oral, among or between any of the Parties and their respective Affiliates, with respect to the subject matter hereof
and thereof. The Confidentiality Agreement shall survive the execution and delivery of this Agreement except that the restrictions on
disclosure (to the extent required to be included in SEC filings made in accordance with the terms of this Agreement in connection with
the Transactions) in the Confidentiality Agreement shall terminate immediately following the execution and delivery of this Agreement
solely for purposes of permitting the actions contemplated hereby to be consummated. This Agreement may be executed in one or more counterparts,
including by DocuSign, facsimile or by email with .pdf attachments, all of which shall be considered one and the same agreement, and shall
become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Applicable Legal Requirements;
Jurisdiction; Specific Performance; Remedies</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws
that might otherwise govern under applicable principles of conflicts of laws thereof. Any claim arising out of or relating to this Agreement
or the Transactions (whether based in contract, tort or otherwise), including any counterclaim, arising out of or relating to this Agreement
or the Transactions or the actions of any Party in the negotiation, administration, performance and enforcement hereof or thereof, shall
be governed by the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts
of laws thereof. In any action or proceeding arising out of or relating to this Agreement or any of the Transactions, each of the Parties
irrevocably and unconditionally (i) consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of
Delaware and any state appellate court therefrom or, if (but only if) such court lacks subject matter jurisdiction, the United States
District Court sitting in New Castle County in the State of Delaware and any appellate court therefrom (collectively, the &ldquo;<B>Delaware
Courts</B>&rdquo;); (ii) agrees not to attempt to deny or defeat such jurisdiction by motion or otherwise request for leave from any such
court; (iii) consents to service of process by first class certified mail, return receipt requested, postage prepaid, to the address at
which such Party is to receive notice in accordance with Section 9.09; (iv) agrees not to commence any such action or proceeding except
in the Delaware Courts; (v) agrees that any claim in respect of any such action or proceeding may be heard and determined in the Delaware
Courts, (vi) waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the
jurisdiction or laying of venue of any such action or proceeding in the Delaware Courts and (vii) waives, to the fullest extent permitted
by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. Each Party agrees
that service of process upon such Party in any action or proceeding arising out of or relating to this Agreement shall be effective if
notice is given by overnight courier at the address set forth in Section 9.09. The Parties agree that a final judgment in any such action
or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by
applicable Legal Requirements; <I>provided</I>, <I>however</I>, that nothing in the foregoing shall restrict any Party&rsquo;s rights
to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would
occur in the event that the Parties do not perform their obligations under the provisions of this Agreement in accordance with its specified
terms or otherwise breach such provisions. The Parties acknowledge and agree that (i) the Parties shall be entitled to an injunction or
injunctions, specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms
and provisions hereof in the courts described in Section 9.05(a) without proof of damages or otherwise, this being in addition to any
other remedy to which they are entitled under this Agreement, and (ii) the right of specific performance is an integral part of the Transactions
and without that right, neither the Company nor Parent would have entered into this Agreement. The right to specific enforcement hereunder
shall include the right of the Company, on behalf of itself and any third party beneficiaries to this Agreement, to cause Parent and Purchaser
to cause the Offer, the Merger and the other Transactions to be consummated on the terms and subject to the conditions set forth in this
Agreement. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable
relief on the basis that the other Parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy
for any reason at law or equity. The Parties acknowledge and agree that any Party seeking an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section 9.05(b) shall
not be required to provide any bond or other security in connection with any such order or injunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES (WHETHER
BASED ON CONTRACT, TORT OR OTHERWISE), INCLUDING ANY COUNTERCLAIM, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS OR
THE ACTIONS OF ANY PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF OR THEREOF. EACH PARTY (I) MAKES THIS
WAIVER VOLUNTARILY AND (II) ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS CONTAINED IN THIS SECTION 9.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Assignability</I></FONT>.
This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective
successors and permitted assigns; <I>provided</I>, <I>however</I>, that neither this Agreement nor any of the rights hereunder may be
assigned by a Party without the prior written consent of the other Parties, and any attempted assignment of this Agreement or any of such
rights without such consent shall be void and of no effect; <I>provided</I>, <I>further</I>, <I>however</I>, and notwithstanding the foregoing
proviso, that Parent may designate, by written notice to the Company, another wholly-owned direct or indirect Delaware corporate Subsidiary
of Parent to act as Purchaser, in which event all references to Purchaser in this Agreement shall be deemed references to such other Subsidiary;
<I>provided</I>, that such assignment shall not impede or delay the consummation of the Transactions or relieve Parent of its obligations
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>No Third Party Beneficiaries</I></FONT>.
Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties) any right, benefit
or remedy of any nature whatsoever under or by reason of this Agreement; except for: (a) if the Offer Acceptance Time occurs, (i) the
right of the holders of Shares to receive the Offer Price or Merger Consideration, as applicable, pursuant to Article 1 or Article 2 following
the Offer Acceptance Time or the Effective Time, as applicable, in accordance with the terms of this Agreement, (ii) the right of the
holders of Company Options and Company RSUs to receive the applicable consideration to which such holders shall become entitled pursuant
to Section 2.08 following the Effective Time in accordance with the terms of this Agreement and (iii) the rights of holders of CVRs to
receive payment in accordance with the terms of this Agreement and the CVR Agreement; (b) the provisions set forth in Section 6.04 with
respect to the Persons referred to therein; and (c) following the valid termination of this Agreement pursuant to Article 8, subject to
Section 8.02 and the last sentence of this Section 9.07, the right of the Company, as sole and exclusive agent for and on behalf of the
stockholders of the Company (which stockholders shall not be entitled to pursue such damages on their own behalf) (who are third party
beneficiaries hereunder solely to the extent necessary for this clause (c) to be enforceable), to pursue any damages (including damages
based on loss of the economic benefit of the Transactions to the stockholders of the Company). Notwithstanding anything herein to the
contrary, the rights granted pursuant to Section 9.07(c) and the provisions of Section 8.02 with respect to the recovery of damages based
on the losses suffered by the stockholders of the Company (including the loss of the economic benefit of the Transactions to the stockholders
of the Company) shall only be enforceable on behalf of the stockholders of the Company by the Company in its sole and absolute discretion,
as the sole and exclusive agent for the stockholders of the Company (which stockholders shall not be entitled to pursue such enforcement
on their own behalf); <I>provided</I> that, in such capacity as sole and exclusive agent for the stockholders of the Company, the Company
shall (i) be entitled to reimbursement (from the stockholders of the Company) from any such recovery of damages of its reasonable and
documented out-of-pocket costs and expenses (including reasonable and documented out-of-pocket attorneys&rsquo; fees determined by reference
to standard hourly rates) that have been incurred by the Company in connection with acting as sole and exclusive agent for the stockholders
of the Company pursuant to Section 9.07(c) and (ii) not be liable to the stockholders of the Company for any action taken, suffered or
omitted to be taken by it in good faith except to the extent that the Company&rsquo;s gross negligence or willful misconduct was the cause
of any direct loss to the stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.08.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Transfer Taxes</I></FONT>.
Except as otherwise provided in Section 2.06(b), all transfer, documentary, sales, use, stamp, registration and other similar Taxes and
fees imposed on the Company with respect to the transfer of Shares pursuant to the Offer or the Merger shall be borne by the Company and
expressly shall not be a liability of holders of Shares, expressly excluding any such Taxes imposed on the holders of Shares under applicable
Legal Requirements relating to Taxes. The Company shall cooperate with Purchaser and Parent in preparing, executing and filing any Tax
Returns with respect to such Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.09.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Notices</I></FONT>. Any
notice or other communication required or permitted to be delivered to any Party under this Agreement shall be in writing and shall be
deemed properly delivered, given and received (a) upon receipt when delivered by hand, (b) two (2) business days after being sent by registered
mail or by courier or express delivery service, or (c) upon confirmation of successful transmission if sent by email followed up within
one (1) business day by dispatch pursuant to one of the other methods described herein; <I>provided</I>, that in each case the notice
or other communication is sent to the physical address or email address set forth beneath the name of such Party below (or to such other
physical address or email address as such Party shall have specified in a written notice given to the other Parties):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">if to Parent or Purchaser (or following the Effective
Time, the Surviving Corporation):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Gilead Sciences, Inc.<BR>
333 Lakeside Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Foster City, CA 94404</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: General Counsel<BR>
Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">with a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Ropes &amp; Gray LLP<BR>
Prudential Tower<BR>
800 Boylston Street<BR>
Boston, MA 02199<BR>
Attention: Emily J. Oldshue; Nicholas C.H. Roper<BR>
Email: emily.oldshue@ropesgray.com; nicholas.roper@ropesgray.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">if to the Company (prior to the Effective Time):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Arcellx, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">800 Bridge Parkway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Redwood City, CA 94065</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: General Counsel &amp; Chief Legal Officer<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">with a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">One Market Plaza, Spear Tower, Suite 3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">San Francisco, California 94105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Robert Ishii; Ross Tanaka</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: rishii@wsgr.com; rtanaka@wsgr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Wilson Sonsini Goodrich&#8239;&amp; Rosati, Professional Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">12235 El Camino Real</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">San Diego, California 92130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Dan Koeppen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: dkoeppen@wsgr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Severability</I></FONT>.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or
provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power
to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior
sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision
that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Obligation of Parent</I></FONT>.
Parent shall ensure that Purchaser duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities
applicable to Purchaser under this Agreement, and Parent shall be jointly and severally liable with Purchaser for the due and timely performance
and satisfaction of each of said covenants, obligations and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; text-transform: none"><I>Construction</I></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and
the neuter gender shall include masculine and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Parties have participated jointly in the negotiation and drafting of this Agreement and agree that any rule of construction
to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, shall not be deemed
to be terms of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo; The words &ldquo;hereof&rdquo;,
&ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. The words &ldquo;date hereof&rdquo; when used in this Agreement shall
refer to the date of this Agreement. The terms &ldquo;or&rdquo;, &ldquo;any&rdquo; and &ldquo;either&rdquo; are not exclusive. The word
&ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; shall mean the degree to which a subject or other thing extends, and such
phrase shall not mean simply &ldquo;if&rdquo;. The word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the
word &ldquo;shall&rdquo;. With respect to any grant of rights to, in or under any intellectual property, the word &ldquo;license&rdquo;
or &ldquo;licenses&rdquo; shall be deemed to include &ldquo;sublicense&rdquo; or &ldquo;sublicenses,&rdquo; as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The words &ldquo;made available to Parent&rdquo; and words of similar import refer to documents (i) posted to the &ldquo;Project
Rajah&rdquo; electronic data room hosted on Venue by DFIN on behalf of the Company prior to 11:59 p.m. Pacific Time one (1) calendar day
prior to the date hereof or (ii) delivered by the Company or its Representatives prior to 11:59 p.m. Pacific Time one (1) calendar day
prior to the date hereof in person or electronically to Parent or Purchaser or their respective Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as otherwise indicated, all references in this Agreement to &ldquo;Sections,&rdquo; &ldquo;Exhibits&rdquo; or &ldquo;Annexes&rdquo;
are intended to refer to Sections of this Agreement and Exhibits or Annexes to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The term &ldquo;dollars&rdquo; and character &ldquo;$&rdquo; shall mean United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified.
Except with respect to Section 9.12(d), if any action is to be taken or given on or by a particular calendar day, and such calendar day
is not a business day, then such action may be deferred until the next business day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All accounting terms used and not defined herein shall have the respective meanings given to them under GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All terms defined in this Agreement shall have the defined meanings when used in any document made or delivered pursuant hereto
unless otherwise defined herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>References herein to any statute includes all rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any statute defined or referred to herein means such statute as from time to time amended, modified or supplemented, including
by succession of comparable successor statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Parties have caused
this Agreement to be executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>ARCELLX, INC.</B></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 47%">/s/ Rami Elghandour</TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Name: Rami Elghandour</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Title: Chief Executive Officer</TD>
    <TD>&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>GILEAD SCIENCES, INC.</B></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt">/s/ Daniel O&rsquo;Day</TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Name: Daniel O&rsquo;Day</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Title: Chairman and CEO</TD>
    <TD>&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>RAVENS SUB, INC.</B></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt">/s/ Andrew Dickinson</TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Name: Andrew Dickinson</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">Title: President and Treasurer</TD>
    <TD>&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certain Definitions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of the Agreement (including this Exhibit
A):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Acceptable Confidentiality Agreement</B>&rdquo;
shall mean any customary binding, written confidentiality agreement that is (a) in effect as of the execution and delivery of this Agreement
or (b) executed, delivered and effective after the execution and delivery of this Agreement and, in respect of such confidentiality agreement
contemplated by this clause (b), (i) contains provisions that are not less favorable in the aggregate to the Company than those contained
in the Confidentiality Agreement (it being understood that such agreement need not contain any &ldquo;standstill&rdquo; or similar provisions
or otherwise prohibit the making of any Acquisition Proposal) and (ii) does not prohibit the Company from providing any information to
Parent in accordance with Section 5.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Acquired Companies</B>&rdquo; shall mean
the Company and each of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Acquisition Proposal</B>&rdquo; shall
mean any proposal or offer from any Person (other than Parent and its Affiliates) or &ldquo;group&rdquo;, within the meaning of Section
13(d) of the Exchange Act, including any amendment or modification to any existing proposal or offer, relating to, in a single transaction
or series of related transactions, any (i) acquisition or license of assets of the Acquired Companies equal to 20% or more of the Acquired
Companies&rsquo; consolidated assets, (ii) acquisition or exclusive license of the Product Candidates, (iii) issuance or acquisition of
20% or more of the outstanding Company Common Stock or 20% or more of any class of equity securities of one or more Acquired Companies
whose assets, individually or in the aggregate, constitute 20% or more of the consolidated assets of the Acquired Companies, (iv) recapitalization,
tender offer or exchange offer that if consummated would result in any Person or group beneficially owning 20% or more of the outstanding
Company Common Stock or 20% or more of any class of equity securities of one or more Acquired Companies whose assets, individually or
in the aggregate, constitute 20% or more of the consolidated assets of the Acquired Companies or (v) merger, consolidation, amalgamation,
share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving the Company that if
consummated would result in any Person or group beneficially owning 20% or more of the outstanding Company Common Stock or 20% or more
of any class of equity securities of one or more Acquired Companies whose assets, individually or in the aggregate, constitute 20% or
more of the consolidated assets of the Acquired Companies, in each case other than the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo; shall mean, as to
any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common control with, such Person.
For this purpose, &ldquo;control&rdquo; (including, with its correlative meanings, &ldquo;controlled by&rdquo; and &ldquo;under common
control with&rdquo;) shall mean the possession, directly or indirectly, of the power to direct or cause the direction of management or
policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by Contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo; is defined in the
preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Anti-Corruption Laws</B>&rdquo; shall
mean the Foreign Corrupt Practices Act of 1977, as amended, the Anti-Kickback Act of 1986, as amended, the UK Bribery Act of 2010, or
any applicable Legal Requirements of similar effect, and the related regulations and published interpretations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Antitrust Laws</B>&rdquo; shall mean
the Sherman Antitrust Act of 1890, as amended, the Clayton Antitrust Act of 1914, as amended, the HSR Act, the Federal Trade Commission
Act of 1914, as amended, all applicable foreign antitrust laws and all other applicable Legal Requirements issued by a Governmental Body
that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of
trade or lessening of competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Assigned Leased Real Property</B>&rdquo;
means the real property formerly leased by the Company located at 25 West Watkins Mill Road, Gaithersburg, Maryland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Assigned Real Property Lease</B>&rdquo;
shall mean each lease, sublease, license, or occupancy agreement, and any amendment thereto or guaranty thereof, relating to the Assigned
Leased Real Property, together with any assignment of lease or consent to assignment, relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Board of Directors</B>&rdquo; is defined
in Recital (C) to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>business day</B>&rdquo; shall mean any
day other than (a) a Saturday, Sunday or any other day on which banking institutions in New York, New York or Foster City, California
are authorized or required by Legal Requirements to remain closed, (b) December 26 through December 31, and (c) the seven (7)-day period
that begins on a Sunday and ends on a Saturday during which period July 4 occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Capitalization Date</B>&rdquo; is defined
in Section 3.03(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Census</B>&rdquo; is defined in Section
3.18(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Change of Control Payment</B>&rdquo;
is defined in Section 3.11(a)(ix) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Closing</B>&rdquo; is defined in Section
2.03(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Closing Amount</B>&rdquo; is defined
in Recital (A) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo; is defined in
Section 2.03(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>CMS</B>&rdquo; is defined in Section
6.02(d) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo; shall mean the Internal
Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Collaboration Agreement</B>&rdquo; is
defined in Section 5.02(b)(x) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Collaboration Partner</B>&rdquo; is defined
in Section 3.14(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo; is defined in the
preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Adverse Change Recommendation</B>&rdquo;
is defined in Section 6.01(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Associate</B>&rdquo; shall mean
each current and former officer or other employee, or individual who is or was at any time an independent contractor, consultant or director,
of or to any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Board Recommendation</B>&rdquo;
is defined in Recital (C) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Common Stock</B>&rdquo; shall
mean the common stock, $0.001 par value per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Disclosure Documents</B>&rdquo;
is defined in Section 3.05(g) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Disclosure Letter</B>&rdquo;
shall mean the disclosure schedule that has been prepared by the Company in accordance with the requirements of the Agreement and that
has been delivered by the Company to Parent on the date of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Equity Plans</B>&rdquo; shall
mean the Arcellx, Inc. 2022 Equity Incentive Plan and the Arcellx, Inc. 2017 Equity Incentive Plan, in each case, as may be amended from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company ESPP</B>&rdquo; shall mean the
Amended and Restated Arcellx, Inc. 2022 Employee Stock Purchase Plan, as may be further amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company IP</B>&rdquo; shall mean any
and all Intellectual Property Rights owned by, or purported to be owned by, any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company IT Assets</B>&rdquo; shall mean
computers, computer software, firmware, middleware, servers, workstations, routers, hubs, switches, data communications lines and all
other information technology equipment, systems and Software, and all associated documentation, owned by any Acquired Company or licensed,
leased or otherwise used by any Acquired Company (excluding any public networks).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Licensed IP</B>&rdquo; shall
mean any and all (a) Intellectual Property Rights owned by a third party and exclusively licensed to, or purported to be exclusively licensed
to, any Acquired Company relating to any Product Candidate (including the exploitation thereof) or (b) Intellectual Property Rights owned
by a third party, non-exclusively licensed to any Acquired Company and material to the business of such Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Option</B>&rdquo; shall mean
an option to purchase Shares (whether granted by the Company pursuant to a Company Equity Plan, assumed by the Company in connection with
any merger, acquisition or similar transaction or otherwise issued or granted).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Preferred Stock</B>&rdquo; shall
mean the preferred stock, $0.001 par value per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Related Parties</B>&rdquo; is
defined in Section 8.03(d) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Returns</B>&rdquo; is defined
in Section 3.17(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company RSU</B>&rdquo; shall mean a restricted
stock unit with respect to Company Common Stock (whether granted by the Company pursuant to a Company Equity Plan, assumed by the Company
in connection with any merger, acquisition or similar transaction or otherwise issued or granted and whether subject to time- or performance-based
vesting).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company SEC Documents</B>&rdquo; is defined
in Section 3.05(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Transfer Agent</B>&rdquo; is
defined in Section 2.06(b)(i) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Confidentiality Agreement</B>&rdquo;
is defined in Section 5.01(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Consent</B>&rdquo; shall mean any approval,
consent, ratification, permission, waiver or authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Continuation Period</B>&rdquo; is defined
in Section 6.03(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Continuing Employees</B>&rdquo; is defined
in Section 6.03(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Contract</B>&rdquo; shall mean any written,
oral or other binding agreement, contract, subcontract, lease, settlement agreement, understanding, instrument, loan, credit agreement,
bond, debenture, note, option, warrant, warranty, purchase order, license, sublicense, commitment or undertaking to the extent in force
and effect or that otherwise has not expired, terminated or been amended, restated or replaced prior to the date hereof, but shall not
include any Employee Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Copyrights</B>&rdquo; is defined in the
definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Country of Concern</B>&rdquo; or &ldquo;<B>Countries
of Concern</B>&rdquo; shall mean the People&rsquo;s Republic of China (including Hong Kong and Macau), Cuba, Iran, North Korea, Russia,
and Venezuela, including in each case any political subdivision, agency, or instrumentality thereof, and any other country designated
as a &ldquo;Country of Concern&rdquo; pursuant to the process set forth in 28 CFR Part 202.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Covered Person</B>&rdquo; shall mean
any Person that (i) is located in, organized or chartered under the laws of, has its principal place of business in, is ordinarily a resident
in, or is 50% or more owned or controlled, directly or indirectly, by entities or persons located in, organized or chartered under the
laws of, or having their principal place of business in, a Country of Concern or (ii) is a Covered Person, including without limitation
through designation as such by the U.S. Attorney General pursuant to the process set forth in 28 CFR Part 202.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>CVR</B>&rdquo; is defined in Recital
(A) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>CVR Agreement</B>&rdquo; means the Contingent
Value Rights Agreement between Parent and the Rights Agent, in substantially the form attached hereto as Annex III (subject to changes
permitted by&nbsp;Section 6.12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Delaware Courts</B>&rdquo; is defined
in Section 9.05(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Delisting Period</B>&rdquo; is defined
in Section 6.11 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Depository Agent</B>&rdquo; is defined
in Section 2.06(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Determination Notice</B>&rdquo; is defined
in Section 6.01(b)(i) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>DGCL</B>&rdquo; shall mean the Delaware
General Corporation Law, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Disclosing Party</B>&rdquo; is defined
in Section 6.02(f) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Dissenting Shares</B>&rdquo; is defined
in Section 2.07 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>DOJ</B>&rdquo; shall mean the U.S. Department
of Justice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>DOJ Final Rule</B>&rdquo; shall mean
the final rule promulgated by the DOJ titled &ldquo;Preventing Access to U.S. Sensitive Personal Information and Government-Related Data
by Countries of Concern or Covered Persons,&rdquo; 90 Fed. Reg. 1636 (Jan. 8, 2025) codified at 28 C.F.R. &sect; 202, including any amendments
thereto and guidance issued thereunder.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>DTC</B>&rdquo; is defined in Section
2.06(b)(ii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Effective Time</B>&rdquo; is defined
in Section 2.03(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>EMA</B>&rdquo; is defined in Section
3.14(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Employee Plan</B>&rdquo; shall mean each
deferred compensation and each bonus, commission or other incentive compensation, stock purchase, stock option and other equity and equity-linked
compensation plan, program, agreement, policy or arrangement; each severance or termination pay, medical, surgical, hospitalization, life
insurance, disability, paid time off and other &ldquo;welfare&rdquo; plan, fund or program (within the meaning of section 3(1) of ERISA
(whether or not subject to ERISA)); each profit sharing, stock bonus, retirement, or other &ldquo;pension&rdquo; plan, fund or program
(within the meaning of section 3(2) of ERISA (whether or not subject to ERISA)); each employment, individual consulting, termination,
severance, transaction, gross-up, change in control, retention or similar agreement; and each other employee benefit plan, fund, program,
policy, agreement or arrangement, in each case, that is sponsored, maintained or contributed to, or required to be contributed to, by
any Acquired Company or by any trade or business, whether or not incorporated, that together with any Acquired Company would be deemed
a &ldquo;single employer&rdquo; within the meaning of Section 4001(b) of ERISA or Section 414 of the Code (an &ldquo;<B>ERISA Affiliate</B>&rdquo;),
or to which an Acquired Company or an ERISA Affiliate is party, whether written or oral, for the benefit of any current or former employee
or other service provider of any Acquired Company or to which any Acquired Company or any of its ERISA Affiliates (or could be reasonably
expected to have any) has any direct or indirect liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Employment Laws</B>&rdquo; is defined
in Section 3.18(c) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Encumbrance</B>&rdquo; shall mean any
lien, pledge, charge, hypothecation, mortgage, security interest, encumbrance, claim, option, right of first refusal, right of first negotiation,
preemptive right, community property interest or similar restriction of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>End Date</B>&rdquo; is defined in Section
8.01(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Entity</B>&rdquo; shall mean any corporation
(including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate,
trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise,
association, organization or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Environmental Law</B>&rdquo; shall mean
any federal, state, local or foreign Legal Requirement relating to pollution or protection of worker health (as it relates to exposure
to Hazardous Materials) or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including
any Legal Requirement relating to emissions, discharges, Releases or threatened Releases of Hazardous Materials, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo; shall mean the Employee
Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>ERISA Affiliate</B>&rdquo; is defined
in the definition of Employee Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>ESPP Offering Period</B>&rdquo; is defined
in Section 2.08(d) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo; shall mean the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Excluded Benefits</B>&rdquo; is defined
in Section 6.03(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Expiration Date</B>&rdquo; is defined
in Section 1.01(c) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Extension Deadline</B>&rdquo; is defined
in Section 1.01(c) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>FDA</B>&rdquo; shall mean the United
States Food and Drug Administration or any successor agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>FDCA</B>&rdquo; shall mean the Federal
Food, Drug and Cosmetic Act, as amended, and all related rules, regulations and guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Federal Health Care Program</B>&rdquo;
shall have the meaning set forth in 42 U.S.C. 1320a-7b(f), including but not limited to Medicare, Medicaid, TRICARE, CHAMPVA, any state
health plan adopted pursuant to Title XIX of the Social Security Act (42 U.S.C. 1395 et seq.), any health insurance program for the benefit
of federal employees, including those under chapter 89 of title 5, United States Code, and any other state or federal health care program
administered by a Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Financial Advisor</B>&rdquo; is defined
in Section 3.24 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Foreign Investment Laws</B>&rdquo; shall
mean all applicable Legal Requirements issued by any Governmental Body that are designed or intended to screen, regulate, restrict, or
review foreign direct investment in, or foreign acquisitions of, domestic entities or assets, including for reasons relating to national
security, public order, critical infrastructure, strategic technologies, or other public interest considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>FTC</B>&rdquo; shall mean the U.S. Federal
Trade Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo; is defined in Section
3.05(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Good Clinical Practices</B>&rdquo; shall
mean the FDA&rsquo;s standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical
trials, including those standards contained in 21 C.F.R. Parts 11, 50, 54, 56, and 312 and all comparable standards of the EMA and any
other Specified Governmental Body, including but not limited to the International Council for Harmonization&rsquo;s Guideline for Good
Clinical Practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Good Laboratory Practices</B>&rdquo;
shall mean the FDA&rsquo;s standards for conducting non-clinical laboratory studies, including those standards contained in 21 C.F.R.
Part 58, the United States Animal Welfare Act, and all comparable standards of the EMA and any other Specified Governmental Body, including
but not limited to the International Council for Harmonisation&rsquo;s Guideline on Nonclinical Safety Studies for the Conduct of Human
Clinical Trials for Pharmaceuticals and the International Council for Harmonisation&rsquo;s Guideline on Safety Pharmacology Studies for
Human Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Good Manufacturing Practices</B>&rdquo;
shall mean the FDA&rsquo;s standards for manufacturing pharmaceutical or biological products, including those standards contained in 21
C.F.R. Parts 210, 211, 600, 601, and 610, and all comparable Legal Requirements, including standards of the EMA and any other Specified
Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Good Tissue Practices</B>&rdquo; shall
mean the FDA&rsquo;s standards for manufacturing and processing human cells, tissues, and cellular and tissue-based products, including
those standards contained in 21 C.F.R. Part 1271, and all comparable Legal Requirements, including standards of the EMA and any other
Specified Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Governmental Authorization</B>&rdquo;
shall mean any: permit, license, certificate, approval, consent, grant, franchise, permission, clearance, registration, qualification,
waiver, exemption or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body
or pursuant to any Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Governmental Body</B>&rdquo; shall mean
any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii) federal,
state, administrative, local, municipal, foreign, international, multinational, supranational or other government; or (iii) governmental
or quasi-governmental authority of any nature including any governmental division, department, agency, commission, instrumentality, official,
ministry, fund, foundation, center, organization, unit or body and any court, arbitrator or other tribunal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Hazardous Materials</B>&rdquo; shall
mean any substance defined or regulated as a hazardous or toxic substance, material or waste or as a pollutant or contaminant, or words
of similar intent or meaning, pursuant to any Environmental Law, and includes asbestos, mold, radioactive material, polychlorinated biphenyls,
per- and polyfluoroalkyl substances, petroleum or petroleum-derived substance or waste.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Health Care Laws</B>&rdquo; shall mean
all Legal Requirements applicable to the pricing, reimbursement, safety, efficacy, approval, development, testing, research, labeling,
manufacture, storage, marketing, promotion, sale, commercialization, import, export or distribution of pharmaceutical or biological products
or otherwise applicable to the operation of the Acquired Companies&rsquo; businesses as currently conducted and as contemplated by the
Acquired Companies to be conducted, including (i) the FDCA, PHSA and the regulations promulgated thereunder, including but not limited
to those requirements relating to the FDA&rsquo;s current Good Manufacturing Practices, Good Tissue Practices, Good Laboratory Practices,
Good Clinical Practices, investigational use, pre-market approval and applications to market new pharmaceutical or biological products;
(ii) the anti-fraud provisions of HIPAA; (iii) the U.S. Patient Protection and Affordable Care Act; (iv) the U.S. Physician Payments Sunshine
Act (42 U.S.C. &sect; 1320a-7h) and state or local Legal Requirements regulating or requiring reporting of interactions between pharmaceutical
manufacturers and members of the health care industry and regulations promulgated thereunder; (v) health care fraud and abuse laws, including
but not limited to federal and state anti-kickback laws (including the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320-7(b))), the
federal Beneficiary Anti-Inducement Statute (42 U.S.C. &sect; 1320a-7a(a)(5)), the Civil Monetary Penalties Law (42 U.S.C. &sect;&sect;
1320a-7a and 1320a-8), the U.S. Federal False Claims Act (31 U.S.C. &sect; 3729 <I>et seq</I>.), and, with respect to each of the foregoing,
similar state or local statutes or regulations; (vi) Titles XVIII (42 U.S.C. &sect;1395 et seq.) and XIX (42 U.S.C. &sect;1396 et seq.)
of the Social Security Act and the regulations promulgated thereunder and any other Legal Requirements pertaining to or governing a governmental
health care program, and the regulations promulgated thereunder; (vii) the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003 (42 U.S.C. &sect;1395w-101 et seq.) and the regulations promulgated thereunder; (viii) Legal Requirements governing government
pricing or price reporting programs and regulations promulgated thereunder, including the Medicaid Drug Rebate Program (42 U.S.C. &sect;
1396r-8) and any state supplemental rebate program, the PHSA, the VA Federal Supply Schedule (38 U.S.C. &sect; 8126) or any state pharmaceutical
assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs; (ix) Legal Requirements governing
the development, conduct, monitoring, patient informed consent, auditing, analysis and reporting of clinical trials (including the Good
Clinical Practice regulations and binding guidance of the FDA); (x) Legal Requirements governing data gathering activities relating to
the detection, assessment, and understanding of adverse events (including pharmacovigilance and adverse event regulations and binding
guidance of FDA and the International Conference on Harmonization); (xi) any Legal Requirement the violation of which is cause for exclusion
from any federal health care program, as such term is defined at 42 U.S.C. &sect; 1320a-7b(f); (xii) all comparable state, federal or
ex-U.S. Legal Requirements relating to any of the foregoing; and (xiii) any rules, regulations, and legally binding directives or binding
guidance promulgated or issued pursuant to such Legal Requirements; and as each of the foregoing may be amended from time to time. Health
Care Laws do not include Privacy Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>HIPAA</B>&rdquo; shall mean the Health
Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act (Title XIII
of the American Recovery and Reinvestment Act of 2009) as set forth at 42 USC &sect; 17931 et seq., as may be amended, and their implementing
regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>HSR Act</B>&rdquo; shall mean the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>In-bound License</B>&rdquo; shall mean
any and all Contracts to which any Acquired Company is a party, or by which it is bound, pursuant to which any Acquired Company is granted
any license, non-assert, option, or other right to use, register, or enforce any Intellectual Property Right that is material to the operation
of the business any Acquired Company, and that is in effect as of the date of this Agreement. Without limiting the foregoing, any agreement
under which an Acquired Company is granted a license under any Intellectual Property Right that covers the making, having made, use, sale,
offer for sale or import of any Product Candidate will be deemed an In-bound License. Notwithstanding the foregoing, &ldquo;In-bound License&rdquo;
excludes personnel agreements, licenses to IT, ERP or accounting systems and commercially available software agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Indebtedness</B>&rdquo; shall mean (i)
any indebtedness for borrowed money (including the issuance of any debt security) to any Person, including all liabilities under any lease
which has been recorded as a capital lease, (ii) any obligations evidenced by notes, bonds, debentures or similar Contracts to any Person
other than any Acquired Company, (iii) any obligations in respect of letters of credit (including standby and commercial) and bankers&rsquo;
acceptances (other than letters of credit used as security for leases), bank guarantees, surety bonds and similar instruments, in each
case to the extent drawn upon, including the principal, interest and fees owing thereon, (iv) all indebtedness created or arising under
any conditional sale or other title retention agreement with respect to property acquired or deferred purchase price of property or services
(other than trade accounts payable in the ordinary course), (v) net obligations of any interest rate, swap, currency swap, forward currency
or interest rate Contracts or other interest rate or currency hedging arrangements, or (vi) any guaranty of any such obligations described
in clauses (i) through (v) of any Person other than any Acquired Company (other than, in any case, accounts payable to trade creditors
and accrued expenses, in each case, arising in the ordinary course of business consistent with past practice); <I>provided</I>, <I>however</I>,
that no agreements, understandings or other arrangements exclusively by and between the Company and its wholly owned Subsidiaries shall
be deemed to be Indebtedness for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Indemnified Persons</B>&rdquo; is defined
in Section 6.04(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Initial Expiration Date</B>&rdquo; is
defined in Section 1.01(c) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Intellectual Property Rights</B>&rdquo;
shall mean any and all intellectual property rights, however denominated, throughout the world and all rights associated therewith, including
all (i) issued patents and patent applications (e.g., provisional, non-provisional and PCT applications), all divisionals, continuations,
continuations in-part, or any other patent application directly or indirectly claiming priority to such patents or patent applications
and all patents issuing from any of the foregoing anywhere in the world, together with all registrations, reissues, re-examinations, patents
of addition, utility model or design rights or other industrial property rights, renewals, supplemental protection certificates, inventor&rsquo;s
certificates, restorations, patent term adjustments, or extensions of any of the foregoing and counterparts thereof anywhere in the world,
including all rights to claim priority therefrom (&ldquo;<B>Patents</B>&rdquo;), (ii) trademarks, service marks, designs, trade dress,
logos, slogans, trade names, Internet domain names (including all intellectual property addresses identified via a name format and generic
top-level domains (gTLDs) and country code top-level domains (ccTLDs)), domain names, uniform resource locators, corporate names, doing
business designations and all other indicia of origin, together with all translations, adaptations, derivations and combinations thereof,
and all social media, including accounts and handles associated therewith and all applications for registration, registrations and renewals
of any of the foregoing and all goodwill associated therewith (&ldquo;<B>Trademarks</B>&rdquo;), (iii) all inventions (and disclosures
thereof), discoveries, commercial, technical, scientific and other know-how and information, proprietary rights in clinical, technical,
scientific, manufacturing, regulatory and other information, knowledge, technology, methods, processes, practices, formulae, formulations,
instructions, skills, techniques, procedures, experiences, technical or proprietary data, including test data, test or proprietary database
results, technical or proprietary data collections, plans, recipes, reports, ideas, technical assistance, designs, drawings, assembly
procedures, computer programs, apparatuses, assays and biological methodology, compositions, specifications, data and results (including
biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, laboratory, preclinical, clinical, safety,
manufacturing and quality control data and know-how, marketing, pricing, distribution, cost and sales information, including regulatory
data, study designs, protocols, laboratory notes and notebooks), in all cases, whether or not confidential, proprietary, patented or patentable,
in written, electronic or any other form now known or hereafter developed, including all intellectual property rights therein, (iv) copyrights
in copyrightable subject matter (&ldquo;<B>Copyrights</B>&rdquo;), (v) software, including source code, object code, algorithms, machine
learning, executable code, systems, network tools, technical or proprietary data, technical or proprietary databases, applications, firmware
(&ldquo;<B>Software</B>&rdquo;) and all related documentation, including all intellectual property rights therein, (vi) trade secrets
or rights in confidential information or know-how (&ldquo;<B>Trade Secrets</B>&rdquo;), (vii) all applications and registrations for any
of the foregoing, (viii) all other intellectual property and proprietary rights and all rights associated therewith in any jurisdiction
in the world (including all rights to collect royalties, products and proceeds in connection with any of the foregoing, and to sue and
bring other claims for past, present or future infringement, misappropriation or other violation of any of the foregoing, and to recover
damages (including attorneys&rsquo; fees and expenses) and lost profits in connection therewith) and (ix) all copies and tangible embodiments
of any of the foregoing (in whatever form or medium). Intellectual Property Rights do not include Personal Data, but, for clarity, do
include know-how relating thereto, including inferences, assumptions and conclusions that can be made based on the use of Personal Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Intervening Event</B>&rdquo; shall mean
an event, occurrence, fact or change that materially affects the business, assets or operations of the Acquired Companies (other than
any event, occurrence, fact or change resulting from a breach of this Agreement by the Company) occurring or arising after the date hereof
that was not known or reasonably foreseeable to the Board of Directors as of the date hereof, which event, occurrence, fact or change
becomes known to the Board of Directors prior to the Offer Acceptance Time, other than (i) changes in the Company Common Stock price,
in and of itself (however, the underlying reasons for such changes may constitute an Intervening Event), (ii) any Acquisition Proposal
or (iii) the fact that, in and of itself, the Company exceeds any internal or published projections, estimates or expectations of the
Company&rsquo;s revenue, earnings or other financial performance or results of operations for any period, in and of itself (however, the
underlying reasons for such events may constitute an Intervening Event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>IRS</B>&rdquo; shall mean the Internal
Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>knowledge</B>&rdquo; with respect to
an Entity shall mean with respect to any matter in question the actual knowledge, after reasonable inquiry, of such Entity&rsquo;s executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Leased Real Property</B>&rdquo; means
all real property leased, subleased, licensed or otherwise occupied by any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Legal Proceeding</B>&rdquo; shall mean
any action, suit, complaint, litigation, mediation, arbitration, enforcement action or investigation, or any administrative proceeding
(including any civil, criminal, administrative, investigative or appellate proceeding) commenced, brought, conducted or heard by or before,
or otherwise involving, any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Legal Requirement</B>&rdquo; shall mean
any federal, state, local, municipal, foreign, international, multinational, supranational, or other law, statute, constitution, resolution,
ordinance, common law, code, edict, decree, rule, regulation, ruling, treaty, order or requirement issued, enacted, adopted, promulgated,
implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of Nasdaq or other
stock exchange).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Licensed Registered IP</B>&rdquo; shall
mean all Registered IP licensed to, or purported to be licensed to, or to which rights are otherwise granted to, or purported to be granted
to, any Acquired Company on an exclusive basis or that are otherwise material to the business of any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Material Adverse Effect</B>&rdquo; shall
mean any change, circumstance, condition, development, effect, event, occurrence or state of facts which, individually or when taken together
with all other events, occurrences, circumstances, changes, conditions, states of facts, developments or effects that have occurred in
the applicable determination period for a Material Adverse Effect, has had or would reasonably be expected to have a material adverse
effect on (a) the ability of the Acquired Companies to consummate the Offer or the Merger on or before the End Date or (b) the business,
assets, financial condition or results of operations of the Acquired Companies, taken as a whole; <I>provided</I>, <I>however</I>, that
no change, circumstance, condition, development, effect, event, occurrence or state of facts to the extent resulting from or relating
to any of the following shall be deemed to constitute or be taken into account in determining whether there is, or would reasonably be
expected to be, a Material Adverse Effect for purposes of clause (b) above: (i) any change in the market price or trading volume of the
Company&rsquo;s stock or change in the Company&rsquo;s credit ratings; <I>provided</I>, <I>however</I>, that the underlying causes of
any such change may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by
another exception herein; (ii) any event, occurrence, circumstance, change or effect resulting from the announcement, pendency or performance
of this Agreement or the consummation of the Transactions, in each case of the foregoing including the impact thereof on relationships,
contractual or otherwise, with customers, suppliers, distributors or partners, or any litigation arising from this Agreement or the Transactions,
in each case of the foregoing, other than for purposes of any representation or warranty contained in Section 3.23 and the condition set
forth in clause (b)(iv) of Annex I solely as such condition relates to Section 3.23, but in any event subject to the disclosures set forth
in the Company Disclosure Letter; (iii) any event, occurrence, circumstance, change or effect generally affecting the industries in which
the Acquired Companies operate, or in the economy generally or other general business, financial or market conditions; (iv) any event,
occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to fluctuations in the value of any
currency or interest rates; (v) any change, circumstance, condition, development, effect, event, occurrence or state of facts arising
directly or indirectly from or otherwise relating to any act of terrorism (including cyber-terrorism), war (whether or not declared),
national or international calamity, natural disaster, pandemic, epidemic or disease outbreak or any other similar event; (vi) the failure
of the Company to meet internal or analysts&rsquo; expectations or projections; <I>provided</I>, <I>however</I>, that the underlying causes
of such failure may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by
another exception herein; (vii) any adverse effect arising directly from or otherwise directly relating to any action taken or omitted
to be taken by the Company at the written direction of Parent or where the Company has requested Parent&rsquo;s consent in accordance
with &lrm;&lrm;Section 5.02 and Parent has unreasonably withheld, conditioned or delayed such consent; or (viii) any change, circumstance,
condition, development, effect, event, occurrence or state of facts arising directly or indirectly from or otherwise relating to a change
in, or action taken required to comply with any change in any Legal Requirement or GAAP; (ix) any event, occurrence, circumstance, change
or effect resulting or arising from the identity of Parent or Purchaser as the acquiror of the Company; (x) any commercial, regulatory,
clinical or manufacturing events, occurrences, circumstances, changes, effects or developments relating to any Product Candidate, in each
case, not involving any wrongdoing by any Acquired Company or any of their respective Affiliates or Representatives, or with respect to
any product of any competitor of the Company (including, in each case, for the avoidance of doubt, with respect to any pre-clinical or
clinical studies, tests or results or announcements thereof, any increased incidence or severity of any previously identified side effects,
adverse effects, adverse events or safety observations or reports of new side effects, adverse events or safety observations); <I>provided</I>
that the underlying causes of any such change may be considered in determining whether a Material Adverse Effect has occurred to the extent
not otherwise excluded by another exception herein; or (xi) any action taken by Parent or its Affiliates in its or their capacity as a
collaboration partner of the Acquired Companies, or pursuant to any requirement of the Collaboration Agreement; <I>provided</I>, <I>however</I>,
that any change, circumstance, condition, development, effect, event, occurrence or state of facts referred to in the foregoing clauses
(iii), (iv), (v) and (viii) may be taken into account in determining whether there is, or would be reasonably expected to be, a Material
Adverse Effect to the extent such change, circumstance, condition, development, effect, event, occurrence or state of facts disproportionately
affects the Acquired Companies relative to other participants in the industries in which the Acquired Companies operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Material Contract</B>&rdquo; is defined
in Section 3.11(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Maximum Amount</B>&rdquo; is defined
in Section 6.04(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Merger</B>&rdquo; is defined in Recital
(B) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Merger Consideration</B>&rdquo; is defined
in Section 2.05(a)(iv) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Minimum Condition</B>&rdquo; is defined
in Annex I to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Nasdaq</B>&rdquo; shall mean The Nasdaq
Stock Market LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>NIH Policy</B>&rdquo; shall mean the
NIH Policy on Enhancing Security Measures for Human Biospecimens; (NOT-OD-25-160).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer</B>&rdquo; is defined in Recital
(A) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer Acceptance Time</B>&rdquo; is defined
in Section 1.01(h) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer Commencement Date</B>&rdquo; shall
mean the date on which Purchaser commences the Offer, within the meaning of Rule 14d-2 under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer Conditions</B>&rdquo; is defined
in Section 1.01(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer Documents</B>&rdquo; is defined
in Section 1.01(e) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer Price</B>&rdquo; is defined in
Recital (A) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Offer to Purchase</B>&rdquo; is defined
in Section 1.01(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Out-bound License</B>&rdquo; shall mean
any and all Contracts to which any Acquired Company is a party, or by which it is bound, pursuant to which any Acquired Company grants
any license, non-assert, option, or other right (including any right to use, register, or enforce) to, or assigned, sold, conveyed or
otherwise transferred any right in, to, or under, any material Intellectual Property Rights, to any third party, and that remains in effect
as of the date of this Agreement. Notwithstanding the foregoing, &ldquo;Out-bound License&rdquo; excludes agreements entered into in the
ordinary course of business consistent with past practice that are not material to the business of any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Owned Registered IP</B>&rdquo; shall
mean all Registered IP owned by, or purported to be owned by, any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>PADFAA</B>&rdquo; shall mean the Protecting
Americans&rsquo; Data from Foreign Adversaries Act of 2024; Pub. Law. No. 118-50(I).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Parent</B>&rdquo; is defined in the preamble
to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Parent Material Adverse Effect</B>&rdquo;
shall mean any change, circumstance, condition, development, effect, event, occurrence or state of facts which, individually or when taken
together with all other events, occurrences, circumstances, changes, conditions, states of facts, developments or effects that have occurred
in the applicable determination period for a Parent Material Adverse Effect, would or would reasonably be expected to materially impair,
prevent or materially delay Parent&rsquo;s or Purchaser&rsquo;s ability to consummate the Transactions prior to the End Date on the terms
set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Parent Related Parties</B>&rdquo; is
defined in Section 8.03(c) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Parties</B>&rdquo; shall mean Parent,
Purchaser and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Patents</B>&rdquo; is defined in the
definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Paying Agent</B>&rdquo; is defined in
Section 2.06(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Payment Fund</B>&rdquo; is defined in
Section 2.06(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Permitted Encumbrance</B>&rdquo; shall
mean (a) any Encumbrance for Taxes (i) that are not delinquent or (ii) the validity of which is being contested in good faith by appropriate
proceedings and for which adequate reserves have been established in accordance with GAAP in the Company&rsquo;s latest financial statements
included in the Company SEC Documents, (b) mechanics&rsquo;, materialmen&rsquo;s, carriers&rsquo;, workmen&rsquo;s, warehouseman&rsquo;s,
repairmen&rsquo;s, landlords&rsquo; and similar liens granted or which arise in the ordinary course of business consistent with past practice,
(c) in the case of real property, Encumbrances imposed on the underlying fee interest in real property subject to a Real Property Lease,
Encumbrances of record, easements, rights-of-way, encroachments, restrictions, conditions and other similar Encumbrances incurred or suffered
in the ordinary course of business consistent with past practice and which, individually or in the aggregate, do not and would not materially
impair the Company&rsquo;s use (or contemplated use) of the applicable real property or otherwise materially impair the present or contemplated
business operations at such location, or zoning, entitlement, building and other land use regulations imposed by Governmental Bodies having
jurisdiction over such real property, and Encumbrances that would otherwise be set forth on a title report, (d) in the case of Intellectual
Property Rights, non-exclusive licenses granted to use such Intellectual Property Rights in the ordinary course of business consistent
with past practice that are not material to the business of any Acquired Company and (e) in the case of any Contract, Encumbrances that
are restrictions against the transfer or assignment thereof that are included in the terms of such Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo; shall mean any individual,
Entity or Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Personal Data</B>&rdquo; shall mean any
data or information that is defined as or constitutes &ldquo;personal data,&rdquo; &ldquo;protected health information,&rdquo; &ldquo;personal
information,&rdquo; &ldquo;personally identifiable information,&rdquo; or a similar term, under the Privacy Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>PHSA</B>&rdquo; shall mean the United
States Public Health Service Act, 42 U.S.C. &sect; 201 et seq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Post-Closing SEC Reports</B>&rdquo; is
defined in Section 6.11 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Pre-Closing Period</B>&rdquo; is defined
in Section 5.01(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Privacy Requirements</B>&rdquo; shall
mean Legal Requirements, the Acquired Companies&rsquo; obligations under Contracts, self-regulatory standards and industry standards with
which the Acquired Companies are legally or contractually obligated to comply or with which they have publicly represented compliance,
or written policies or terms of use of the Acquired Companies, in each case with respect to the foregoing, to the extent regarding privacy,
information security, artificial intelligence, data protection applicable to the Processing of Sensitive Data by the Company and its Subsidiaries
(such Legal Requirements, &ldquo;<B>Privacy Laws</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Process</B>&rdquo; or &ldquo;<B>Processing</B>&rdquo;
shall mean any operation or set of operations which is performed on Personal Data, whether or not by automated means, such as the receipt,
access, acquisition, collection, recording, organization, compilation, sale, rental, structuring, storage, safeguarding, adaptation or
alteration, retrieval, consultation, use, disclosure by transfer, transmission, dissemination or otherwise making available, alignment
or combination, restriction, disposal, erasure or destruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Product Candidates</B>&rdquo; shall mean
all drug, pharmaceutical, biological, human cells, tissues, and cellular and tissue-based products, therapeutic or diagnostic products
and product candidates being developed, tested, labeled, manufactured, distributed, marketed, sold, stored or otherwise commercialized
by or on behalf of any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Purchaser</B>&rdquo; is defined in the
preamble to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Real Property Lease</B>&rdquo; shall
mean each lease, sublease, license, or occupancy agreement, and any amendment thereto or guaranty thereof, relating to the Leased Real
Property, including, without limitation, the Assigned Real Property Lease and Contracts relating to any outstanding tenant improvement
allowances payable under any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Receiving Party</B>&rdquo; is defined
in Section 6.02(f) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Registered IP</B>&rdquo; shall mean all
Patents, Trademarks (including, for clarity, domain names), Copyrights and other Intellectual Property Rights that are registered, filed
or issued under the authority of, with or by any Governmental Body or other intellectual property registrar, and all applications for
any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Release</B>&rdquo; shall mean any emission,
spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring, emptying, dumping, disposal, migration or release of Hazardous
Materials from any source into or upon the environment, including the air, soil, improvements, surface water, groundwater, the sewer,
septic system, storm drain, publicly owned treatment works, or waste treatment, storage, or disposal systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Representatives</B>&rdquo; shall mean
officers, directors, employees, attorneys, accountants, investment bankers, consultants, agents, financial advisors, other advisors and
other representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Rights Agent</B>&rdquo; means an agent
selected by Parent and reasonably acceptable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Sales Agreement</B>&rdquo; shall mean
that certain At-The-Market Equity Offering Sales Agreement, dated as of May 8, 2023, by and between the Company and Stifel, Nicolaus &amp;
Company, Incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Sarbanes-Oxley Act</B>&rdquo; is defined
in Section 3.05(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Schedule 14D-9</B>&rdquo; is defined
in Section 1.02(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo; shall mean the United
States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Securities Act</B>&rdquo; shall mean
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Security Breach</B>&rdquo; shall mean
any (i) unauthorized or unlawful acquisition of, access to, loss of, or misuse (by any means) of Sensitive Data in the possession or control
of the Acquired Companies, or any third-party service provider on behalf of the Acquired Companies, (ii) unauthorized or unlawful Processing
of Sensitive Data maintained by the Acquired Companies, or by any third-party service provider on behalf of the Acquired Companies, or
(iii) a phishing, ransomware, denial of service (DoS) or other cyberattack that results in a monetary loss or a significant business disruption
to the Acquired Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Sensitive Data</B>&rdquo; shall mean
all (i) Personal Data, (ii) Sensitive Personal Information, and (iii) other confidential or proprietary business, customer, or Trade Secret
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Sensitive Personal Information</B>&rdquo;
shall mean a set of sensitive personal information relating to U.S. persons, in any format, regardless of whether the data is anonymized,
pseudonymized, aggregated, de-identified, or encrypted, which consists of (1) covered personal identifiers, (2) precise geolocation data,
(3) biometric identifiers, (4) human omics data, (5) government-related data, (6) personal health data, (7) personal financial data, or
(8) any combination thereof, as each such term (1)-(8) are defined in the DOJ Final Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Shares</B>&rdquo; is defined in Recital
(A) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Software</B>&rdquo; is defined in the
definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Specified Agreement</B>&rdquo; is defined
in Section 8.01(e) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Specified Governmental Bodies</B>&rdquo;
is defined in Section 3.14(a) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Stockholder List Date</B>&rdquo; is defined
in Section 1.02(b) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Subsidiary</B>&rdquo; An Entity shall
be deemed to be a &ldquo;Subsidiary&rdquo; of another Person if such Person directly or indirectly owns, beneficially or of record, (i)
an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority
of the members of such Entity&rsquo;s board of directors or other governing body, or (ii) at least 50% of the outstanding equity or financial
interests of such Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Superior Offer</B>&rdquo; shall mean
a <I>bona fide </I>written Acquisition Proposal not solicited in violation of this Agreement that the Board of Directors determines, in
its good faith judgment, after consultation with outside legal counsel and its financial advisor, is reasonably likely to be consummated
in accordance with its terms, taking into account all legal, regulatory and financing aspects of the proposal and the Person making the
proposal and other aspects of the Acquisition Proposal that the Board of Directors deems relevant, and if consummated, would result in
a transaction more favorable to the Company&rsquo;s stockholders (solely in their capacity as such) from a financial point of view than
the Transactions (including after giving effect to proposals, if any, made by Parent pursuant to Section 6.01(b)(i)); <I>provided</I>,
<I>however</I>, that for purposes of the definition of &ldquo;Superior Offer,&rdquo; the references to &ldquo;20%&rdquo; in the definition
of Acquisition Proposal shall be deemed to be references to &ldquo;50%.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Supporting Stockholder</B>&rdquo; is
defined in Recital (E) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Surviving Corporation</B>&rdquo; is defined
in Recital (B) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Takeover Laws</B>&rdquo; shall mean any
&ldquo;moratorium,&rdquo; &ldquo;control share acquisition,&rdquo; &ldquo;fair price,&rdquo; &ldquo;supermajority,&rdquo; &ldquo;affiliate
transactions,&rdquo; or &ldquo;business combination statute or regulation&rdquo; or other similar state anti-takeover laws and regulations
(including Section 203 of the DGCL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Tax</B>&rdquo; shall mean any tax, including
any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, unemployment tax, social
security, Medicare, national health insurance or similar taxes, excise tax, alternative or minimum tax, ad valorem tax, transfer tax,
stamp tax, sales tax, use tax, property tax, business tax, withholding tax or payroll tax, or other tax of any kind whatsoever (including
any levy, assessment, impost, imposition, duty (including any customs duty), or governmental fees or charges), in each case, in the nature
of a tax, and including any penalty, interest or other additions thereto, imposed, assessed or collected by or under the authority of
any Governmental Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Tax Return</B>&rdquo; shall mean any
return (including any information return), report, statement, declaration, estimate, schedule, form, election, certificate or other document
or information filed with or supplied to, or required to be filed with or supplied to, any Governmental Body in connection with the determination,
assessment, reporting, withholding, collection or payment of any Tax and any attachments thereto or amendments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Termination Condition</B>&rdquo; is defined
in Annex I to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Termination Fee</B>&rdquo; is defined
in Section 8.03(c) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Trade Secrets</B>&rdquo; is defined in
the definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Trademarks</B>&rdquo; is defined in the
definition of Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Transactions</B>&rdquo; shall mean (i)
the execution and delivery of the Agreement and (ii) all of the transactions contemplated by the Agreement, including the Offer and the
Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Treasury Regulations</B>&rdquo; shall
mean the regulations promulgated under the Code by the U.S. Department of the Treasury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>WARN Act</B>&rdquo; shall mean the Worker
Adjustment and Retraining Notification Act and the regulations promulgated thereunder or any similar foreign, state or local law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25in; text-align: right"><B>Annex I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25in; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Conditions to the Offer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligation of Purchaser to accept for payment,
and (prior to the Offer Acceptance Time) pay for, Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject
to the satisfaction of the conditions set forth in clauses (a) through (h) below. Accordingly, notwithstanding any other provision of
the Offer or the Agreement to the contrary, Purchaser shall not be required to accept for payment or (prior to the Offer Acceptance Time
and subject to any applicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act) pay for, and may delay
the acceptance for payment of, or (prior to the Offer Acceptance Time and subject to any such rules and regulations) the payment for,
any tendered Shares, and, to the extent permitted by the Agreement, may terminate the Offer: (i) upon termination of the Agreement; and
(ii) at any scheduled Expiration Date (subject to any extensions of the Offer pursuant to Section 1.01(c) of the Agreement), if: (A) the
Minimum Condition, the Termination Condition and conditions set forth in clauses (e) and (g) shall not be satisfied by one minute after
11:59 p.m. Eastern Time on the Expiration Date; or (B) any of the additional conditions set forth below shall not be satisfied or waived
in writing by Parent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there shall have been validly tendered, and not validly withdrawn, in the Offer a number of Shares that, considered together with
all other Shares owned by Purchaser and its affiliates (as such term is defined in Section 251(h)(6) of the DGCL), represent one more
Share than 50% of the total number of Shares outstanding at the time of the expiration of the Offer (the &ldquo;<B>Minimum Condition</B>&rdquo;);
<I>provided</I>, <I>however</I>, that for purposes of determining whether the Minimum Condition has been satisfied, the Parties shall
exclude Shares tendered in the Offer that have not yet been &ldquo;received&rdquo; by the &ldquo;depository&rdquo; (as such terms are
defined in Section 251(h)(6) of the DGCL);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) the representations and warranties of the Company set forth in the first sentence of Section 3.01 (Due Organization), &lrm;Section
3.02 (Organizational Documents), &lrm;clauses (i)-(ii) of Section 3.03(c) solely as such representations related to the Company, and Section
3.03(f) (Capitalization, Etc.), Section 3.04 (Authority; Binding Nature of Agreement), &lrm;Section 3.22 (Takeover Laws), &lrm;Section
3.24 (Opinion of Financial Advisor) and &lrm;Section 3.25 (Brokers and Other Advisors) of the Agreement shall be true and correct in all
material respects as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance
Time (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such
date or period);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the representations and warranties of the Company set forth in the first sentence of &lrm;Section 3.03(a), &lrm;Section 3.03(d)
and &lrm;Section 3.03(e) (Capitalization, Etc.) of the Agreement shall be true and correct (except for de minimis inaccuracies) in all
respects as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time
(except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date
or period);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the representation and warranty of the Company set forth in Section 3.06(b) (No Material Adverse Effect) of the Agreement shall
be true and correct in all respects as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of
the Offer Acceptance Time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the representations and warranties of the Company set forth in the Agreement (other than those referred to in clauses (i) through
(iii) above) shall be true and correct (disregarding for this purpose all &ldquo;Material Adverse Effect&rdquo; and &ldquo;materiality&rdquo;
qualifications contained in such representations and warranties) as of the date of the Agreement and at and as of the Offer Acceptance
Time as if made on and as of the Offer Acceptance Time (except to the extent any such representation or warranty expressly relates to
an earlier date or period, in which case as of such date or period), except where the failure of such representations and warranties to
be so true and correct has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) the Company shall not be in willful and material breach of its obligations under Section 5.03 and (ii) with respect
to all other obligations, covenants and agreements the Company is required to comply with or perform at or prior to the Offer Acceptance
Time, the Company shall have complied with or performed in all material respects such obligations, covenants and agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>since the date of the Agreement, there shall not have occurred a Material Adverse Effect that is continuing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(i) the waiting period (or any extension thereof) applicable to the Offer under the HSR Act shall have expired or been terminated,
(ii) any other approvals pursuant to the Antitrust Laws set forth on <U>Section 6.02(b)</U> of the Company Disclosure Letter shall have
been given and obtained and, (iii) if Parent and the Company have entered into an agreement with any Governmental Body regarding the timing
of the consummation of the Offer, that agreement shall permit such consummation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent and Purchaser shall have received a certificate executed on behalf of the Company by the Company&rsquo;s Chief Executive
Officer and Chief Financial Officer confirming that the conditions set forth in clauses (b), (c) and (d) of this Annex I have been satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there shall not have been issued by any Governmental Body of competent jurisdiction in any jurisdiction in which Parent or the
Company has material business operations, and remain in effect, any judgment, temporary restraining order, preliminary or permanent injunction
or other order, decree or ruling restraining, enjoining or otherwise preventing the acquisition of or payment for Shares pursuant to the
Offer or the consummation of the Offer or the Merger or subsequent integration, nor shall any Legal Requirement have been promulgated,
enacted, issued or deemed applicable to the Offer or the Merger by any Governmental Body in any jurisdiction in which Parent or the Company
has material business operations which prohibits or makes illegal the acquisition of or payment for Shares pursuant to the Offer or the
consummation of the Merger or subsequent integration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Agreement shall not have been terminated in accordance with its terms (the &ldquo;<B>Termination Condition</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing conditions shall be in addition to,
and not a limitation of, the rights of Parent and Purchaser to extend, terminate or modify the Offer pursuant to the terms of the Agreement.
The foregoing conditions are for the sole benefit of Parent and Purchaser, may be asserted by Parent or Purchaser regardless of the circumstances
giving rise to any such conditions (including any action or inaction by Parent or Purchaser) and (except for the Minimum Condition and
the Termination Condition) may be waived by Parent and Purchaser, in whole or in part, at any time and from time to time, in the sole
and absolute discretion of Parent and Purchaser. The failure by Parent or Purchaser at any time to exercise any of the foregoing rights
shall not be deemed a waiver of any such right and each such right shall be deemed an ongoing right which may be asserted at any time
and from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex I - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Annex II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Amended and Restated Certificate
of Incorporation of Arcellx, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex II - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Annex III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>CVR Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 100; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex III - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONTINGENT VALUE RIGHTS AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">This
</FONT>CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [&#9679;], 2026 (this &ldquo;<FONT STYLE="color: windowtext"><U>Agreement</U></FONT>&rdquo;),
is entered into by and between Gilead Sciences, Inc., a Delaware corporation <FONT STYLE="color: windowtext">(&ldquo;<U>Parent</U>&rdquo;)</FONT>,
and [&#9679;], a [&#9679;] (as the &ldquo;<FONT STYLE="color: windowtext"><U>Rights Agent</U>&rdquo; (as hereinafter defined))</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">WHEREAS,
this Agreement is entered into pursuant to the Agreement and Plan of Merger, dated as of February 22</FONT>, 2026 (the &ldquo;<U>Merger
Agreement</U>&rdquo;)<FONT STYLE="color: windowtext">, by and among Parent, </FONT>Ravens Sub, Inc.<FONT STYLE="color: windowtext">, a
Delaware corporation and a direct wholly owned subsidiary of Parent (&ldquo;<U>Purchaser</U>&rdquo;) and Arcellx, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), pursuant to which (a) Parent has </FONT>commenced a tender offer (as it may be amended from time to
time as permitted under the Merger Agreement, the &ldquo;<U>Offer</U>&rdquo;) to acquire all of the outstanding shares of Company Common
Stock, other than shares to be cancelled pursuant to Sections 2.05(a)(i) and 2.05(a)(ii) of the Merger Agreement, for (x) $115.00 per
Share, net to the seller in cash, without interest, subject to any withholding of Tax in accordance with the terms of the Merger Agreement
and (y) one CVR as hereinafter described, and (b) as soon as practicable following the consummation of the Offer, Purchaser will be merged
with and into the Company (the &ldquo;<U>Merger</U>&rdquo;), with the Company continuing as the surviving corporation in the Merger (the
&ldquo;<U>Surviving Corporation</U>&rdquo;), on the terms and subject to the conditions set forth in the Merger Agreement; <FONT STYLE="color: windowtext">and
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, as an integral part
of the consideration of the Offer and the Merger, pursuant to and subject to the terms and conditions of the Merger Agreement, (a) holders
of Company Common Stock (other than shares of Company Common Stock to be cancelled pursuant to Sections 2.05(a)(i), 2.05(a)(ii) and 2.05(a)(iii)
of the Merger Agreement and any Dissenting Shares), (b) holders of Company RSUs, and (c) holders of Company Options that, at the Effective
Time, are then outstanding and unexercised, whether or not vested, and which have a per share exercise price that is less than the Closing
Amount, in each case of the foregoing clauses (a)-(c), as of immediately prior to the Effective Time, will become entitled to receive
one contingent cash payment, such payment being contingent upon, and subject to, the achievement of the Milestone (as defined below) on
or prior to the Milestone Expiration Date (as defined below), subject to and in accordance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">NOW,
THEREFORE, in </FONT>consideration of the foregoing and the consummation of the transactions referred to above, <FONT STYLE="color: windowtext">Parent
</FONT>and <FONT STYLE="color: windowtext">the Rights Agent</FONT> agree, for the equal and proportionate benefit of all <FONT STYLE="color: windowtext">Holders
</FONT>(as hereinafter defined), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: none">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT> DEFINITIONS; certain rules of construction</P>



<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Definitions</U>. Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the <FONT STYLE="color: windowtext">Merger
Agreement</FONT>. As used in this <FONT STYLE="color: windowtext">Agreement</FONT>, the following terms will have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assignee</U>&rdquo;
has the meaning set forth in <U>Section 6.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 101; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">&ldquo;<U>Business
Day</U></FONT>&rdquo; means any day other than (a) a Saturday, Sunday or any other day on which banking institutions in New York, New
York or Foster City, California are authorized or required by Legal Requirements to remain closed, (b) December 26 through December 31,
and (c) the seven (7)-day period that begins on a Sunday and ends on a Saturday during which period July 4 occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Company</U>&rdquo;
has the meaning set forth in the Recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Company Common Stock</U>&rdquo;
means the common stock, $0.001 par value per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>CVR Register</U>&rdquo;
has the meaning set forth in <U>Section 2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">&ldquo;<U>CVRs</U></FONT>&rdquo;
has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Delaware Courts</U>&rdquo;
has the meaning set forth in <U>Section 6.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">&ldquo;<U>DTC</U></FONT>&rdquo;
means The <FONT STYLE="color: windowtext">Depository Trust Company or any successor thereto</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Equity Award CVR</U>&rdquo;
means a CVR received by a Holder in respect of Company Options or Company RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">&ldquo;<U>Holder</U></FONT>&rdquo;
means a Person in whose name a <FONT STYLE="color: windowtext">CVR </FONT>is registered in the <FONT STYLE="color: windowtext">CVR Register
at the applicable time</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Licensee</U>&rdquo;
means a Third Party that is granted a license or sublicense to research, develop, manufacture, commercialize, or otherwise exploit the
Product, beyond the mere right to purchase the Product from Parent and its Affiliates, and excludes (i) Third Party subcontractors that
act solely for Parent or its Affiliates in the supply chain or that perform discrete services (as opposed to being granted broad rights
or responsibilities) on behalf of Parent or its Affiliates and (ii) any Third Party to which Parent has granted such license or sublicense
as a result of a generic product litigation settlement or a compulsory license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Merger</U>&rdquo;
has the meaning set forth in the Recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Merger Agreement</U>&rdquo;
has the meaning set forth in the Recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Milestone</U>&rdquo;
means the cumulative worldwide Sales achieved after Closing exceeding $6,000,000,000 on or prior to the Milestone Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Milestone Expiration
Date</U>&rdquo; means December 31, 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Amount</U>&rdquo; means, for a given Holder, the product of (a) $5.00 and (b) the number of CVRs held by such Holder as reflected on the
CVR Register as of the close of business on the date of the Milestone Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Date</U>&rdquo; means March 31, 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Offer</U>&rdquo;
has the meaning set forth in the Recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Officer&rsquo;s
Certificate</U>&rdquo; means a certificate signed by the Chief Executive Officer, the Chief Financial Officer, a Vice President or any
other person duly authorized to act on behalf of Parent for such purpose or for any general purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Parent</U>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">&ldquo;<U>Permitted
Transfer</U></FONT>&rdquo; means a transfer of <FONT STYLE="color: windowtext">CVRs (a) up</FONT>on death of a Holder by will or intestacy;
<FONT STYLE="color: windowtext">(b)&nbsp;</FONT>pursuant to a court order; <FONT STYLE="color: windowtext">(c)&nbsp;</FONT>by operation
of law (<FONT STYLE="color: windowtext">including </FONT>by consolidation or merger) or without consideration in connection with the dissolution,
liquidation or termination of any corporation, limited liability company, partnership or other entity; <FONT STYLE="color: windowtext">(d)&nbsp;</FONT>in
the case of <FONT STYLE="color: windowtext">CVRs </FONT>held in book-entry or other similar nominee form, from a nominee to a beneficial
owner and, if applicable, through an intermediary, to the extent allowable by <FONT STYLE="color: windowtext">DTC, (e)&nbsp;with the written
consent of Parent; (f)&nbsp;if the Holder is a partnership or limited liability company, a distribution by the transferring partnership
or limited liability company to its partners or members, as applicable (<U>provided</U>&nbsp;that such distribution or transfer does not
subject the CVRs to a requirement of registration under the Securities Act or the Exchange Act); or (g)&nbsp;as provided in&nbsp;<U>Section&nbsp;2.7</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Product</U>&rdquo;
means Company&rsquo;s product candidate known as anitocabtagene autoleucel or &ldquo;anito-cel,&rdquo; as it exists immediately prior
to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Purchaser</U>&rdquo;
has the meaning set forth in the Recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">&ldquo;<U>Rights
Agent</U></FONT>&rdquo; means the <FONT STYLE="color: windowtext">Rights Agent </FONT>named in the first paragraph of this <FONT STYLE="color: windowtext">Agreement</FONT>,
until a successor <FONT STYLE="color: windowtext">Rights Agent </FONT>will have become such pursuant to the applicable provisions of this
<FONT STYLE="color: windowtext">Agreement</FONT>, and thereafter &ldquo;<FONT STYLE="color: windowtext">Rights Agent</FONT>&rdquo; will
mean such successor <FONT STYLE="color: windowtext">Rights Agent</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Sales</U>&rdquo;
means, for the Product in a particular period, the sum of (a) and (b):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the amount stated in Parent&rsquo;s &ldquo;Product Sales&rdquo; line of its externally published audited consolidated financial
statements with respect to the Product for such period, less any sales, transfers or dispositions to any Licensees. This amount reflects
the gross invoice price at which the Product was sold, transferred or otherwise disposed of (other than for use as clinical supplies or
free samples for charitable, compassionate use or regulatory purposes) by Parent and its Affiliates to such Third Parties (for clarity,
excluding sales, transfers or dispositions to any Licensees) in such period reduced by&nbsp;gross-to-net&nbsp;deductions, if not previously
deducted from such invoiced amount, taken in accordance with the then-currently used GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">By way of example, the&nbsp;gross-to-net&nbsp;deductions
taken in accordance with GAAP include items such as the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>rebates and chargebacks based on contractual arrangements or statutory requirements, including amounts due to payers and healthcare
providers under various programs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>patient co-pay assistance, representing financial assistance to qualified patients;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>cash discounts based on contractual terms, historical customer payment patters and expectations regarding future customer payment
patterns;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>distributor fees under inventory management agreements; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>allowances for sales returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for Licensees, the sales amounts reported to Parent and its Affiliates in accordance with the applicable agreement with respect
to the Product between Parent or its Affiliates, on the one hand, and any Licensee, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Surviving Corporation</U>&rdquo;
has the meaning set forth in the Recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;<U>Third Party</U>&rdquo;
means a Person that is not Parent or the Company or any of their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">1.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Rules of Construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and
the neuter gender shall include masculine and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The parties have participated jointly in the negotiation and drafting of this Agreement and agree that any rule of construction
to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified.
If any action is to be taken or given on or by a particular calendar day, and such calendar day is not a Business Day, then such action
may be deferred until the next Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including&rdquo; and variations thereof, shall not be deemed
to be terms of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo; The words &ldquo;hereof,&rdquo;
&ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. The words &ldquo;date hereof&rdquo; when used in this Agreement shall
refer to the date of this Agreement. The terms &ldquo;or,&rdquo; &ldquo;any&rdquo; and &ldquo;either&rdquo; are not exclusive. The word
&ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; shall mean the degree to which a subject or other thing extends, and such
phrase shall not mean simply &ldquo;if.&rdquo; The word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the
word &ldquo;shall.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as otherwise indicated, all references in this Agreement to &ldquo;Sections,&rdquo; &ldquo;Exhibits&rdquo; or &ldquo;Annexes&rdquo;
are intended to refer to Sections of this Agreement and Exhibits or Annexes to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The term &ldquo;dollars&rdquo; and character &ldquo;$&rdquo; shall mean United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All accounting terms used and not defined herein shall have the respective meanings given to them under GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All terms defined in this Agreement shall have the defined meanings when used in any document made or delivered pursuant hereto
unless otherwise defined herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>References herein to any statute includes all rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any reference to (i) any Governmental Body includes any successor to that Governmental Body; and (ii) any applicable Legal Requirement
refers to such applicable Legal Requirement as amended, modified, supplemented, or replaced from time to time (and, in the case of statutes,
include any rule and regulation promulgated under such statute) and references to any section of any applicable Legal Requirement includes
any successor to such section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: none">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT> CONTINGENT Value RIGHTS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="color: windowtext"><U>CVRs</U></FONT>. The <FONT STYLE="color: windowtext">contingent value rights </FONT>represent
the rights of <FONT STYLE="color: windowtext">Holders </FONT>to receive contingent cash payments pursuant to this <FONT STYLE="color: windowtext">Agreement
(&ldquo;<U>CVRs</U>&rdquo;)</FONT>. <FONT STYLE="color: windowtext">The initial Holders will be determined pursuant to the terms of the
Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Nontransferable</U>. The <FONT STYLE="color: windowtext">CVRs may </FONT>not be sold, assigned, transferred, pledged, encumbered
or in any other manner disposed of, in whole or in part, other than through a <FONT STYLE="color: windowtext">Permitted Transfer; the
foregoing shall apply notwithstanding that certain of the CVRs will be held through DTC</FONT>. Any attempted sale, assignment, transfer,
pledge, encumbrance or disposition of CVRs, in whole or in part, in violation of this <U>Section 2.2</U>, shall be void ab initio and
of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Certificate; Registration; Registration of Transfer; Change of Address</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The <FONT STYLE="color: windowtext">CVRs </FONT>will not be evidenced by a certificate or other instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The <FONT STYLE="color: windowtext">Rights Agent, </FONT>acting solely for this purpose as a non-fiduciary agent of Parent, will
keep a register (the &ldquo;<FONT STYLE="color: windowtext"><U>CVR Register</U></FONT>&rdquo;) for the purpose of recording the names
and addresses of the applicable Holders, as well as transfers of <FONT STYLE="color: windowtext">CVRs </FONT>as herein provided. The entries
in the CVR Register shall be conclusive absent manifest error, and Parent and the Rights Agent shall treat each Person whose name is recorded
in the Register pursuant to the terms hereof as a Holder hereunder for all purposes of this Agreement. The Register shall be available
for inspection by the Parent at any reasonable time and from time to time upon reasonable prior notice. The parties intend that any imputed
interest in or with respect to the CVRs under this Agreement be treated as being issued and maintained in &ldquo;registered form&rdquo;
within the meaning of Sections 163(f), 871(h)(2), and 881(c)(2) of the Code and any regulations thereunder, including without limitation
under United States Treasury Regulations Section 5f.103-1(c) and Proposed Regulations Section 1.163-5 (and any successor provisions),
and the provisions of this Agreement shall be construed in a manner that gives effect to such intent. The CVR Register shall set forth
(x) with respect to holders of Company Common Stock that hold such shares in book-entry form through DTC immediately prior to the Effective
Time, one (1) position for Cede &amp; Co. (as nominee of DTC) representing all such shares of Company Common Stock that were converted
into the right to receive the Offer Price or Merger Consideration as a consequence of the Merger in accordance with the terms of the Merger
Agreement, and (y) with respect to (A) holders of shares of Company Common Stock that hold such shares in certificated form immediately
prior to the Effective Time that were accepted for payment in the Offer or converted into the right to receive the Merger Consideration
as a consequence of the Merger in accordance with the terms of the Merger Agreement, upon delivery to the Paying Agent by each such holder
of the applicable stock certificates, together with a validly executed letter of transmittal and such other customary documents as may
be reasonably requested by the Paying Agent, in accordance with the Merger Agreement, (B) holders of shares of Company Common Stock that
hold such shares in book-entry form through the Company&rsquo;s transfer agent immediately prior to the Effective Time that were accepted
for payment in the Offer or converted into the right to receive the Merger Consideration as a consequence of the Merger in accordance
with the terms of the Merger Agreement, upon delivery to the Paying Agent by each such holder of a customary agent&rsquo;s message and
such other customary documents as may be reasonably requested by the Paying Agent, in accordance with the Merger Agreement, (C) holders
of Company Options that, at the Effective Time, are then outstanding and unexercised, whether or not vested, and which have a per share
exercise price that is less than the Closing Amount, and (D) holders of Company RSUs, in each case of <U>clauses (A)</U> through <U>(D)</U>,
the applicable number of CVRs to which each such holder is entitled pursuant to the Merger Agreement (other than, in the case of the foregoing
clauses (x), (y)(A) and (y)(B), those who are entitled to appraisal rights under Section 262 of the DGCL and have properly exercised and
perfected their respective demands for appraisal of such shares in the time and manner provided in Section 262 of the DGCL and, as of
the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL). The CVR Register
will be updated as necessary by the Rights Agent to reflect the addition or removal of Holders (pursuant to any Permitted Transfers),
upon the written receipt of such information by the Rights Agent. The <FONT STYLE="color: windowtext">Rights Agent </FONT>will have no
responsibility whatsoever directly to the street name holders with respect to transfers of <FONT STYLE="color: windowtext">CVRs. </FONT>With
respect to any payments to be made under <FONT STYLE="color: windowtext"><U>Section 2.4</U></FONT>, the <FONT STYLE="color: windowtext">Rights
Agent </FONT>will accomplish the payment to any former street name holders of shares of <FONT STYLE="color: windowtext">Company Common
Stock </FONT>by sending one lump payment to <FONT STYLE="color: windowtext">DTC</FONT>. The <FONT STYLE="color: windowtext">Rights Agent
</FONT>will have no responsibilities whatsoever with regard to the distribution of payments by <FONT STYLE="color: windowtext">DTC </FONT>to
such street name holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the restrictions on transferability set forth in <FONT STYLE="color: windowtext"><U>Section&nbsp;2.2</U></FONT>, every
request made to transfer a <FONT STYLE="color: windowtext">CVR </FONT>must be in writing and accompanied by such documentation as may
be reasonably requested by the Rights Agent and a written instrument of transfer in form reasonably satisfactory to the <FONT STYLE="color: windowtext">Rights
Agent</FONT> pursuant to its customary policies and guidelines, which may include a guaranty of signature by an &ldquo;eligible guarantor
institution&rdquo; that is a member or participant in the Securities Transfer Medallion Program, duly executed by the Holder thereof,
the Holder&rsquo;s attorney duly authorized in writing, the Holder&rsquo;s personal representative or the Holder&rsquo;s survivor, and
setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will,
subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other
terms and conditions of this Agreement (including the provisions of <U>Section 2.2</U>), register the transfer of the CVRs in the CVR
Register. No service charge shall be made for any registration of transfer of a CVR, but Parent and the Rights Agent may require the Holder
to pay a sum sufficient to cover any Tax or governmental charge that is imposed in connection with any such registration of transfer.
The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by
a Holder of a CVR of applicable Taxes or charges unless and until the Rights Agent is satisfied that all such Taxes or charges have been
paid by the Holder or that no payment of any such Taxes or charges is required. All duly transferred CVRs registered in the CVR Register
will be the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those
held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>A <FONT STYLE="color: windowtext">Holder </FONT>may make a written request to the <FONT STYLE="color: windowtext">Rights Agent
</FONT>to change such <FONT STYLE="color: windowtext">Holder</FONT>&rsquo;s address of record in the <FONT STYLE="color: windowtext">CVR
Register</FONT>. The written request must be duly executed by the <FONT STYLE="color: windowtext">Holder</FONT>. Upon receipt of such
written notice, the <FONT STYLE="color: windowtext">Rights Agent </FONT>will, subject to its reasonable determination that the transfer
instrument is in proper form, as promptly as practicable record the change of address in the <FONT STYLE="color: windowtext">CVR Register</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Payment Procedures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the Milestone is achieved on or prior to the Milestone Expiration Date, then, on or prior to the Milestone Payment Date, Parent
shall (i) deliver to the Rights Agent a written notice indicating that the Milestone has been achieved (the &ldquo;<U>Milestone Notice</U>&rdquo;)
and an Officer&rsquo;s Certificate certifying the same, and (ii) deposit or cause to be deposited with the Rights Agent by wire transfer
to the account designated by the Rights Agent for payment to the Holders who are not Holders of Equity Award CVRs the aggregate amount
necessary to pay the applicable Milestone Payment Amount to each Holder who is not a Holder of an Equity Award CVR, and the Rights Agent
shall as promptly as practicable (but in any event within five (5) Business Days) pay to each Holder of record of the CVRs (other than
Equity Award CVRs) as of 5:00 PM EST on the Milestone Payment Date, the Milestone Payment Amount by check mailed to the address of each
Holder as reflected in the CVR Register or, in the case of any former street name holders of shares of <FONT STYLE="color: windowtext">Company
Common Stock, </FONT>by sending one lump payment to <FONT STYLE="color: windowtext">DTC pursuant to <U>Section 2.3(b)</U></FONT>. The
funds deposited with the Rights Agent pursuant to this <U>Section 2.4(a)</U> shall be held by the Rights Agent as agent for Parent and
deposited in one (1) or more segregated non-interest-bearing bank accounts to be maintained by the Rights Agent in its name as agent for
Parent. Parent will pay through the Surviving Corporation&rsquo;s or another of its Affiliates&rsquo; payroll system, payroll provider
or standard accounts payable procedure, as applicable, for payment to the Holders of Equity Award CVRs the amount necessary to pay any
applicable Milestone Payment Amount to each Holder of an Equity Award CVR (less applicable Tax withholdings and other authorized deductions)
within five (5) Business Days of the Milestone Payment Date, subject to <U>Section 2.4(b)</U>. Notwithstanding the foregoing or anything
herein to the contrary, in no event shall Parent be required to pay any Milestone Payment Amount (a) more than once or (b) if the Milestone
is not achieved on or prior to the Milestone Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="color: windowtext">Parent and any of its Affiliates and the Rights Agent </FONT>shall be entitled to deduct and withhold,
or cause to be deducted and withheld, from any amounts payable or otherwise deliverable pursuant to this <FONT STYLE="color: windowtext">Agreement</FONT>
to any Holder such amounts as are required to be deducted and withheld therefrom under the Code or the Treasury Regulations thereunder
or any other Legal Requirement. With respect to Holders who received Equity Award CVRs, any such withholding may be made, or caused to
be made, by Parent through the Surviving Corporation&rsquo;s or its Affiliates&rsquo; (including Parent&rsquo;s) payroll system, payroll
provider or standard accounts payable procedure, as applicable, or any successor of the foregoing. To the extent such amounts are so deducted
or withheld, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts
would otherwise have been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any portion of any Milestone <FONT STYLE="color: windowtext">Payment Amount </FONT>that remains undistributed to the <FONT STYLE="color: windowtext">Holders
</FONT>six (6) months after the Milestone Payment Date will be delivered by the <FONT STYLE="color: windowtext">Rights Agent </FONT>to
<FONT STYLE="color: windowtext">Parent</FONT>, upon demand, and any <FONT STYLE="color: windowtext">Holder </FONT>will thereafter look
only to <FONT STYLE="color: windowtext">Parent </FONT>for payment of such <FONT STYLE="color: windowtext">Milestone Payment Amount, without
interest (except deemed interest for Tax purposes as applicable under Section 483 of the Code or any similar provision of state, local
or non-U.S. Legal Requirements)</FONT>, but such Holder will have no greater rights against <FONT STYLE="color: windowtext">Parent </FONT>than
those accorded to general unsecured creditors of <FONT STYLE="color: windowtext">Parent </FONT>under applicable Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither <FONT STYLE="color: windowtext">Parent </FONT>nor the <FONT STYLE="color: windowtext">Rights Agent </FONT>will be liable
to any Person in respect of any Milestone <FONT STYLE="color: windowtext">Payment Amount </FONT>delivered to a public official pursuant
to any applicable abandoned property, escheat or similar Legal Requirement. If any <FONT STYLE="color: windowtext">Milestone Payment Amount
</FONT>has not been paid immediately prior to the date on which such <FONT STYLE="color: windowtext">Milestone Payment Amount </FONT>would
otherwise escheat to or become the property of any <FONT STYLE="color: windowtext">Governmental Body</FONT>, any such Milestone <FONT STYLE="color: windowtext">Payment
Amount </FONT>will, to the extent permitted by applicable Legal Requirement, become the property of <FONT STYLE="color: windowtext">Parent</FONT>,
free and clear of all claims or interest of any Person previously entitled thereto. In addition to and not in limitation of any other
indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost
or expense the Rights Agent may incur or be subject to in connection with transferring such property to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except to the extent otherwise required pursuant to a &ldquo;determination&rdquo; within the meaning of Section 1313(a) of the
Code, Parent, the Rights Agent and/or Holders, as applicable, shall determine the portion of the Milestone Payment Amount required to
be treated as interest for U.S. federal income tax purposes pursuant to Section 483 of the Code and the Treasury Regulations promulgated
thereunder or any similar provision of applicable state, local or non-U.S. Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall be responsible for information for U.S. federal income Tax reporting required under the Code and regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Voting, Dividends or Interest; No Equity or Ownership Interest in <FONT STYLE="color: windowtext">Parent</FONT></U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The <FONT STYLE="color: windowtext">CVRs </FONT>will not have any voting or dividend rights, and, subject to <U>Section 2.4(e)</U>,
which shall apply for Tax purposes only, interest will not accrue on any amounts payable on the <FONT STYLE="color: windowtext">CVRs </FONT>to
any <FONT STYLE="color: windowtext">Holder</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The <FONT STYLE="color: windowtext">CVRs </FONT>will not represent any equity or ownership interest in <FONT STYLE="color: windowtext">Parent
</FONT>or in any constituent company to the <FONT STYLE="color: windowtext">Merger</FONT>. It is hereby acknowledged and agreed that a
CVR shall not constitute a security of Parent or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Diligence Obligation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="color: windowtext">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></FONT>Parent owes no obligation or duty, as a fiduciary or otherwise, to the Rights Agent, any Holder or any other Person in connection
with its operation of the Surviving Corporation&rsquo;s business on and following the Closing. The Rights Agent (on behalf of itself and
on behalf of the Holders) acknowledges that (i) Parent makes (x) no guarantees or promises that the Milestone will be achieved at all
or by a specific date or is otherwise achievable, and (y) no statements, assessments or predictions regarding the likelihood of the Milestone
being achieved has been or is provided hereby, and no reliance on any statements, assessments or predictions with respect to the Milestone
should be made, (ii) there is no assurance that the Holders will receive any payment under this Agreement, including as described under
<U>Section 2.4</U>, unless, and if and only if, the Milestone is achieved on or prior to the Milestone Expiration Date, (iii) Parent has
not prior to the date hereof, promised or projected any amounts to be received by the Holders in respect of any payments described in
<U>Section 2.4</U> and no statements of Parent, that have been, or may be, made, may, or will, be construed as Parent making any such
promise or projection, (iv) none of the Rights Agent and any Holder is relying on or has relied on any promises, projections, representation
or warranty of any kind or other information, documents or materials (or absence thereof), or will rely on any promises, projections,
representation or warranty of any kind or other information, documents or materials (or absence thereof), in respect of any payments described
in <U>Section 2.4</U>, including with respect to the operation of the Surviving Corporation&rsquo;s business following the Closing, (v)
Parent shall have the right to, or not to, own, operate, use, (sub)license, research, develop, commercialize and otherwise practice, use
and exploit the assets of the Surviving Corporation&rsquo;s business in any way that Parent deems appropriate in its sole business judgment
and (vi) (A) neither Parent nor any of its Affiliates shall have any obligation to make any particular level of efforts or engage in any
particular or specific activities in connection with the ownership of the Surviving Corporation or any other Person relevant to the Milestone
Payment Amount or Product or otherwise in connection with achieving the Milestone, and (B) Parent does not have any obligation, express
or implied, to research, develop, manufacture, commercialize, or otherwise practice, use or exploit the assets of the Surviving Corporation&rsquo;s
business, in any manner, including in order to make, maximize or expedite the payments described in <U>Section 2.4</U>. The Rights Agent
(on behalf of itself and on behalf of the Holders) hereby (a) disclaims reliance on any such promises, projections, representations, warranties
or other information, documents or materials (or absence thereof), and (b) understands and agrees that no such promises, representations,
warranties, projections and other information, documents and materials (or absence thereof) have been, or will be, made by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Ability to Abandon the CVR</U>. A Holder may at any time, at such Holder&rsquo;s option, abandon all of such Holder&rsquo;s
remaining rights in a CVR by transferring such CVR to Parent without consideration therefor, which a Holder may effect via delivery of
a written abandonment notice to Parent. Nothing in this Agreement shall prohibit Parent or any of its Affiliates (including the Surviving
Corporation) from offering to acquire or acquiring any CVRs for consideration from the Holders, in private transactions or otherwise,
in its sole discretion. Any CVRs acquired by Parent or any of its Affiliates (including the Surviving Corporation) shall be automatically
deemed extinguished and no longer outstanding or entitled to any Milestone Payment for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: none">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; THE <FONT STYLE="color: windowtext">RIGHTS AGENT</FONT></P>



<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Certain Duties and Responsibilities</U>. The <FONT STYLE="color: windowtext">Rights Agent </FONT>will not have any liability
for any actions taken or not taken in connection with this <FONT STYLE="color: windowtext">Agreement</FONT>, except to the extent such
liability arises as a result of its willful or intentional misconduct, bad faith or gross negligence (which gross negligence, bad faith,
or willful or intentional misconduct must be determined by a final, non-appealable judgment of a court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Certain Rights of <FONT STYLE="color: windowtext">the Rights Agent</FONT></U>. The <FONT STYLE="color: windowtext">Rights Agent
</FONT>undertakes to perform such duties and only such duties as are specifically set forth in this <FONT STYLE="color: windowtext">Agreement</FONT>,
and no implied covenants or obligations will be read into this <FONT STYLE="color: windowtext">Agreement </FONT>against the <FONT STYLE="color: windowtext">Rights
Agent</FONT>. In addition:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the <FONT STYLE="color: windowtext">Rights Agent </FONT>may rely and will be protected and held harmless by Parent in acting or
refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent,
order or other paper or document believed by it in the absence of bad faith to be genuine and to have been signed or presented by the
proper party or parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>whenever the <FONT STYLE="color: windowtext">Rights Agent </FONT>deems it desirable that a matter be proved or established prior
to taking, suffering or omitting any action hereunder, the <FONT STYLE="color: windowtext">Rights Agent </FONT>may rely upon an <FONT STYLE="color: windowtext">Officer&rsquo;s
Certificate</FONT>, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the
absence of bad faith, gross negligence or willful misconduct on its part (which bad faith, gross negligence or willful misconduct must
be determined by a final, non-appealable judgment of a court of competent jurisdiction), incur no liability and be held harmless by Parent
for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in the absence of
bad faith reliance upon such certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the <FONT STYLE="color: windowtext">Rights Agent </FONT>may engage and consult with counsel of its selection and the written advice
of such counsel or any opinion of counsel will be full and complete authorization and protection to the Rights Agent in respect of any
action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the permissive rights of the <FONT STYLE="color: windowtext">Rights Agent </FONT>to do things enumerated in this <FONT STYLE="color: windowtext">Agreement
</FONT>will not be construed as a duty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the <FONT STYLE="color: windowtext">Rights Agent </FONT>will not be required to give any note or surety in respect of the execution
of such powers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to, any of the statements
of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall
be deemed to have been made by Parent only;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent will have no liability and shall be held harmless by Parent in respect of the validity of this Agreement or the
execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent and the enforceability of this Agreement
against the Rights Agent assuming the due execution and delivery hereof by Parent); nor shall it be responsible for any breach by Parent
of any covenant or condition contained in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="color: windowtext">Parent </FONT>agrees to indemnify <FONT STYLE="color: windowtext">the Rights Agent </FONT>for,
and hold <FONT STYLE="color: windowtext">the Rights Agent </FONT>harmless against, any loss, liability, damage, judgment, fine, penalty,
demand, suit or expense arising out of or in connection with the Rights Agent&rsquo;s performance of its express duties under this Agreement
(excluding any Taxes, interest, penalties or other costs or expenses imposed on the payment of fees hereunder), including the reasonable
and documented out-of-pocket costs and expenses of defending the Rights Agent against any charges, demands, suits or loss arising out
of or in connection with <FONT STYLE="color: windowtext">the execution, administration, exercise and performance by the Rights Agent</FONT>
of its express duties under this <FONT STYLE="color: windowtext">Agreement</FONT>, <FONT STYLE="color: windowtext">including </FONT>the
reasonable costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or, solely to the
extent the Rights Agent is the prevailing party, enforcement of its rights hereunder, unless such loss has been determined by a court
of competent jurisdiction to have resulted from the Rights Agent&rsquo;s willful misconduct, bad faith, gross negligence or fraud (which
willful misconduct, bad faith, gross negligence or fraud must be determined by a final, non-appealable judgment of a court of competent
jurisdiction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>notwithstanding anything to the contrary herein, in no event shall the Rights Agent be liable for any special, punitive, indirect,
consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits) arising out of any act or
failure to act hereunder, even if the Rights Agent has been advised of the likelihood of such loss or damage or has foreseen the possibility
or likelihood of such damages. Notwithstanding anything to the contrary contained herein, the aggregate liability of the Rights Agent
arising in connection with this Agreement, whether in contract, or in tort, or otherwise, is limited to, and shall not exceed the amounts
paid or payable hereunder by Parent to the Rights Agent as fees and charges during the twelve (12) months immediately preceding the event
for which recovery from the Rights Agent is being sought;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent agrees (i) to pay the reasonable and documented out-of-pocket fees and expenses of the Rights Agent in connection with this
Agreement, in accordance with a fee schedule to be mutually agreed upon by Parent and the Rights Agent on or prior to the date hereof
and (ii) to reimburse the Rights Agent for all Taxes and governmental charges paid or incurred by it in connection with the administration
by the Rights Agent of its duties hereunder (other than Taxes imposed on or measured by the Rights Agent&rsquo;s net income and franchise
or similar Taxes imposed on it (in lieu of net income Taxes)); <I>provided</I> that, if the Rights Agent determines in the absence of
bad faith that it has received a refund of any Tax or governmental charge borne by Parent pursuant to this clause (ii), then the Rights
Agent shall promptly repay such refund to Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for
believing that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent shall not be deemed to have knowledge of any event of which it was entitled to receive notice thereof hereunder,
and the Rights Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith, in each
case, unless and until such notice has been given in accordance with <U>Section 6.1</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>unless otherwise specifically prohibited by the terms of this Agreement and subject to applicable Law, the Rights Agent and any
stockholder, affiliate, member, director, officer, agent, representative or employee of the Rights Agent may buy, sell or deal in any
of the securities of Parent or become pecuniarily interested in any transaction in which Parent may be interested, or contract with or
lend money to Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement. Nothing herein
shall preclude the Rights Agent or any such stockholder, affiliate, director, member, officer, agent, representative or employee from
acting in any other capacity for Parent or for any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent may perform any of its duties hereunder either directly or, with the prior written consent of Parent, by or through
nominees, correspondents, designees, or subagents; <I>provided</I>, <I>however</I>, that in the event the Rights Agent performs any of
its duties hereunder by or through any nominee, correspondent, designee, or subagent with such consent of Parent, the Rights Agent shall
not be answerable, accountable or liable hereunder for any act, omission, default, neglect or misconduct of such nominee, correspondent,
designee, or subagent, as applicable, to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence,
bad faith or willful or intentional misconduct (each as determined by a final, non-appealable judgment of a court of competent jurisdiction)
in the selection or continued employment thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent shall act hereunder solely as agent for Parent and it shall not assume any obligations or relationship of agency
or trust with any of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent shall not have any duty or responsibility with respect to any action or default by Parent or the Company, including,
without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law
or otherwise or to make any demand upon Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made
by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution
or other third party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with
respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility
to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Parent or any of its Affiliates; <I>provided</I>
that this <U>Section 3.2(p)</U> shall not affect the Rights Agent&rsquo;s obligation to make payments in accordance with and subject to
<U>Section 2.4</U> and the other terms of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the provisions of this <U>Section 3.2</U> shall survive the termination of this Agreement and the resignation, replacement or removal
of the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">3.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Resignation and Removal; Appointment of Successor</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The <FONT STYLE="color: windowtext">Rights Agent </FONT>may resign at any time by giving written notice thereof to <FONT STYLE="color: windowtext">Parent
</FONT>specifying a date when such resignation will take effect, which notice will be sent at least thirty (30) days prior to the date
so specified. <FONT STYLE="color: windowtext">Parent </FONT>has the right to remove <FONT STYLE="color: windowtext">the Rights Agent </FONT>at
any time. <FONT STYLE="color: windowtext">Notice </FONT>of such removal will be given by <FONT STYLE="color: windowtext">Parent </FONT>to
<FONT STYLE="color: windowtext">the Rights Agent</FONT>, which notice will be sent at least thirty (30) days prior to the date so specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the <FONT STYLE="color: windowtext">Rights Agent provides notice of its intent to resign</FONT>, is removed or becomes incapable
of acting, then <FONT STYLE="color: windowtext">Parent</FONT> will as soon as is reasonably possible appoint a qualified successor <FONT STYLE="color: windowtext">Rights
Agent </FONT>who may be a <FONT STYLE="color: windowtext">Holder </FONT>but may not be an officer of <FONT STYLE="color: windowtext">Parent</FONT>.
The successor <FONT STYLE="color: windowtext">Rights Agent </FONT>so appointed will, forthwith upon its acceptance of such appointment
in accordance with <FONT STYLE="color: windowtext"><U>Section&nbsp;3.4</U></FONT>, become the successor <FONT STYLE="color: windowtext">Rights
Agent</FONT>. Notwithstanding the foregoing, if Parent fails to make such appointment within a period of thirty (30) calendar days after
giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated
Rights Agent, then the incumbent Rights Agent or any Holder may apply to any court of competent jurisdiction for the appointment of a
new Rights Agent. The successor Rights Agent so appointed shall, forthwith upon its acceptance of such appointment in accordance with
<U>Section 3.4</U>, become the successor Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="color: windowtext">Parent </FONT>will give notice of each resignation and each removal of a <FONT STYLE="color: windowtext">Rights
Agent </FONT>and each appointment of a successor <FONT STYLE="color: windowtext">Rights Agent </FONT>by mailing written notice of such
event by first-class mail to the <FONT STYLE="color: windowtext">Holders </FONT>as their names and addresses appear in the <FONT STYLE="color: windowtext">CVR
Register</FONT>. Each notice will include the name and address of the successor <FONT STYLE="color: windowtext">Rights Agent</FONT>. If
<FONT STYLE="color: windowtext">Parent </FONT>fails to send such notice within twenty (20) days after acceptance of appointment by a successor
<FONT STYLE="color: windowtext">Rights Agent</FONT>, the successor <FONT STYLE="color: windowtext">Rights Agent </FONT>will cause the
notice to be mailed at the expense of <FONT STYLE="color: windowtext">Parent; <I>provided</I> that failure to give any notice provided
for in this <U>Section 3.3(c)</U>, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the
appointment of the successor Rights Agent, as the case may be, in each case, in accordance with this <U>Section 3.3</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="color: windowtext">The Rights Agent will reasonably cooperate with Parent and any successor Rights Agent as reasonably
requested in connection with the transition of duties and responsibilities of the Rights Agent to the successor Rights Agent, including
transferring the CVR Register to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional
expenditure without compensation or reimbursement by Parent or assume any additional liability in connection with the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">3.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Acceptance of Appointment by Successor</U>. Every successor <FONT STYLE="color: windowtext">Rights Agent </FONT>appointed hereunder
will execute, acknowledge and deliver to <FONT STYLE="color: windowtext">Parent </FONT>and to the predecessor <FONT STYLE="color: windowtext">Rights
Agent </FONT>an instrument accepting such appointment and a counterpart of this <FONT STYLE="color: windowtext">Agreement</FONT>, and
thereupon such successor <FONT STYLE="color: windowtext">Rights Agent</FONT>, without any further act, deed or conveyance, will become
vested with all the rights, powers, liabilities, trusts and duties of the predecessor <FONT STYLE="color: windowtext">Rights Agent</FONT>.
On request of <FONT STYLE="color: windowtext">Parent </FONT>or the successor <FONT STYLE="color: windowtext">Rights Agent</FONT>, the
predecessor <FONT STYLE="color: windowtext">Rights Agent </FONT>will execute and deliver an instrument transferring to the successor <FONT STYLE="color: windowtext">Rights
Agent </FONT>all the rights, powers and trusts of the predecessor <FONT STYLE="color: windowtext">Rights Agent, except such rights, powers,
liabilities, trusts and duties which survive its resignation or removal under the terms hereunder</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">3.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Appointment of Rights Agent</U>. Parent hereby appoints the Rights Agent to act as rights agent with the express terms and conditions
set forth in this Agreement (and no implied terms and conditions), and the Rights Agent hereby accepts such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: none">4.</FONT> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;COVENANTS</P>



<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">4.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="color: windowtext"><U>List of Holders</U></FONT>. <FONT STYLE="color: windowtext">Parent </FONT>will furnish or cause
to be furnished to the <FONT STYLE="color: windowtext">Rights Agent </FONT>in such form as <FONT STYLE="color: windowtext">Parent </FONT>receives
from the <FONT STYLE="color: windowtext">Company</FONT>&rsquo;s transfer agent (or other agent performing similar services for the Company
with respect to other shares of Company Common Stock, Company RSUs or Company Options that, at the Effective Time, are then outstanding
and unexercised, whether or not vested, and which have a per share exercise price that is less than the Closing Amount), the names and
addresses of the <FONT STYLE="color: windowtext">Holders </FONT>within twenty (20) <FONT STYLE="color: windowtext">Business Days </FONT>of
the <FONT STYLE="color: windowtext">Effective Time (or as soon as practicable thereafter)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: none">5.</FONT> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;AMENDMENTS</P>



<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">5.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments without Consent of <FONT STYLE="color: windowtext">Holders</FONT></U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Without the consent of any <FONT STYLE="color: windowtext">Holders or the Rights Agent</FONT>, <FONT STYLE="color: windowtext">Parent</FONT>
at any time and from time to time, <FONT STYLE="color: windowtext">may enter into one (1) or more amendments hereto</FONT>, to evidence
the succession of another <FONT STYLE="color: windowtext">Person </FONT>to <FONT STYLE="color: windowtext">Parent </FONT>and the assumption
by any such successor of the covenants of <FONT STYLE="color: windowtext">Parent </FONT>herein as provided in, and to the extent consistent
with, <FONT STYLE="color: windowtext"><U>Section 6.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Without the consent of any <FONT STYLE="color: windowtext">Holders or the Rights Agent</FONT>, <FONT STYLE="color: windowtext">Parent
and the Surviving Corporation</FONT>, at any time and from time to time, <FONT STYLE="color: windowtext">may enter into one or more amendments
hereto</FONT>, for any of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to evidence the succession of another <FONT STYLE="color: windowtext">Person </FONT>as a successor <FONT STYLE="color: windowtext">Rights
Agent </FONT>and the assumption by any such successor of the covenants and obligations of the <FONT STYLE="color: windowtext">Rights Agent
</FONT>herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent and the Rights Agent
will consider to be for the protection of the Holders; <I>provided</I> that, in each case, such provisions do not adversely affect the
interests of the Rights Agent or the Holders (as a group and in their capacity as such);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision
herein, or to make any other provisions with respect to matters or questions arising under this <FONT STYLE="color: windowtext">Agreement</FONT>;
<I>provided</I> that, in each case, <FONT STYLE="color: windowtext">such provisions do not adversely affect the interests of the Rights
Agent or the Holders (as a group and in their capacity as such)</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as may be necessary or appropriate to ensure that the <FONT STYLE="color: windowtext">CVRs </FONT>are not subject to registration
under the <FONT STYLE="color: windowtext">Securities Act (</FONT>and the rules and regulations promulgated thereunder) or the <FONT STYLE="color: windowtext">Exchange
Act</FONT>, and to ensure that the CVRs are not subject to any similar registration or prospectus requirement under applicable securities
Legal Requirements outside of the United States; <I>provided</I> that, in each case, such amendments do not change the Milestone, the
Milestone Expiration Date or the Milestone Payment Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to reduce the number of CVRs, in the event and to the extent any Holder agrees to renounce such Holder&rsquo;s rights under this
Agreement in accordance with <U>Section 6.4</U>; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this <FONT STYLE="color: windowtext">Agreement</FONT>,
unless such addition, elimination or change is adverse to the interests of the Rights Agent or the <FONT STYLE="color: windowtext">Holders
(as a group and in their capacity as such)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Promptly after the execution by <FONT STYLE="color: windowtext">Parent </FONT>and the <FONT STYLE="color: windowtext">Rights Agent
</FONT>of any amendment pursuant to the provisions of this <FONT STYLE="color: windowtext"><U>Section&nbsp;5.1</U></FONT>, <FONT STYLE="color: windowtext">Parent
</FONT>will mail (or cause the <FONT STYLE="color: windowtext">Rights Agent </FONT>to mail) a notice thereof by first class mail to the
<FONT STYLE="color: windowtext">Holders </FONT>at their addresses as they appear on the <FONT STYLE="color: windowtext">CVR Register</FONT>,
setting forth such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments with Consent of Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Without limiting the right to amend pursuant to <FONT STYLE="color: windowtext"><U>Section&nbsp;5.1</U></FONT>, with the consent
of the <FONT STYLE="color: windowtext">Holders </FONT>of not less than twenty percent (20%) of the outstanding <FONT STYLE="color: windowtext">CVRs</FONT>,
whether evidenced in writing or taken at a meeting of the <FONT STYLE="color: windowtext">Holders, Parent</FONT> and the <FONT STYLE="color: windowtext">Rights
Agent may enter into one or more amendments hereto </FONT>for the purpose of adding, eliminating or changing any provisions of this <FONT STYLE="color: windowtext">Agreement</FONT>,
even if such addition, elimination or change is materially adverse to the interests of the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Promptly after the execution by <FONT STYLE="color: windowtext">Parent </FONT>and the <FONT STYLE="color: windowtext">Rights Agent
</FONT>of any amendment pursuant to the provisions of this <FONT STYLE="color: windowtext"><U>Section&nbsp;5.2</U></FONT>, <FONT STYLE="color: windowtext">Parent
</FONT>will mail (or cause the <FONT STYLE="color: windowtext">Rights Agent </FONT>to mail) a notice thereof by first class mail to the
<FONT STYLE="color: windowtext">Holders </FONT>at their addresses as they appear on the <FONT STYLE="color: windowtext">CVR Register</FONT>,
setting forth such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">5.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Execution of Amendments</U>. In executing any amendment permitted by this <FONT STYLE="color: windowtext"><U>Section 5</U></FONT>,
the <FONT STYLE="color: windowtext">Rights Agent </FONT>will be entitled to receive, and will be fully protected in relying upon, an opinion
of counsel selected by <FONT STYLE="color: windowtext">Parent (including in-house counsel) </FONT>stating that the execution of such amendment
is authorized or permitted by this <FONT STYLE="color: windowtext">Agreement</FONT>. Except as provided under <U>Section 5.1</U>, no supplement
or amendment shall be effective unless duly executed by the Parent and the Rights Agent; <I>provided</I>, <I>however</I>, that no amendment
shall be effective unless notice thereof has been provided to the Rights Agent. The <FONT STYLE="color: windowtext">Rights Agent </FONT>may,
but is not obligated to, enter into any such amendment that affects the <FONT STYLE="color: windowtext">Rights Agent</FONT>&rsquo;s own
rights, privileges, covenants or duties under this <FONT STYLE="color: windowtext">Agreement </FONT>or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">5.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Effect of Amendments</U>. Upon the execution of any amendment under this <FONT STYLE="color: windowtext"><U>Section 5</U></FONT>,
this <FONT STYLE="color: windowtext">Agreement </FONT>will be modified in accordance therewith, such amendment will form a part of this
<FONT STYLE="color: windowtext">Agreement </FONT>for all purposes and every <FONT STYLE="color: windowtext">Holder </FONT>will be bound
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-transform: none">6.</FONT> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;OTHER PROVISIONS OF GENERAL APPLICATION</P>



<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notices to the Rights Agent and <FONT STYLE="color: windowtext">Parent</FONT></U>. All notices and other communications required
or permitted to be given to any party hereunder shall be in writing and shall be deemed properly delivered on (a) the date and time of
delivery if delivered personally, (b) if to the Parent, the date and time of transmittal if delivered by email (<I>provided</I>, no &ldquo;bounce
back&rdquo; or similar message of non-delivery is received with respect thereto), which email must state that it is being delivered pursuant
to this <U>Section 6.1</U>, (c) the first (1st) Business Day following the date of dispatch if delivered utilizing a next day service
by a recognized next day courier or (d) upon confirmed receipt if delivered by registered or certified mail, return receipt requested,
postage prepaid. All notices or other communications hereunder shall be delivered to the addresses or email addresses set forth below,
or pursuant to such other instructions as the party to receive such notice or communication shall have specified in a written notice given
to the other parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Rights Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Facsimile: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to Parent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Gilead Sciences, Inc.<BR>
333 Lakeside Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Foster City, CA 94404</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Ropes &amp; Gray LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">800 Boylston Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Boston, MA 02199</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Attention:</TD><TD>Emily J. Oldshue</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 1in">Email:</TD><TD>emily.oldshue@ropesgray.com</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 116; Options: NewSection; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notice to Holders</U>. Where this <FONT STYLE="color: windowtext">Agreement </FONT>provides for notice to <FONT STYLE="color: windowtext">Holders</FONT>,
such notice will be sufficiently given (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid,
to each <FONT STYLE="color: windowtext">Holder </FONT>affected by such event, at the Holder&rsquo;s address as it appears in the <FONT STYLE="color: windowtext">CVR
Register</FONT>, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice.
In any case where notice to <FONT STYLE="color: windowtext">Holders </FONT>is given by mail, neither the failure to mail such notice,
nor any defect in any notice so mailed, to any particular <FONT STYLE="color: windowtext">Holder </FONT>will affect the sufficiency of
such notice with respect to other <FONT STYLE="color: windowtext">Holders</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="color: black">6.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></FONT><U>Parent Successors and Assigns</U>. Parent shall not assign any of its rights, interests or obligations hereunder, other
than in accordance with this <U>Section 6.3</U>. Parent may assign, in its sole discretion and without the consent of any other party,
any or all of its rights, interests and obligations hereunder to one or more Affiliate(s) of Parent or to any purchaser or exclusive licensee
of all or substantially all rights to the Product, including in connection with a change of control of Parent (each, an &ldquo;<U>Assignee</U>&rdquo;);
<I>provided</I> that the Assignee agrees to assume and be bound by all of the terms of this Agreement. Any such Assignee may thereafter
assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder
to one or more additional Assignees in compliance with this <U>Section 6.3</U>. In connection with any assignment to an Assignee, Parent
(and such assignor, if applicable) will remain liable for performance by Parent (and such assignor, if applicable) of its obligations
hereunder. This Agreement will be binding upon, inure to the benefit of and be enforceable by each Assignee, and this Agreement shall
not restrict Parent&rsquo;s or any of its Affiliates&rsquo; or Assignee&rsquo;s ability to merge or consolidate, subject to compliance
with this <U>Section 6.3</U> to the extent there is an applicable assignment in connection with such merger or consolidation. Each of
Parent&rsquo;s non-Affiliate Assignees shall expressly assume by an instrument supplemental hereto, executed and delivered to the Rights
Agent, the due and punctual payment of the CVRs and the due and punctual performance and observance of all of the covenants and obligations
of this Agreement to be performed or observed by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Benefits of <FONT STYLE="color: windowtext">Agreement</FONT></U>. Nothing in this <FONT STYLE="color: windowtext">Agreement</FONT>,
express or implied, will give to any <FONT STYLE="color: windowtext">Person </FONT>(other than the Rights Agent, Parent, Parent&rsquo;s
successors and assignees, the <FONT STYLE="color: windowtext">Holders, and the Holders&rsquo; successors and assigns pursuant to a Permitted
Transfer</FONT>) any benefit or any legal or equitable right, remedy or claim under this <FONT STYLE="color: windowtext">Agreement </FONT>or
under any covenant or provision contained herein, all such covenants and provisions being for the sole benefit of the, Rights Agent, Parent,
Parent&rsquo;s successors and assignees, the <FONT STYLE="color: windowtext">Holders, and the Holders&rsquo; successor and assigns pursuant
to a Permitted Transfer</FONT>. The rights of Holders are limited to the right to receive payment from the Rights Agent in respect of
the CVRs if and when due and payable in accordance with <U>Section 2.4</U>. All other obligations of Parent or its successor or assigns
hereunder may only be enforced by the Rights Agent. Notwithstanding anything to the contrary contained herein, any Holder may agree to
renounce, in whole or in part, such Holder&rsquo;s rights under this Agreement by written notice to the Rights Agent and Parent, which
notice, if given, shall be irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 117; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Governing Law</U>. This Agreement, the CVRs and any other matters or disputes relating thereto shall be governed by, and construed
in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles
of conflicts of laws thereof. In any action or proceeding arising out of or relating to this Agreement or the CVRs: (i)&nbsp;each of the
parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of: (A) the Chancery Court of the
State of Delaware and any state appellate court therefrom, (B) if (but only if) the court in <U>clause (A)</U> lacks subject matter jurisdiction,
the Superior Court of the State of Delaware sitting in New Castle County and any state appellate court therefrom or (C) if (but only if)
the courts in <U>clauses (A)</U> and <U>(B)</U> lack subject matter jurisdiction, the United States District Court in the State of Delaware
and any appellate court therefrom (collectively, the courts described in <U>clauses (A)</U> through <U>(C)</U>, the &ldquo;<U>Delaware
Courts</U>&rdquo;); and (ii)&nbsp;each of the parties irrevocably consents to service of process by first class certified mail, return
receipt requested, postage prepaid, to the address at which such party is to receive notice in accordance with <U>Section 6.1</U>. Each
of the parties irrevocably and unconditionally (1)&nbsp;agrees not to commence any such action or proceeding except in the Delaware Courts,
(2)&nbsp;agrees that any claim in respect of any such action or proceeding may be heard and determined in the Delaware Courts, (3)&nbsp;waives,
to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction or laying
of venue of any such action or proceeding in the Delaware Courts and (4)&nbsp;waives, to the fullest extent permitted by law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. The parties agree that a final judgment
in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by applicable Legal Requirements; <I>provided</I>, <I>however</I>, that nothing in the foregoing shall restrict any party&rsquo;s
rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment. In the event of any litigation
or other proceeding between the parties to this Agreement arising out of or in any way related to the Milestone or the Milestone Payment
Amount, the prevailing party in such litigation or other proceeding shall be entitled to recover its reasonable attorneys&rsquo; fees,
costs and expenses incurred in connection with such litigation or other proceeding, in addition to any other relief to which such party
may be entitled; <I>provided</I>, <I>however</I>, that in no event will any party to this Agreement be required to pay any contingency
based attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability
of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction
declares that any term or provision of this Agreement is invalid or unenforceable, the parties agree that the court making such determination
shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a
term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term
or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted
to it in the prior sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable
term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Counterparts and Signature</U>. This Agreement may be executed in two or more counterparts, including by e-signature or by email
with .pdf attachments, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts
have been signed by each of the parties and delivered to the other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 118; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Termination</U>. This <FONT STYLE="color: windowtext">Agreement </FONT>will terminate and be of no force or effect, the parties
hereto will have no liability hereunder (other than with respect to monies due and owing by Parent to the Rights Agent prior to the effectiveness
of such termination), and no payments will be required to be made, upon the earlier to occur of <FONT STYLE="color: windowtext">(a)&nbsp;the
payment by the Rights Agent or Parent or one (1) or more of its Affiliates, as applicable, to each Holder as reflected in the CVR Register
of the</FONT> full amount of the Milestone Payment <FONT STYLE="color: windowtext">Amount </FONT>required to be paid under the terms of
this <FONT STYLE="color: windowtext">Agreement and (b) the failure to achieve the Milestone prior to the Milestone Expiration Date. No
termination shall affect the Holders&rsquo; rights to any payment accrued prior to the effective date of such termination and the provisions
of this <U>Section 6</U> shall survive any such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Entire <FONT STYLE="color: windowtext">Agreement</FONT></U>. This <FONT STYLE="color: windowtext">Agreement</FONT>, the <FONT STYLE="color: windowtext">Merger
Agreement </FONT>(including its Exhibits, Annexes and the Company Disclosure Letter) and the Confidentiality Agreement constitute the
entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties and
their respective Affiliates, with respect to the subject matter hereof and thereof. If and to the extent that any provision of this <FONT STYLE="color: windowtext">Agreement
</FONT>is inconsistent or conflicts with the <FONT STYLE="color: windowtext">Merger Agreement</FONT>, this <FONT STYLE="color: windowtext">Agreement
</FONT>will govern and be controlling with respect to CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Confidentiality</U>. The Rights Agent and Parent agree that all books, records, information and data pertaining to the business
of the other party that are exchanged or received pursuant to the negotiation or the carrying out of this Agreement, including the amount
and terms of fees for services, shall remain confidential and shall be used solely to perform their respective obligations under this
Agreement, and shall not be voluntarily disclosed to any other person, except as may be required by applicable Legal Requirements. However,
each party may disclose relevant aspects of the other party&rsquo;s confidential information to its officers, Affiliates, agents, subcontractors
and employees to the extent reasonably necessary and to be used solely to perform its duties and obligations under this Agreement if such
disclosure is not prohibited by applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Force Majeure</U>. Notwithstanding anything to the contrary contained herein, none of the Rights Agent, Parent or any of its
Subsidiaries will be liable for any delays or failures in performance resulting from acts beyond its reasonable control including acts
of God, pandemics, epidemics, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunctions of computer
facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor disputes,
strikes, or shortages, war or civil unrest, it being understood that such parties shall use commercially reasonable efforts to resume
performance as soon as reasonably practicable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">[<I>Remainder
of page intentionally left blank</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 119; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: windowtext">IN
</FONT>WITNESS WHEREOF, each of the parties has caused this <FONT STYLE="color: windowtext">Agreement </FONT>to be executed on its behalf
by its duly authorized officers as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">GILEAD
    SCIENCES, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above
written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">[Rights
    Agent]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm267044d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TENDER AND SUPPORT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This TENDER AND SUPPORT AGREEMENT
(this &ldquo;<U>Agreement</U>&rdquo;), dated as of February&nbsp;22, 2026, is entered into by and among Gilead Sciences,&nbsp;Inc., a
Delaware corporation (&ldquo;<U>Parent</U>&rdquo;), Ravens Sub,&nbsp;Inc., a Delaware corporation and a wholly-owned subsidiary of Parent
(&ldquo;<U>Purchaser</U>&rdquo;), and one or more stockholders of Arcellx,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
set forth on <U>Schedule A</U> hereto (each, a &ldquo;<U>Stockholder</U>&rdquo; and, if applicable, collectively, the &ldquo;<U>Stockholders</U>&rdquo;).
All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement
(as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as of the date hereof,
each Stockholder is the record or beneficial owner (as defined in Rule&#8239;13d-3 under the Exchange Act) of the number of shares of
Company Common Stock [and Company Options and Company RSUs, if any, in each case] set forth opposite such Stockholder&rsquo;s name on
<U>Schedule A</U> (all such shares of Company Common Stock, [Company Options and Company RSU] set forth on <U>Schedule A</U> next to the
Stockholder&rsquo;s name, together with any shares of Company Common Stock that are hereafter issued to or otherwise directly or indirectly
acquired or beneficially owned (as defined in Rule&nbsp;13d-3 under the Exchange Act) by any Stockholder prior to the valid termination
of this Agreement in accordance with <U>Section&#8239;5.2</U>, [including for the avoidance of doubt any shares of Company Common Stock
acquired by such Stockholder upon the exercise of Company Options or vesting of Company RSUs after the date hereof,] being referred to
herein as the &ldquo;<U>Subject Shares</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution hereof, Parent, Purchaser and the Company are entering into an Agreement and Plan of Merger, dated as of the date hereof
(as it may be amended from time to time pursuant to the terms thereof, the &ldquo;<U>Merger Agreement</U>&rdquo;), which provides, among
other things, for Purchaser to commence an offer to purchase (the consummation of which is subject to the Offer Conditions) all of the
outstanding shares of Company Common Stock, and, following completion of the Offer, for the Merger of Purchaser with and into the Company,
upon the terms and subject to the conditions set forth in the Merger Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as a condition to
their willingness to enter into the Merger Agreement, and as an inducement and in consideration for Parent and Purchaser to enter into
the Merger Agreement, each Stockholder, severally and not jointly, and on such Stockholder&rsquo;s own account with respect to the Subject
Shares, has agreed to enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&#8239;I<BR>
</B></FONT><B>AGREEMENT TO TENDER AND VOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&#8239;1.1
 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Agreement to Tender</U>. Subject to the terms of this Agreement, each Stockholder hereby agrees
to validly and irrevocably tender or cause to be validly and irrevocably tendered in the Offer all of such Stockholder&rsquo;s Subject
Shares [(other than Company Options that are not exercised and Company RSUs that are not vested during the term of this Agreement)] pursuant
to and in accordance with the terms of the Offer, free and clear of all Encumbrances, except for Permitted Encumbrances (as defined below).
Without limiting the generality of the foregoing, as promptly as practicable after, but in no event later than ten (10)&#8239;business
days after, the commencement (within the meaning of Rule&#8239;14d-2 under the Exchange Act) of the Offer (or in the case of any shares
of Company Common Stock acquired by such Stockholder subsequent to such tenth (10<SUP>th</SUP></FONT>) business day, as promptly as practicable
after the acquisition of such shares), as the case may be (but, if such shares are acquired prior to the expiration of the Offer, in no
event later than expiration of the Offer), each Stockholder shall deliver or cause to be delivered pursuant to the terms of the Offer
(a)&#8239;in the case of Subject Shares represented by a certificate or held in direct registry form through the Company&rsquo;s transfer
agent, a letter of transmittal with respect to all of such Stockholder&rsquo;s Subject Shares complying with the terms of the Offer, together
with the certificate(s)&nbsp;(or affidavits of loss in lieu thereof)&#8239;representing all such Subject Shares that are certificated
or (b)&#8239;in the case of a Shares held in book-entry form, written instructions to such Stockholder&rsquo;s broker, dealer or other
nominee that such Subject Shares be tendered, including a reference to this Agreement, and requesting delivery of an &ldquo;agent&rsquo;s
message&rdquo; (or such other evidence, if any, of transfer as the Paying Agent may reasonably request) with respect to such Subject Shares,
and (c)&#8239;all other documents or instruments required by the terms of the Offer in order to effect the valid tender of such Stockholder&rsquo;s
Subject Shares in accordance with the terms of the Offer and the Merger Agreement [(it being understood that this sentence shall not apply
to Company Options that are not exercised or Company RSUs that are not vested during the term of this Agreement)]. Each Stockholder agrees
that, once any of such Stockholder&rsquo;s Subject Shares are tendered in accordance with the terms hereof, such Stockholder will not
withdraw and will cause not to be withdrawn such Subject Shares from the Offer at any time, unless and until this Agreement shall have
been validly terminated in accordance with <U>Section&#8239;5.2</U>. [For clarity, no Stockholder shall be required, for purposes of this
Agreement, to exercise any unexercised Company Options held by such Stockholder.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;1.2 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Agreement
to Vote</U>. Subject to the terms of this Agreement, each Stockholder hereby irrevocably and unconditionally agrees that, during the time
this Agreement is in effect, at any annual or special meeting of the stockholders of the Company, however called, including any adjournment
or postponement thereof, and in connection with any action proposed to be taken by written consent (if permitted at such time) of the
stockholders of the Company, in which the vote, consent or other approval of the stockholders of the Company is sought with respect to
the Offer, the Merger, the Merger Agreement or any Acquisition Proposal, such Stockholder shall, in each case to the fullest extent that
such Stockholder&rsquo;s Subject Shares are entitled to vote thereon: (a)&#8239;appear at each such meeting or otherwise cause all such
Subject Shares to be counted as present thereat for purposes of determining a quorum; and (b)&#8239;be present (in person or by proxy)
and vote (or cause to be voted), or deliver (or cause to be delivered) a written consent (if permitted at such time) with respect to,
all of its Subject Shares (i)&#8239;against any Acquisition Proposal (other than the Merger), (ii)&#8239;against any change in membership
of the Board of Directors that is not recommended or approved by the Board of Directors, and (iii)&#8239;against any other proposed action,
agreement or transaction involving the Company that is intended, or would reasonably be expected, to prevent, materially impair, or delay
the consummation of the Offer, the Merger or the other Transactions, including (x)&#8239;any extraordinary corporate transaction, such
as a merger, consolidation or other business combination involving the Company (other than the Merger); (y)&#8239;a sale, lease, license
or transfer of a material amount of assets (including, for the avoidance of doubt, intellectual property rights) of the Company or any
reorganization, recapitalization or liquidation of the Company; or (z)&nbsp;any change in the present capitalization of the Company or
any amendment or other change in the Company&rsquo;s organizational documents. Each Stockholder shall retain at all times the right to
vote such Stockholder&rsquo;s Subject Shares in such Stockholder&rsquo;s sole discretion, and without any other limitation, on any matters
other than those set forth in this <U>Section&#8239;1.2</U> that are at any time or from time to time presented for consideration to the
Company&rsquo;s stockholders generally.&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&#8239;II<BR>
</B></FONT><B>REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder represents
and warrants, on its own account with respect to the Subject Shares, to Parent and Purchaser as to such Stockholder on a several basis,
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.1
&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorization; Binding Agreement</U>. To the extent such Stockholder is not an individual,
such Stockholder is duly organized and validly existing in good standing under the Legal Requirements of the jurisdiction in which
it is incorporated or constituted (to the extent such concepts are recognized in such jurisdiction) and the consummation of the
transactions contemplated hereby are within such Stockholder&rsquo;s entity powers and have been duly authorized by all necessary
entity actions on the part of such Stockholder. Such Stockholder has full power and authority to execute, deliver and comply with
its obligations under this Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly and
validly executed and delivered by such Stockholder and, assuming the due authorization, execution and delivery by Parent and
Purchaser, constitutes a legal, valid and binding obligation of such Stockholder enforceable against such Stockholder in accordance
with its terms, except as enforcement thereof may be limited against the Company by (i)&nbsp;bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting the enforcement of creditors&rsquo; rights or remedies in general as from time to time in
effect or (ii)&nbsp;generally and by general principals of equity and subject to any conflict with the federal securities laws. No
other action of such Stockholder is necessary to authorize this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.2 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Contravention</U>.
Neither the execution and delivery of this Agreement by such Stockholder nor the consummation of the transactions contemplated hereby
nor compliance by such Stockholder with any provisions herein will (a)&#8239;if such Stockholder is not an individual, violate, contravene
or conflict with or result in any breach of any provision of the certificate of incorporation or bylaws (or other similar governing documents)
of such Stockholder, (b)&#8239;require any consent, approval, order, authorization, action or permit of, or filing with or notification
to, any Person on the part of such Stockholder, except for compliance with the applicable requirements of the Securities Act, the Exchange
Act or any other United States or federal securities laws and the rules&#8239;and regulations promulgated thereunder, (c)&#8239;violate,
conflict with, or result in a breach of any provisions of, or require any consent, waiver or approval or result in a default or loss of
a benefit (or give rise to any right of termination, cancellation, modification or acceleration or any event that, with the giving of
notice, the passage of time or otherwise, would constitute a default or give rise to any such right) under any of the terms, conditions
or provisions of any Contract or other legally binding instrument or obligation to which such Stockholder is a party or by which such
Stockholder or any of its assets may be bound, (d)&#8239;result (or, with the giving of notice, the passage of time or otherwise, would
result) in the creation or imposition of any Encumbrance on any Subject Shares of such Stockholder (other than one created by Parent or
Purchaser), or (e)&#8239;violate any Legal Requirement or judgment applicable to such Stockholder or by which any of its Subject Shares
are bound (except as may be required by applicable federal or state securities laws), except as would not, in the case of each of clauses
(a)&#8239;through (e), reasonably be expected to prevent or materially delay or materially impair the consummation by such Stockholder
of the transactions contemplated by this Agreement or otherwise adversely impact such Stockholder&rsquo;s ability to comply with such
Stockholder&rsquo;s obligations hereunder. No trust of which the Stockholder is a trustee requires the consent of any beneficiary to the
execution and delivery of this Agreement or to the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.3 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Ownership
of Subject Shares; Total Shares</U>. As of the date hereof, such Stockholder is, and (except with respect to any Subject Shares Transferred
in accordance with <U>Section&#8239;4.1</U> hereof or accepted for payment pursuant to the Offer) at all times during the Agreement Period
(as defined below) will remain, the record or beneficial owner (as defined in Rule&#8239;13d-3 under the Exchange Act), as is the case
on the date hereof, of all such Stockholder&rsquo;s Subject Shares and has good and marketable title to all such Subject Shares free and
clear of any Encumbrances, except for (a)&#8239;any such Encumbrance that may be imposed pursuant to (i)&#8239;this Agreement and (ii)&#8239;any
applicable restrictions on transfer under the Securities Act or any state securities law and (b)&#8239;community property interests under
applicable Legal Requirement (collectively, &ldquo;<U>Permitted Encumbrances</U>&rdquo;). The number of Subject Shares listed on <U>Schedule
A</U> opposite such Stockholder&rsquo;s name are the only equity interests or other securities in the Company beneficially owned or owned
of record by such Stockholder as of the date hereof. Other than the Subject Shares, such Stockholder does not own any Company Common Stock[,
Company Options, Company RSUs] or any other interests in, options to purchase or rights to subscribe for or otherwise acquire any securities
of the Company and has no interest in or voting rights with respect to any Company Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.4 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Voting
Power</U>. [Except with respect to Company Options and Company RSUs (but including any Company Common Stock issued upon exercise of Company
Options or upon the vesting of Company RSUs),] such Stockholder has full voting power with respect to all such Stockholder&rsquo;s Subject
Shares, and full power of disposition, full power to issue instructions with respect to the matters set forth herein and full power to
agree to all of the matters set forth in this Agreement, in each case with respect to all such Stockholder&rsquo;s Subject Shares. None
of such Stockholder&rsquo;s Subject Shares are subject to any stockholders&rsquo; agreement, proxy, voting trust or other agreement or
arrangement with respect to the voting of such Subject Shares, except as provided pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.5 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Reliance</U>.
Such Stockholder has been represented by or had the opportunity to be represented by independent counsel of his, her or its own choosing
and has had the right and opportunity to consult with his, her or its attorney, and to the extent, if any, that such Stockholder desired,
such Stockholder availed himself, herself or itself of such right and opportunity. Such Stockholder understands and acknowledges that
Parent and Purchaser are entering into the Merger Agreement in reliance upon such Stockholder&rsquo;s execution and delivery of and compliance
with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.6 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Litigation</U>. With respect to such Stockholder, as of the date hereof, there is no Legal Proceeding pending against, or, to the knowledge
of such Stockholder, threatened against such Stockholder or any of such Stockholder&rsquo;s properties or assets (including any shares
of Company Common Stock[, Company Options or Company RSUs] beneficially owned by such Stockholder) that could reasonably be expected to
prevent or materially delay or materially impair the consummation by such Stockholder of the transactions contemplated by this Agreement
or otherwise materially impair such Stockholder&rsquo;s ability to comply with such Stockholder&rsquo;s obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;2.7 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Brokers</U>.
No broker, finder, financial advisor, investment banker or other Person is entitled to any brokerage, finder&rsquo;s, financial advisor&rsquo;s
or other similar fee or commission from the Company in connection with the transactions contemplated hereby based upon arrangements made
by or on behalf of such Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&#8239;III<BR>
</B></FONT><B>REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and Purchaser represent
and warrant to the Stockholders that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;3.1 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization
and Qualification</U>. Each of Parent and Purchaser is a duly organized and validly existing corporation in good standing under the Legal
Requirements of the jurisdiction of its organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;3.2 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Authority
for this Agreement</U>. Each of Parent and Purchaser has all requisite entity power and authority to execute, deliver and comply with
its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement
by Parent and Purchaser have been duly and validly authorized by all necessary entity action on the part of each of Parent and Purchaser,
and no other entity proceedings on the part of Parent and Purchaser are necessary to authorize this Agreement. This Agreement has been
duly and validly executed and delivered by Parent and Purchaser and, assuming the due authorization, execution and delivery by the Stockholder,
constitutes a legal, valid and binding obligation of each of Parent and Purchaser, enforceable against each of Parent and Purchaser in
accordance with its terms, subject to bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally
and by general principals of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&#8239;IV<BR>
</B></FONT><B>ADDITIONAL COVENANTS OF THE STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby covenants
and agrees that until the valid termination of this Agreement in accordance with <U>Section&#8239;5.2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.1 &#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Transfer; No Inconsistent Arrangements</U>. Except as provided hereunder or under the Merger Agreement, from and after the date hereof
and until this Agreement is validly terminated in accordance with <U>Section&#8239;5.2</U>, such Stockholder shall not, directly or indirectly,
(a)&#8239;create or permit to exist any Encumbrance, other than Permitted Encumbrances, on any of such Stockholder&rsquo;s Subject Shares,
(b)&#8239;transfer, sell (including short sell), assign, gift, hedge, pledge, grant a participation interest in, hypothecate or otherwise
dispose (whether by sale, liquidation, dissolution, dividend or distribution) of, or enter into any derivative arrangement with respect
to (collectively, &ldquo;<U>Transfer</U>&rdquo;), any of such Stockholder&rsquo;s Subject Shares, or any right or interest therein (or
consent to any of the foregoing), (c)&#8239;enter into any Contract with respect to any Transfer of such Stockholder&rsquo;s Subject Shares
or any interest therein, (d)&#8239;grant or permit the grant of any proxy, power-of-attorney or other authorization or consent in or with
respect to any such Stockholder&rsquo;s Subject Shares, (e)&#8239;deposit or permit the deposit of any of such Stockholder&rsquo;s Subject
Shares into a voting trust or enter into a voting agreement or arrangement with respect to any of such Stockholder&rsquo;s Subject Shares,
or (f)&#8239;take or permit any other action that would in any way prevent, materially delay or materially impair the compliance with
such Stockholder&rsquo;s obligations hereunder or the transactions contemplated hereby, otherwise make any representation or warranty
of such Stockholder herein untrue or incorrect in any material respect, or have the effect of preventing or disabling such Stockholder
from complying with any of its obligations under this Agreement. Any action taken in violation of the foregoing sentence shall be null
and void <I>ab initio</I>. Each Stockholder hereby authorizes Parent to direct the Company to impose stop orders to prevent the Transfer
of any Subject Shares on the books of the Company in violation of this Agreement. Notwithstanding the foregoing, (x)&#8239;any Stockholder
that is an individual may Transfer Subject Shares (i)&#8239;to any member of such Stockholder&rsquo;s immediate family, (ii)&#8239;to
a trust for the sole benefit of such Stockholder or any member of such Stockholder&rsquo;s immediate family, the sole trustees of which
are such Stockholder or any member of such Stockholder&rsquo;s immediate family, (iii)&#8239;by will or under the laws of intestacy upon
the death of such Stockholder, (iv)&nbsp;pursuant to, and in compliance with, a written plan in effect as of the date of this Agreement
and provided to Parent prior to execution of this Agreement that meets the requirements of&nbsp;Rule&nbsp;10b5-1&nbsp;under&nbsp;the Securities
Exchange Act of 1934, as amended, or (v)&nbsp;to a partnership, limited liability company or other type of entity of which the Stockholder
or its immediate family are the legal and beneficial owners of all of the outstanding equity securities or similar interests and (y)&#8239;any
Stockholder may Transfer Subject Shares to any Affiliate of such Stockholder; <U>provided</U> that in any such case, such Transfer shall
be permitted only if all of the representations and warranties in this Agreement with respect to such Stockholder would be true and correct
at the time of such Transfer and the transferee shall have executed and delivered to Parent and Purchaser a counterpart to this Agreement
pursuant to which such transferee shall be bound by all of the terms and provisions of this Agreement and agree and acknowledge that such
Person shall constitute a Stockholder for all purposes of this Agreement. If any involuntary Transfer of any of such Stockholder&rsquo;s
Subject Shares in the Company shall occur (including, but not limited to, a sale by such Stockholder&rsquo;s trustee in any bankruptcy,
or a sale to a purchaser at any creditor&rsquo;s or court sale), the transferee (which term, as used herein, shall include any and all
transferees and subsequent transferees of the initial transferee) shall take and hold such Subject Shares subject to all of the restrictions,
liabilities and rights under this Agreement, which shall continue in full force and effect until valid termination of this Agreement in
accordance with <U>Section&#8239;5.2</U>. Each Stockholder agrees that it shall not, and shall cause each of its affiliates not to, become
a member of a &ldquo;group&rdquo; (as defined under Section&#8239;13(d)&#8239;of the Exchange Act) for the purpose of taking any actions
inconsistent with the transactions contemplated by this Agreement or the Merger Agreement. Notwithstanding the foregoing, such Stockholder
may make Transfers of its Subject Shares as Parent may agree in writing in its sole discretion. Each Stockholder shall notify Parent as
promptly as practicable in writing of the number of any additional shares of Company Common Stock[, Company Options or Company RSUs] of
which such Stockholder acquires record or beneficial ownership on or after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.2 &#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Exercise of Appraisal Rights</U>. Such Stockholder forever waives and agrees not to exercise any appraisal rights or dissenters&rsquo;
rights, including pursuant to Section&#8239;262 of the DGCL, in respect of such Stockholder&rsquo;s Subject Shares that may arise in connection
with the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.3 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Documentation
and Information</U>. Such Stockholder shall not make any public announcement regarding this Agreement, the Merger Agreement or the transactions
contemplated hereby or thereby without the prior written consent of Parent (such consent not to be unreasonably withheld, conditioned
or delayed), except as may be required by applicable Legal Requirement (provided that, other than in the case of an amendment to a Schedule
13D or 13G that discloses this Agreement, reasonable notice of any such disclosure will be provided to Parent and Parent shall have a
reasonable opportunity to review and comment on such communication). Such Stockholder consents to and hereby authorizes the Company, Parent
and Purchaser to publish and disclose in all documents and schedules filed with the SEC, including Schedule 14D-9, and any press release
or other disclosure document that Parent, the Company or Purchaser reasonably determines to be necessary in connection with the Offer,
the Merger and any of the other Transactions, in each case regarding such Stockholder&rsquo;s identity and ownership of the Subject Shares,
the existence of this Agreement, the nature of such Stockholder&rsquo;s commitments and obligations under this Agreement and any other
information that Parent or the Company reasonably determines is required to be disclosed by Legal Requirement, and such Stockholder acknowledges
that Parent and Purchaser may, in Parent&rsquo;s sole discretion, file this Agreement or a form hereof with the SEC or any other Governmental
Body. Such Stockholder agrees to promptly give Parent any information it may reasonably request for the preparation of any such disclosure
documents, and such Stockholder agrees to promptly notify Parent of any required corrections with respect to any information supplied
by such Stockholder specifically for use in any such disclosure document, if and to the extent it becomes aware that any such information
shall have become false or misleading in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.4 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Adjustments</U>.
In the event of any stock split, stock dividend, merger, reorganization, recapitalization, reclassification, combination, exchange of
shares or similar transaction with respect to the capital stock of the Company affecting the Subject Shares, the terms of this Agreement
shall apply to the resulting securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.5 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Waiver
with Respect to Certain Actions</U>. Each Stockholder hereby agrees not to commence or participate in, and to take all actions necessary
to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against the Company, Parent, Purchaser,
any Subsidiary of the Company or any of their respective successors, directors or officers relating to the negotiation, execution or delivery
of this Agreement or the Merger Agreement or the consummation of the Merger or the other Transactions, including any such claim (a)&#8239;challenging
the validity of, or seeking to enjoin or delay the operation of, any provision of this Agreement or the Merger Agreement (including any
claim seeking to enjoin or delay the acceptance of the Offer or the Merger) or (b)&#8239;alleging a breach of any duty of the Board of
Directors in connection with the Merger Agreement, this Agreement or the transactions contemplated thereby or hereby.&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.6 &#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Solicitation</U>. Subject to <U>Section&nbsp;5.12</U>, until the earlier of the Offer Acceptance Time and the termination of the Merger
Agreement, Stockholder shall not, and shall cause its Subsidiaries not to, and shall instruct its and their respective Representatives
not to, directly or indirectly including through another Person: (i)&nbsp;conduct or continue any solicitation, knowing encouragement,
discussions or negotiations with any Persons with respect to an Acquisition Proposal, (ii)&nbsp;solicit, initiate or knowingly facilitate
or knowingly encourage any inquiries regarding, or the making of any proposal or offer that constitutes, or could reasonably be expected
to lead to, an Acquisition Proposal, (ii)&nbsp;engage in, continue or otherwise participate in any discussions or any negotiations regarding,
or furnish to any other Person any non-public information in connection with or for the purpose of soliciting or knowingly encouraging
or facilitating, an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal,
(iii)&nbsp;approve, adopt, endorse or recommend or enter into any letter of intent, acquisition agreement, agreement in principle or similar
agreement with respect to an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition
Proposal, (iv)&nbsp;knowingly encourage or recommend any other holder of Company Common Stock to vote against the Merger or to not tender
Company Common Stock into the Offer; or (v)&nbsp;resolve, propose or agree to do any of the foregoing. Stockholder shall be responsible
for any action taken by its Representatives acting in their authorized capacities on behalf of the Stockholder that would violate this
<U>Section&nbsp;4.6</U> if taken by the Stockholder. Notwithstanding the foregoing, such Stockholder or its Representative may, solely
in response to an inquiry or proposal that did not result from a material breach of this <U>Section&#8239;4.6</U>, inform a Person that
has made or, to the knowledge of the Stockholder or its Representative (as applicable), is considering making an Acquisition Proposal
of the restrictions of this <U>Section&#8239;4.6</U> and of the Merger Agreement. For clarity, if such Stockholder is a venture capital
or private equity investor, the term &ldquo;Representative&rdquo; (a)&#8239;shall include any general partner of such Stockholder that
is still affiliated with such Stockholder, but (b)&#8239;shall exclude (i)&#8239;any limited partner, (ii)&#8239;any general partner that
is no longer affiliated with such Stockholder, and (iii)&#8239;any employees or other Representatives, in each case of clauses (i)&#8239;to
(iii), who do not have actual knowledge of the Transactions. Each Stockholder acknowledges and agrees that, for purposes of determining
whether a breach of this <U>Section&#8239;4.6</U> has occurred, the actions of such Stockholder&rsquo;s directors and Representatives
acting in their authorized capacities on behalf of such Stockholder shall be deemed to be the actions of such Stockholder, and such Stockholder
shall be responsible for any breach of this <U>Section&#8239;4.6</U> by its directors and Representatives acting in their authorized capacities
on behalf of such Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;4.7 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices
of Certain Events</U><I>. </I>Each Stockholder shall notify Parent of any development occurring after the date hereof that causes, or
that would reasonably be expected to cause, any breach of any of the representations and warranties of such Stockholder set forth in <U>Article&#8239;II</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&#8239;V<BR>
</B></FONT><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.1 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given
and received (a)&#8239;upon receipt, if delivered personally, (b)&#8239;two (2)&#8239;business days after deposit in the mail, if sent
by registered or certified mail, (c)&#8239;on the next business day after deposit with an overnight courier, if sent by overnight courier,
(d)&#8239;when delivered by e-mail, which e-mail must state that it is being delivered pursuant to this <U>Section&#8239;5.1</U> and which
notice will not be effective unless either (A)&#8239;a duplicate copy of such email notice is sent on the same day for next business day
delivery, fees prepaid, via a reputable nationwide overnight courier service or (B)&#8239;the receiving party delivers a written confirmation
of receipt to the sender of such notice (excluding &ldquo;out of office,&rdquo; delivery failure or similar automated replies); <U>provided</U>
that the notice or other communication is sent to the address or e-mail address set forth (i)&#8239;if to Parent or Purchaser, to the
address or e-mail address set forth in Section&#8239;9.09 of the Merger Agreement and (ii)&#8239;if to a Stockholder, to such Stockholder&rsquo;s
address or e-mail address set forth on a signature page&#8239;hereto, or to such other address or e-mail address as such party may hereafter
specify in writing for the purpose by notice to each other party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.2 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination</U>.
This Agreement shall terminate automatically with respect to a Stockholder, without any notice or other action by any Person, upon the
first to occur of (a)&#8239;the valid termination of the Merger Agreement in accordance with its terms, (b)&#8239;the Effective Time,
(c)&#8239;the termination of this Agreement by written notice from Parent to the Stockholders or (d)&#8239;any amendment or change to
the Merger Agreement or the Offer that is effected without Stockholder&rsquo;s consent that decreases the amount, or changes the form,
of consideration payable to all stockholders of the Company pursuant to the terms of the Merger Agreement (the period from the date hereof
through such time being referred to as the &ldquo;<U>Agreement Period</U>&rdquo;). Upon the valid termination of this Agreement in accordance
with this <U>Section&#8239;5.2</U>, no party shall have any further obligations or liabilities under this Agreement; <U>provided</U>,
<U>however</U>, that (x)&#8239;nothing set forth in this <U>Section&#8239;5.2</U> shall relieve any party from liability for any willful
and material breach of this Agreement prior to termination hereof, (y)&#8239;the provisions of this <U>Article&#8239;V</U> shall survive
any valid termination of this Agreement in accordance with this <U>Section&#8239;5.2</U> and (z) Parent shall cause Purchaser to promptly return or caused to be returned to the Stockholder any Stockholder Subject Shares tendered
by the Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.3 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendments
and Waivers</U>. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties. No failure
on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any party
in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or
remedy. No single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof
or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim arising out of this Agreement, or
any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly
set forth in a written instrument duly executed and delivered on behalf of such party and any such waiver or failure to insist on strict
compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent
or other failure. The rights and remedies provided herein shall be cumulative and not exclusive of any rights or remedies provided by
any Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.4 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Expenses</U>.
All fees and expenses incurred in connection herewith and the transactions contemplated hereby shall be paid by the party incurring such
fees and expenses, whether or not the Offer or the Merger is consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.5 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement; Counterparts</U>. This Agreement, together with <U>Schedule A</U>, the Merger Agreement and the other documents and certificates
delivered pursuant hereto, constitute the entire agreement, and supersede all prior agreements and understandings, both written and oral,
among the parties with respect to the subject matter of this Agreement. This Agreement may be executed in counterparts, including by DocuSign,
facsimile or by email with .pdf attachments, all of which shall be considered one and the same agreement, and shall become effective when
one or more counterparts have been signed by each of the parties and delivered to the other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.6 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Assignment.</U>
This Agreement shall not be assigned by any party (including by operation of law, by merger or otherwise) without the prior written consent
of the other parties; <U>provided</U>, that Parent or Purchaser may assign any of their respective rights and obligations to one or more
Affiliates at any time, but no such assignment shall relieve Parent or Purchaser of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&#8239;5.7
 &#8239;&#8239;&#8239;&#8239;</FONT> <U>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;
This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that
might otherwise govern under applicable principles of conflicts of laws thereof. Any claim arising out of or relating to this Agreement
or the transactions contemplated hereby (whether based in contract, tort or otherwise), including any counterclaim, arising out of or
relating to this Agreement or the transactions contemplated hereby or the actions of any party in the negotiation, administration, performance
and enforcement hereof or thereof, shall be governed by the laws of the State of Delaware, regardless of the laws that might otherwise
govern under applicable principles of conflicts of laws thereof. In any action or proceeding arising out of or relating to this Agreement
or any of the transactions contemplated hereby, each of the parties irrevocably and unconditionally (i)&nbsp;consents and submits to the
exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and any state appellate court therefrom or, if (but only
if) such court lacks subject matter jurisdiction, the United States District Court sitting in New Castle County in the State of Delaware
and any appellate court therefrom (collectively, the &ldquo;<U>Delaware Courts</U>&rdquo;); (ii)&nbsp;agrees not to attempt to deny or
defeat such jurisdiction by motion or otherwise request for leave from any such court; (iii)&nbsp;consents to service of process by first
class certified mail, return receipt requested, postage prepaid, to the address at which such party is to receive notice in accordance
with <U>Section&nbsp;5.1</U>; (iv)&nbsp;agrees not to commence any such action or proceeding except in the Delaware Courts; (v)&nbsp;agrees
that any claim in respect of any such action or proceeding may be heard and determined in the Delaware Courts, (vi)&nbsp;waives, to the
fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction or laying of
venue of any such action or proceeding in the Delaware Courts and (vii)&nbsp;waives, to the fullest extent permitted by law, the defense
of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. Each party agrees that service of process
upon such party in any action or proceeding arising out of or relating to this Agreement shall be effective if notice is given by overnight
courier at the address such party is to receive notice in accordance with <U>Section&nbsp;5.1</U>. The parties agree that a final judgment
in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other
manner provided by applicable Legal Requirements; <I>provided</I>, <I>however</I>, that nothing in the foregoing shall restrict any party&rsquo;s
rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;The parties
agree that irreparable damage would occur in the event that any Stockholder did not perform any of the provisions of this Agreement in
accordance with their specific terms or otherwise breached any such provisions. It is accordingly agreed that Parent and Purchaser shall
be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
of this Agreement in addition to any other remedy to which they are entitled at law or in equity. Any and all remedies herein expressly
conferred upon Parent and Purchaser will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Legal
Requirement or equity upon Parent or Purchaser, and the exercise by Parent or Purchaser of any one remedy will not preclude the exercise
of any other remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;
EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES (WHETHER BASED ON
CONTRACT, TORT OR OTHERWISE),&nbsp;INCLUDING ANY COUNTERCLAIM, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY OR THE ACTIONS OF ANY PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT
HEREOF OR THEREOF. EACH PARTY (I)&nbsp;MAKES THIS WAIVER VOLUNTARILY AND (II)&nbsp;ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO ENTER
INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN THIS <U>SECTION&nbsp;5.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.8 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Parties
in Interest</U>. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing in this Agreement,
express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.9 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or
provision of this Agreement is invalid or unenforceable, the parties agree that the court making such determination shall have the power
to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior
sentence, the parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision
that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.10 &#8239;&#8239;&#8239;&#8239;<U>Construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;For purposes of this Agreement,
whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine
and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine
and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;The parties
have participated jointly in the negotiation and drafting of this Agreement and agree that any rule&nbsp;of construction to the effect
that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;As used
in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, shall not be deemed to be terms
of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo; The words &ldquo;hereof&rdquo;,
 &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. The words &ldquo;date hereof&rdquo; when used in this Agreement shall
refer to the date of this Agreement. The terms &ldquo;or&rdquo;, &ldquo;any&rdquo; and &ldquo;either&rdquo; are not exclusive. The word
 &ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; shall mean the degree to which a subject or other thing extends, and such
phrase shall not mean simply &ldquo;if&rdquo;. The word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the
word &ldquo;shall&rdquo;. With respect to any grant of rights to, in or under any intellectual property, the word &ldquo;license&rdquo;
or &ldquo;licenses&rdquo; shall be deemed to include &ldquo;sublicense&rdquo; or &ldquo;sublicenses,&rdquo; as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;Except
as otherwise indicated, all references in this Agreement to &ldquo;Sections&rdquo; or &ldquo;Schedule&rdquo; are intended to refer to
Sections of this Agreement and Schedule to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;The headings
contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be
referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;Whenever
this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified. If any action
is to be taken or given on or by a particular calendar day, and such calendar day is not a business day, then such action may be deferred
until the next business day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;All terms defined in this Agreement
shall have the defined meanings when used in any document made or delivered pursuant hereto unless otherwise defined herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;References
herein to any statute includes all rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;Any statute
defined or referred to herein means such statute as from time to time amended, modified or supplemented, including by succession of comparable
successor statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.11 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Further
Assurances</U>. Each Stockholder will execute and deliver, or cause to be executed and delivered, all further documents and instruments
and use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper
or advisable under applicable Legal Requirements and regulations, to comply with its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.12 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Capacity
as Stockholder</U>. Each Stockholder signs this Agreement solely in such Stockholder&rsquo;s capacity as a stockholder of the Company,
and not, if applicable, in such Stockholder&rsquo;s capacity as a director, officer or employee of the Company. Nothing herein shall in
any way restrict a director or officer of the Company in the taking of any actions (or failure to act) in his or her capacity as a director
or officer of the Company, or in the exercise of his or her fiduciary duties as a director or officer of the Company, or prevent or be
construed to create any obligation on the part of any director or officer of the Company from taking any action in his or her capacity
as such director or officer, and no action taken in any such capacity as an officer or director of the Company shall be deemed to constitute
a breach of this Agreement; <U>provided</U>, that, for the avoidance of doubt, nothing herein shall be understood to relieve any party
to the Merger Agreement of any obligation under, or of any liability for breach of any provision of, the Merger Agreement. Notwithstanding anything to the contrary in this Agreement or any other agreement or document executed or delivered in connection with
the transactions contemplated hereby, nothing in this Agreement or any such other agreement or document shall: (a) release, waive, discharge,
compromise, settle or affect any rights or claims that Stockholder or its Affiliates may have for (i) indemnification, advancement of
expenses, contribution or reimbursement under any applicable law, the certificate of incorporation, bylaws or other organizational documents
of any person or party, any agreement or arrangement providing for such indemnification, advancement, contribution or reimbursement, or
any insurance policy covering Stockholder or any of its Affiliates, (ii) any breach of or default under this Agreement, the Merger Agreement
or any other agreement or document executed or delivered by Parent or Purchaser, (iii) any rights under this Agreement or the Merger Agreement,
or (iv) any rights or claims that are expressly reserved, acknowledged or granted by this Agreement or any other agreement or document
executed or delivered in connection with the transactions contemplated hereby; or (b) limit, impair or affect any rights or claims that
Stockholder and/or its Affiliates may have against any other person or party arising out of or relating to any matter, event, circumstance,
action, omission, transaction or occurrence that is outside the transactions contemplated hereby or the subject matter of this Agreement
or any other agreement or document executed or delivered in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.13 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties</U>. The representations and warranties contained in this Agreement and in any certificate or other writing delivered pursuant
hereto shall not survive the Effective Time or the valid termination of this Agreement in accordance with <U>Section&#8239;5.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.14 &#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Agreement Until Executed</U>. This Agreement shall not be effective unless and until (a)&#8239;the Merger Agreement is executed by all
parties thereto and (b)&#8239;this Agreement is executed by all parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.15 <U>No Ownership
Interest</U>. Except as otherwise provided herein, nothing contained in this Agreement shall be deemed to vest in Parent or Purchaser
any direct or indirect ownership or incidence of ownership of or with respect to the Subject Shares. All rights, ownership and economic
benefits of and relating to the Subject Shares shall remain vested in and belong to Stockholder, and neither Parent nor Purchaser shall
have any authority to manage, direct, restrict, regulate, govern, or administer any of the policies or operations of the Company as a
result of this Agreement or exercise any power or authority to direct Stockholder in the voting of any of the Subject Shares, except as
otherwise provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5.16 &#8239;&#8239;&#8239;&#8239;&#8239;<U>Stockholder
Obligation Several and Not Joint</U>. The obligations of each Stockholder hereunder shall be several and not joint, and no Stockholder
shall be liable for any breach of the terms of this Agreement by any other Stockholder. Further, Parent and Purchaser agree that no Stockholder
will be liable for claims, losses, damages, liabilities or other obligations of, or incurred by, the Company resulting from the Company&rsquo;s
breach of the Merger Agreement except to the extent that breach of such Stockholder&rsquo;s obligations hereunder was also involved in
such breach by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#8239;5.17 &#8239;&#8239;&#8239;&#8239;&#8239;[<U>Exclusion
for Certain Company Option Exercises</U>. Notwithstanding anything to the contrary herein, Subject Shares surrendered to the Company in
respect of payment of the exercise price upon exercise of Company Options or for the withholding due upon such exercise shall not be Subject
Shares subject to this Agreement, and this Agreement does not impose any restriction on such Transfer.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of Page&#8239;Intentionally Left
Blank. Signature Pages&#8239;Follow.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties are executing
this Agreement on the date set forth in the introductory clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PARENT:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GILEAD SCIENCES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASER:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RAVENS SUB,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Tender and Support Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties are executing
this Agreement on the date set forth in the introductory clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDER:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Tender and Support Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5pt; white-space: nowrap; vertical-align: bottom; width: 32%; border: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Stockholder</B></FONT></TD>
    <TD STYLE="padding-left: 5pt; white-space: nowrap; vertical-align: bottom; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company Common Stock</B></FONT></TD>
    <TD STYLE="padding-left: 5pt; white-space: nowrap; vertical-align: bottom; width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Company Stock Options]</B></FONT></TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Company RSUs]</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5pt; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-bottom: 1.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>]</FONT></TD>
    <TD STYLE="padding-left: 5pt; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>]</FONT></TD>
    <TD STYLE="padding-left: 5pt; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>]</FONT></TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm267044d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 30%"><IMG SRC="tm267044d1_ex99-1img01.jpg" ALT=""></TD>
  <TD STYLE="vertical-align: bottom; width: 70%; text-align: left"><IMG SRC="tm267044d1_ex99-1img02.jpg" ALT=""></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>CONTACTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B><U>Gilead</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Ashleigh Koss, Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>public affairs@gilead.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Jacquie Ross, Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: right; text-indent: 1in"><U>investor
relations@gilead.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: right; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Arcellx</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kristalle
Cooks, Media<BR>
pr@Arcellx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">Myesha Lacy, Investors<BR>
ir@Arcellx.com<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: #212529"><B>GILEAD
SCIENCES TO ACQUIRE ARCELLX TO MAXIMIZE LONG-TERM POTENTIAL OF ANITO-CEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &ndash; <B><I>Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma </I></B>&ndash;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &ndash; <B><I>FDA Accepted Anito-cel BLA for the&nbsp;Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma </I></B>&ndash;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> &ndash; <B><I>Provides Gilead with Full Control of Anito-cel, Accelerating Development and Commercialization while Eliminating Profit-Share, Milestones, and Royalties </I></B>&ndash;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOSTER CITY, Calif. &amp; REDWOOD CITY, Calif. &ndash; February 23,
2026 &ndash; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq:
ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of
$7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for
patients with cancer and other incurable diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kite, a Gilead company, and Arcellx have an existing collaboration
to co-develop and co-commercialize Arcellx&rsquo;s lead pipeline candidate, anitocabtagene&nbsp;autoleucel (anito-cel), an investigational
BCMA-directed CAR T-cell therapy for patients with multiple myeloma. Despite advancements in treatment, many patients with multiple myeloma
eventually relapse and require additional lines of therapy. As disease progresses, patients often experience diminishing responses, increasing
toxicity and fewer viable options, especially those who are heavily pretreated or unable to tolerate existing therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In clinical studies to date, anito-cel has demonstrated deep and durable
responses with a predictable and manageable safety profile, addressing key challenges associated with current CAR T-cell therapies in
multiple myeloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BLA for anito-cel as a fourth-line treatment for patients with
relapsed or refractory multiple myeloma is supported by results from the Phase 1 study (NCT04155749) and the pivotal Phase 2 iMMagine1
study (NCT05396885) and has been accepted by the U.S. Food and Drug Administration with an anticipated Prescription Drug User Fee Act
(PDUFA) action date of December 23, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This agreement reflects our conviction in the potential of anito-cel
and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma,&rdquo; said Daniel
O&rsquo;Day,&nbsp;Chairman&nbsp;and Chief Executive Officer, Gilead Sciences. &quot;Beyond the potential launch this year, anito-cel could
become a foundational treatment for multiple myeloma over time, including earlier lines of therapy. In addition, the anito-cel&nbsp;D-domain
BCMA&nbsp;binder could be&nbsp;important to our&nbsp;work in&nbsp;in vivo cell therapy, further strengthening our&nbsp;potential&nbsp;in&nbsp;oncology
and&nbsp;inflammation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition to anito-cel, <FONT STYLE="color: #212529">Arcellx&rsquo;s
D-Domain CAR technology platform has generated proprietary, target-binding domains with improved specificity and enhanced binding affinity
that could potentially be used for next-generation CAR T-cell and bispecific therapies. There is potential to leverage the D-domain BCMA
binder in vivo cell therapy efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&ldquo;The story of Arcellx is one of innovation, passion,
resilience and teamwork. I could not be prouder of our team, our contribution to the myeloma field, and the impact anito-cel and our D-Domain
platform are poised to have for patients and clinicians,&rdquo; said Rami Elghandour, Chairman and Chief Executive Officer, Arcellx. &ldquo;We
are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx&rsquo;s legacy. Kite is
well-positioned to maximize access to anito-cel, benefiting more patients, and the company&rsquo;s commitment to be the leader in cell
therapy is one I admire. I&rsquo;m grateful to our Board of Directors for this opportunity, our shareholders who supported our journey,
our partners who believed in us, the patients and physicians who participated in our studies, and most of all, our team members who did
the impossible and left an indelible mark on the future of medicine.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>Terms of the Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The transaction was approved by both the Gilead
and Arcellx Boards of Directors and is anticipated to close during the second quarter of 2026, subject to the satisfaction or waiver of
customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned
by Gilead, equals at least a majority of the then-outstanding Arcellx shares, the receipt of regulatory approvals and other customary
offer conditions. Gilead currently owns approximately 11.5 percent of Arcellx&rsquo;s outstanding common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the terms of the merger agreement entered
into in connection with the transaction, a wholly-owned subsidiary of Gilead will commence a tender offer to acquire all of the outstanding
shares of Arcellx&rsquo;s common stock that Gilead does not already own for an offer price of (1) $115 per share in cash, which represents
a 68 percent premium to Arcellx&rsquo;s 30-day volume-weighted average share price as of February 20, 2026, plus (2) one non-transferable
contingent value right (CVR) that entitles the holder to receive an additional $5 per CVR upon the achievement of cumulative global net
sales of anito-cel of at least $6.0 billion from launch through year-end 2029. If the tender offer is successfully completed, Gilead will
acquire all remaining shares of Arcellx not tendered in the offer through a second step merger for the same consideration as is paid in
the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Upon FDA approval of anito-cel, the proposed
transaction is expected to be accretive to earnings per share in 2028 and thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">BofA Securities, Inc. and Morgan Stanley &amp;
Co. LLC are acting as financial advisors to Gilead. Ropes&nbsp;&amp;&nbsp;Gray&nbsp;LLP is serving as legal counsel to Gilead. Centerview
Partners LLC is acting as exclusive financial advisor to Arcellx. Wilson Sonsini Goodrich &amp; Rosati, P.C. is serving as legal counsel
to Arcellx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Arcellx</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arcellx, Inc. is a clinical-stage biotechnology company focused on
delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell
therapies are one of the forward pillars of medicine, and its mission is to advance humanity by developing novel therapies that are safer,
more effective, and more broadly accessible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Gilead Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gilead Sciences, Inc. is a biopharmaceutical company that has pursued
and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company
is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19,
and cancer. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era
of discovery, job creation and public health preparedness &ndash; while continuing to invest globally to ensure patients everywhere benefit
from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This communication contains forward-looking statements related to Gilead,
Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than
statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent,
belief or current expectation of Gilead and Arcellx and members of their respective senior management teams. In some cases, forward-looking
statements can be identified by the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
&ldquo;will,&rdquo; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these
words. Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance
and opportunities, post-closing operations and the outlook for the companies&rsquo; businesses, including, without limitation, the timing
of the expected commercial launch of anito-cel and Gilead&rsquo;s ability to streamline preparation and accelerate adoption and access
to antico-cel if the transaction is consummated; the potential for anito-cel to become a foundational treatment, including for earlier
lines of therapy; regulatory applications and related timelines, including the PDUFA date for anito-cel&rsquo;s BLA; the potential of
Arcellx&rsquo;s cell therapy platform; filings and approvals relating to the transaction&#894; the expected timing of the completion of
the transaction&#894; the ability satisfy the various closing conditions and complete the transaction&#894; the expectation that the transaction
will be accretive to Gilead following FDA approval of anito-cel in the future; and any assumptions underlying any of the foregoing. Investors
are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and
are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently
anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations
contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger&#894; uncertainties
as to how many of Arcellx&rsquo;s stockholders will tender their stock in the offer&#894; the possibility that competing offers will be
made&#894; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental
entity may prohibit, delay or refuse to grant approval for the consummation of the transaction&#894; the effects of the transaction on
relationships with employees, other business partners or governmental entities&#894; the difficulty of predicting the timing or outcome
of regulatory approvals or actions, if any; the risk that, if the transaction is consummated, the businesses will not be integrated successfully
and that other anticipated benefits from the transaction will not be realized; any negative effects on the existing collaboration between
Arcellx and Gilead that may result from the announcement of a transaction, or the failure to complete the transaction; the risk that the
milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof; the impact
of competitive products and pricing&#894; other business effects, including the effects of industry, economic or political conditions
outside of the companies&rsquo; control&#894; transaction costs&#894; actual or contingent liabilities; and other risks and uncertainties
detailed from time to time in the companies&rsquo; periodic reports filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to
be filed by Arcellx and the Schedule TO and related tender offer documents to be filed by Gilead and Ravens Sub, Inc., a wholly owned
subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead, and Gilead assume no obligation
and disclaim any intent to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tender offer described in this document has not yet commenced.
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities
of Arcellx, nor is it a substitute for any tender offer materials that Gilead, Ravens Sub, Inc. or Arcellx will file with the SEC. A solicitation
and an offer to buy securities of Arcellx will be made only pursuant to an offer to purchase and related materials that Gilead intends
to file with the SEC. At the time the tender offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the SEC,
and Arcellx will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. ARCELLX&rsquo;S
STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL
AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related
letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9,
will be sent to all stockholders of Arcellx at no expense to them. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation
Statement on Schedule 14D-9 and other related documents will be made available for free at the SEC&rsquo;s web site at&nbsp;www.sec.gov.
Additional copies may be obtained for free by contacting Gilead or Arcellx. Free copies of these materials and certain other offering
documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor
Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the
offer, which will be named in the Tender Offer Statement on Schedule TO. Investors and security holders of Arcellx may also obtain, free
of charge, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents that the Company has filed with or
furnished to the SEC under the &ldquo;Financials&rdquo; section of Arcellx&rsquo;s website at&nbsp;https://ir.arcellx.com/financials/sec-filings/default.aspx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the Offer to Purchase, the related Letter of Transmittal
and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Arcellx file annual, quarterly
and current reports, proxy statements and other information with the SEC. Gilead&rsquo;s and Arcellx&rsquo;s filings with the SEC are
also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gilead,
Kite, and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. The Arcellx name and logo are trademarks
of Arcellx.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>gild-20260222.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaqNWbOdzZR+uYkxtmB8bVnKzy0o70FK2SwB92s2cYUJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:GILD="http://gilead.com/20260222" elementFormDefault="qualified" targetNamespace="http://gilead.com/20260222">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gilead.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gild-20260222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gild-20260222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>gild-20260222_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>gild-20260222_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gild-20260222.xsd#Cover" roleURI="http://gilead.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gilead.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm267044d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm267044d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X , # 2(  A$! Q$!_\0
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ML8\EPSMRTJE]U-+3KIT ^=O@QS_P<C?&@D D^%_& R0"0$^#'@ * 3R  [<
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M4]O=31:=X?\ #OQL\+:GK=^\%M%<W-VEK9P22FTM;2XN+F-'2 /(R _J&_\
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M\4_VC_B?^TKXQ_9T_9\\6>!?A-IWPD^'_A3QM\0OB%XN\(MX_P!7UC5O'O\
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M\3Z'H%AX;\%OXDTQS9#5=%(GN]1A&GC9>HABN#)+(NQ9%=Y+1W26VK^?IKV
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DB/0O"VE^*?%E]9V(73M(U#Q%JU]>VEJT@DFFDN;AI"BD!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm267044d1_ex99-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm267044d1_ex99-1img02.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  D *@# 2(  A$! Q$!_\0
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MX^I0Q%6G0KU,/*T(X"LN9SIMJ+E#W6I-H+/IK_7J?O!17XW_ +7G[:?[0/P
M_;T_X)4?LQZ!<^ [SP=^UIK?Q>T/X[7,WA[4+K49;CP!X(T'6-/N/!.I/JD
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M\RS#*\=!TL9@,7B<)BJ+;?L\3AJ]:C6Y5*$9*,JD9SC?7DG1;2YT?RA?%/\
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MPT?K>$Q,ZD/K,LSK+EQOMI1G?ZA6B_\ 9Z<9NOAIPC5BO:5:PKVO]W3;M?\
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:OV]3D_F>3ZFBBM)M\UNEMNG00M%%%; ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 22, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 22,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 LAKESIDE DRIVE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">FOSTER CITY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm267044d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gild-20260222.xsd</File>
    <File>gild-20260222_lab.xml</File>
    <File>gild-20260222_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm267044d1_8k.htm">tm267044d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm267044d1_8k.htm": {
   "nsprefix": "GILD",
   "nsuri": "http://gilead.com/20260222",
   "dts": {
    "schema": {
     "local": [
      "gild-20260222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20260222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20260222_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm267044d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://gilead.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-02-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm267044d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-02-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm267044d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-26-018314-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-018314-xbrl.zip
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MZB]KJ2>'?@!XD$^^=?GHDM5A]=!W'?L54U_J>>3WM>1[W%HY=/X"W0J?)@A
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M+BR.SV%8P4%/(3Q\&L1N5?9T7'*GLK,2;OI.J^;K(@0?8GG?*&!!1.?WP(D
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MP)A<7ARJTT6@B?2&S0)[A8L95GTER+*<,&MNR,I2+N-S<"[7'*1)0"@')Q%
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MO4H*/?QR634Z<7]GVY>7KV%<7^; C,NJO,I3I#+I4'!N2&# T8'+,2;>MU2
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M=P3<)A<=4321;90(#/H2LRFZPBM0"^37.@D!;"&H(N3D1/N];9<C@ *L*)X
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M-QABW#H4A3,*5+?<,GD-:&-#!>MYSX/%FN"//U:>J:^,!L/;PFT,8A?7QEA
M!W),>D<NI0P<M$$<.2C",![!9$QO'Q_#N1C\A&(QL%HU0L>MS[.&&Z^A3PGY
M4@/;Q-%%/FLP5)"B&V@YY_]>D#'"N,\<1;FHPR9,#K]8+W$I6MK0> OAPJ9P
M9A;M7%]R9PET2G*Y )MRCV2MX39:Z1]4D(Z@#"D61<PG*\XI%"QQ9NM?(VV
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MXLL,*6S:_<QP%2B)A,5E0"TY;&D,N8#8-;&=^ZGKO.VO'-U3IEMD6.-Z*HC
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M[XF:1<<\IJ*JSKW=KW?1#^(6/SF*R0W0^N )<"O88JRDW: 63>6/AE7NOL9
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M:2J,+,S=2EI&"7(1-YK%*7:@:^QL[&00JOK./CFMQ*88.%?O9:14Y@0K[4O
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M#^FU9T0XS-L^TE[Z>UAUK>!M+6#^__L]]73\_M,!GB%[GP]/X5PYN7\UQ$/
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MN3\RHR[;C0?Y:3]TV_-,FLQG]LNJUWP7G%XOX#Z?BLNDI$5Y%QQ&\X2GX[#
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MZB9BH7H-9N<ET>UVWDV'*K_ZY0RX*Y<HD3"*\NC3JI?/U,&-61;WS<TZ.%K
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MM6*"E?D0K6.7E"8N$M8N\+[];5WH9.5I'P[DW"W[ICUEZ Z&MJ=EJM1/H7Y
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M\[ N_TA/CNPE-9W; "MII4#IVT<6*'WU%"C]<<;ZJ\TVUI&@YT.*H-?J'?R
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MN66Q7A_I&AW[DHYV-%5%:E^!OERA!@2.L3Y#<=,VW9O-WG3'B27^3]P'/Q:
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MXK74TV,E!.K2,-1X_0E75?B'UH[7DW? G*#P8RW8D!O'1(90O()^)+:U[[2
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M=()C1*K(BC,=J:6U:(D'"@6?0H@,(\>=*#;*1MI>XI&)8Z\Y[B6M)BL)3%%
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MSBS!3@(9NKG/_GA^\IQC@)B+(Y3$U[TS^WV*>@G$[+R91[G&=N 0V'+IMWG
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MWN];Z.F$,^<<Z*0@+6&D;\C"R?C <9I5U,67G3V=".J%U/?RP&(0XP^SD17
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M;LEV"TIAR]J-6*S0?](C1]>!THA;2T$D4H@XD=\/,T]0FDWOUT#X4CVB7&0
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M X[CI@),)#"1&!9IP*PUU4=P).O91V?=W!^<:S6OKY&6Q)D?:4Z#JFW=? 1
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M!Y$I$(_=\<CX3Q/FT\5J "B:S&HJ0^#A)2&N<X?<UG-'%=1/&W!0NSVB!C*
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M^-\ - Z9+>P_Z)( \V^[;V(&"@0XP>B/5.M9W6SJ1N=[ND=Y$O=1V*!G9;Q
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MZ9U9QE>HI#S\Y_!I]'OJL]'N20F&26: > ;YPS1PDQ(4]&1N+/ZY>,M6C1D
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MTN_CJ!,C!*''?0I]W:2']B>_[I,[.D^]Q7/:EDR5_6LE_3PQ,?M-!"]BG9I
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M4&G@\7=6&GA^5QKX"P^"'T_[($!)&B-5 V<"J'2I&_KFL'=%.6F%K1<MV$M
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M2IG5M"+<"\>EPK<FJC1H">'L(!UTPO,;S$DG?XC*B2B62+MG7I>X3*$,#*\
M?^"'&N8KB0N22!R(($,H=,JXP3;)A*%D"&8&LF@"@/AM^ SX-QKEI3>J##_E
M_9$<D7M_Q$N'7Y'Q3;JVQ[G1D?%)$CED)-6IO9X@WEII+DT?!ZU%67[D$P"2
M6\!%6>S9ZZBO[9.)BJ5YC[JK^7'GF#AN 2@;Z1N?\3B1-7I1P"Q. 3_1:1(Y
MHY6.)GO).63JZ=UM >4*EUZWY7(R >OBC!QP@,+Z;>K=!=FQ'4_%KMTZK[_9
MBW\++)?N0*[KE2"T@K28=9"IHPBD/<O59EGORZX'ZM$%]+"&O%+]2GFC9LKN
M9_^.DN]Q+YWLFGE7!=7&KUJVE9>Z@GXDR@ZJ@8.:2+MM@!G[B">'Z&9[">(3
M157>!.^AF_K==E<L29X7(C+GE"&5IX&P:)Q2$'7A+^6TV<$+>?ACGCUZ\.A9
M[F9M>PW-M;%++?8M#$]>1#<S!)$^2D&[#0^AY.3NHF3(@9J5'0*WPYI])EUF
M]O;@ [;N<=O%OO/X7K"WF-97F$4ME^XAFWI=S>#<@E:M1;:YW+< QI#34'6U
M9#^,1POWWQ68J+HQ%"O3TI@,/]>'+-KWE'M]^IWE7A_>Y5[OT$4^=PC>WGO3
M!G;(*H1*X@G32L>&!O_(0$)H,28N6V1GYQ/B^D"WD\BK\#.(RW9KX2M1P(_X
M.&_1G;DIW4:7QZ&/Y<*-9-NEN8 @3F[)Q3SWA.4%1?[L"4F'G#@SONJ'2(Z0
M)*:GR.:'-1X=8]\@AK2?:1X[W8T4W\Y\4R..'69/SVG%]^2(2"\ "(@C@^XZ
M/-P(,)!SLH3F/@0,!+DI>8G7E03*=#)BP;1>7E%'H2$D'719#<Z!<;PM$U/G
M7(JFPL0BOJ6^8?2_>(]B,!/\K1U^]/_AVCWFQSGNM\W^'#%*SDA\B/.\1--#
MQJ4;M3**5<B";$L_]K!2N@\2I%?ELMY8;S(G#D"WVV<DJ<)VJ17>)V BX*#R
M$ME;!FJG]'2$YMX_,]',M,02_8QS3$)@X+8@^HV%QL$&6$,-?B_DZ5K  M>M
M^H"[];+ZB.S9""UZ. GM='H^K6D/)]5MP\^;U>Q+3*JT0WR)R<T^?VZ_G+$X
MMHW_ K-Q:^V&6HI?^)0LKNJ*N+N!W+[>3?FXM_1:WNTX' 4#T8I/Y<UVS$"J
MQ*))U@V+^*/#'ME8NZD.;L\(")]ZJG7!>;:L("NDIR@G*E?NT(>DIO0;$V,4
M1WGF["?Z?\//Y14*V,'BF3$/3A2QT),;;H6(_6KFMXB&LD@&*A7!'S 15$#A
MD2AZ<--QRT(/8RI,#-<>2PY:M<#X[6ZYHPB"$Y?]^2TN T29^_'H9ZX+! WX
MIL[=+29K->OLCTE0T0JX#+L[JVB#+\2!SWCT+J@"-%$6-F".,UDNVAF>CM<S
MZ4H*EL%RGB+ .S$IH]"EHSO;3WS@0#\1S@T3BDBVB]*.\H'?WM,R+-[ %2]+
M*!SHAJ8=ZBQ%L2_G$\(>G_T/SK)/6H75PD=Q=-AI!CL-7<C;"Q'A7=.%260Q
M2D*.LTXX!X';&=5 ^@00,]3NA>4_ T #GE[Z%5AL5;M%-PT7*C8_;V#QPQ'#
M./<))M4Q7&U8?LK4JIP3Z987YI#QH&VN( #<%CP<90DC6 ,"-Z >AV&C[K3<
MG9HS1+U2@<Y7'0/-C8]EN;'[$1Q#*)K.*"6/O1RDM>C^N7!_!K(S2>)3V5!J
M"V K;&'? &A0KPM"6??8$T9)\(.I&PJM>SI(BF#=#R^K#<,BZ'%JN/]9NYM.
M^/'@H0%8CQ_$J1$IX^*HL)\*6T9U!O5^\[( NM/6&Y=$0?AL6.EZ76?L57=Y
MON+UUJ$L8Q^I#5L0B_D<##N;ZYB:W-H@[\!-P0,$)PE*@XW/7H4>WR,@Y*/6
M!(&'<(X!XXB 0]Y?!;](KUI',D%USY.P<(.2Y\^^L^3YH[OD^5WRW+O-G4,6
M/:NSHW!$ L],OC57Z'C&X-:]J@&>$B0;RQ9DKZKV$L%4*'Z)[O<"<NBL7(>:
M',V.*/"<WP'  <19T&F$F:N26O650)PAA!4H5DX)DE>M]:2C5 +"NAKC:@3J
MFE'SY'O\ZL0C<%"R"X_5JWI+C8_$'T/5"R@3-*47'W&'N3L/XTQY0><\=_71
M,/C"X>4T0 ?M&TIW4/:?6;N0:,"+MO1<2J_$2IY"=>/.8/?U7$HQX$#]#=.6
M5AHE119F\'[(%0;2+C136=6V.^E8HO -O,T67]U5Z=7'#:TA PTG;AQ>]12"
MGH.DD^C9T,VP4!$*.T7N";5YAEDH0ELK'P/#=IA3@YXT>M!>I$/AX8_.*9PA
MV@^69;F:>LAW H1)LQ1BODU)RX?IY/S*8Y,$KO#5!,B;"$ITY,7E5F<VXS?6
M,]TR>8(7JAJ>/^KOIB3TD6O<^)5-G-_]:)(JXF'X7"_GHK\G:(]@S;E@G>*?
M_]O=^4/Q1X #B9W@8XL\(5D8+"+J7PZO$B\@L!"/D\^#"*(69IARJKR=XB4K
M%WOU_NW;_IFG#?7U#J*["MOA(Z]U"QT4I^K5U(5^.0!JZ?@B +<[[MH6*O?L
MUWSNX:2&_Z17P*U= NJNMB6D@=#BY=D%'-XJCYMG&T$$J#1IB0K<\%_.@1'-
M=3BZ!9W/)330&Q%3$5]WW[TPIA%+K^YM42'!\LKC]6,:H!G6G2L.@CP04%&#
M9V3?) ]<#!65L7\&2GEQ/9CZ $'RY8P;*L3=<4L=0(* /$0V80:4S[DEFLT=
MFTG/AVP<-/JO>_1]O$AH]/'<T)X&GW;!'VM9Q/I7T72Q!V@?=, ,&J8HS%('
M'D>"B!7.C!<3QJ0#$'1%@-7U%>3?B.$5,HBBW*,ZSS IZ&7-18+HZ/B=IW'L
M 51P1?$X%G2)BUW>2A'*_DS+P#N$^D'H(2ZZLW$CCS!]0G^6HX*%M:YJ:)S/
M$@_SR C@5>[IJ<47UI<DO 'AN_>/CUT@7_WY$XX:%T@^X?DGIWP>7=W6XRAT
M18RT=JJD!!S.^;%:7012C(I[UF4MUMDK =^_719K7,0#%V&>!9D"-ZJY.W1R
M(TOOM3U)@0L%6=#0!3=5-5?H!\/*A3LS5P"VFUV6T+UE6@AR+9NX_ZK=4Q-@
M3C<&Z99*LT#\>( ;K[8D8 )/^0=69>#([3CG$PG*9\!8Q=3:4[?DBFI-D, 8
ME9 MBZD="Y_%*\Z!4-.-R0)HP8%.U(R%7.$2HG5*'H50GOL(G83GP2J+UCD
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MTD/&H_3_7&2OW;QAN71G*2'?#3YS#W?*4445'33VY.HX7Z;^0A<_&GY3Q.?
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M&BOMKN65W&*OO<-F'6_W!4F^@$OO\<IR$\&>2R@<IX# &#HS_KW5$&_?DNQ
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M5J%YL9>L:J%)P6X"B!!7;0WO&=WILFB6%;28L$>-]/8A;V#,LN1NE55N4'/
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MVHL(_!,=O*"3;CPRQRZ^&+MS!YO9&SD[R7.=]_!G'NP)B.;]['4+0YDI<FX
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M*0>JVS8(K,$%/&-:U5G5S':K%LMHW"5$FM'#=[2.3M, 1]?E#;( /2B](6F
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MH]_6LWJ98X3'/X%^U2W\)C]V(:!*W4'[+'D9<.YR; D9JN,_-Z>B6[#.:8+
MGJAW$0/CZ? /7">GZ6@ KVK?G(M]5].=<QBHE0'2'ZQD:1,H9T'+UJJF*)>\
M%><7?J2#SOR:/N"?3XYO;NI<#ITL74^1%CI7_UQ<@;$AS(J[1''\)C8M%3:(
M+0N3Q#-75FTH-!I=;RE]&P2#F*X[9"#A>@3LHPZVBN@%3R,6_5:U9"-\9&,=
M=D--C"X%T%\&X*$S1'&MMTU-_@S3A"&, !#AY<4>_3C?G,29.VG%TSXE5%YG
M&#EFB*X+8&^%;A9,W'?:]G)G_LK5AO][MN32#.:OL)</ZUT"VE*UI"-I3>26
M.8+#4AGZ65V#5+P  >%R,"G6F^=<DI#NM>P*D?:M%+D;XLB#_"7?1)R6@%N6
M&$&7@IOW.),#@<@ 8%G&U-:)>D!4@^A@5> /IEV /"#*(>1R&!MI^9;1<>FA
MQF)0=HQD<1E[2D,PD^;>+$8,("PSIRMNB1GU1$S+XILR+;&%2?2&ZCM48].#
M!6/4*L-X0EYHSVJ)^> @]C.LE5ZV/;HZ<\R@@V:/13S?;!$PN.T[K*FD[ZK,
M*?'8D"E#=S5UHE=0<7&GO+-_+?YW,(@@2#&^<\B-I4<R"U$2P,&7_]M+X6&1
M#KIRSEU$G2%"F4N^Q8EXT[Z$ 4#?P+VI];<)GV8M/"M2AE 2=[:0T;3V)/?3
MDXM<+OQEQ4Q%%\RPE4NE!J.;,L@&?7-"8F1P^-AG#QBET;.9UV4K9.((\=!
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MK2_G]D 8,"QE,E\L(I"@&W+\!$LA%Z(3Z>F%.O*Z%?1"^<=LM]S0HL%[NB@
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MF@(,4I=5N<,M%+['O!]ID$*H[RQ=(FQ-B)L--\&NF5UBR"8O!/I,9!O$2SS
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MF_?@P &5\S5D,KS-U 80>9-CI+_;_8+PED;01AQ!&Q/'B@9=2 QD=T<\%B_
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MF;&]P')@F,6Z8C%X<8,N>)-LWUW!P4&^"$TA+-1EIFI7?J<1%#]!IY.<K9U
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M-UFIU@]Y&'=941+Q<=NL?*[BI.M[LXB5VC, 3V^? LBN9[UUAR>C3R">&Q%
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M"N;C7W0Z79]&)V^QE6_^]U^.@R8%IQP,VO 2V__?I*IT@./UM[]>G[K;N#Z
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M+3F0RT:M43XM:W.W].2$JP=,N:#",O99IAU=C,:![^]*/Z#P+@Z_-_;X71K
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M9/S027?89'>G,:]"(\>;M!^CK\#Z1"@!TML66 *,A3D^E+3%"^(M_)9PEEI
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MAFJ_LI7444\U2L5):Z@@807V->_O#=NTS-1P9;0<(+8JP;^ $<JGI^1I<BK
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M+8Z[IJ;78TWPZ@[L46,'HCI#5!^")SX!#WQ5SD_/(NCU#M*\O#C &PA54KX
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MB;=#DZ8#%"]"LE)5ETN1@%\0NFR&XFQ5I;P6: ':N=Z(]C4HX3F(]44XX>]
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MKDYK%88'0"[E 10'\VDZ+\AQ.T]CN\)I*V0D  )7LRQ1W-D0[#.@4.5U""P
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MY[HCVRFLA*.8F<#6KO9,V T0XG1#7QDX)M%U^B5,;G(UQR3:S"]92@C:BCY
MRY>51@!Z=A'WAP</X+M"!\,[& B'ZU)\1P=GOJ5![P+=!!'?I1H<>)P:@.[0
M\5-<MK,&H=Y6@Q R!;3Y4L+9YDVUFDEJ4YLM4.GN)3D#L0X(]&A!0)5.R4&T
M96!5.BG/D4KN".G?F:SJNBR)#[>.);$Y66A6O'&CJ?RE/()/HZ/IE$SLS 2Z
MWLZ'P[2NRVH')=QN 1G?IB25(2,7IH!/>H[-^E2HJ\WFWTB$0T-U,YU)R52R
M4E(B,$W0GQF$G9N$7+7*&7!A,3?\7MH 0[0C<IBT7:<)UWEFH+WK/;S?IWLO
MZC8H='^O+DVV-!T=K-EZ5S<GI3E&[D<,W>HN7U:'E\Q$VQ6=O;HMK^35C6#G
MV'0:KU3;(Y+;'ZRN,0Q?C9V!J_&C7M/01,'(W)5=X@[P%=JU^^(*1$/J]]9F
M=JAW+"D8%2*B#K%3B974)H:K4#+XN!P)9"ZMQ&ED*$+A#.'=2/-;)F<"IG]L
M=+4\SL*_I'(%J'C9]<A$_6=. X89B=4F6]]F++:68N2L-'B"9$TQ9_-35 /A
MIS;+9W+RZY :!^]_L+^'+6+35PFM5EV:_DE'JK7'I,1\P. #$4:83A[I=&8P
M@Y+.<[X$I\-:Z*,5C7'>JRS2AW)BL7-'\1ZS*[QADW*X69?4.&]F%F8"O%9M
MCU[-U^3W8I4/.O!F1BO36<)A NA(4HE)3,8S"$7JENL63&#G<<K$=08ISX N
M7,N3% B62@[-[H=N5Y6Z!8/%&"P\3UXI/^W7X ';WPL),2UF'N"UR0 OV 4P
M\2546#U=HP$K<J0<1>/R@-#G3/;W"I@\_Q 1A=,X#'KX\U/I.C>>H!V'Y^"T
M_-!($'9.NCMYX+F#])*;^4B\>9QZ>% ($2:-)<;E4HF_8,=K&/S.+</>JKD@
M/M& #Z"S)S#3AE^O"V%_3R P ^#"JWIV;Y@G=<T_6E<*WJC!FE=AQSFKHB*9
M:'55,AJ!""!E9$B:6.#XJCL?__&&[%)ZFM4S3VO^)&EXH!)/E(6)A_K/M"1,
M5^I&QTL_7NTSAS/([A9URH$XO\V\4<PN4FBL]AX8-UEL?6BK_.D@LL_F/5:W
MI]-_OWI?!$MCR.55S&U06#$I%E[.<A&KEL( X0A9VW?IKC6+O#IGGZ8-CS47
M2X6K);/TK?=#6"<VX)VQUCP]34R:)Z0\2IL;JK?.NQ"7W!V-!;Q\LX@C/6)R
M(-[(&RO(.Q*,][*,4/A^GF>TLSO0>AGSA[N6,7_X-6-^"R;O%O(1K^TWM5+I
M*CQN3]K#4H6QQ7YYL#@%?W8Y]HE_6$>ND?4XY-3357S-T/[,Y#$\L9VJH<[5
M:;O5T5EFIVV^<G\OD&YDM-4?;R+CH:RZ#P[WJL";CM+.\XQ?T^2S/MIDI%''
M0<I%BO\RJ#A[FI$3[+G>EJ55\,:%\#*8#HCH[AH%)8%=76W/QD8D[ZYL.>MF
M>1YM798GD#T-_,>CT'\,<SK1"?. ?)H[Z,[?%@XK]$[**L;X=%>/YW$NKI]2
M\$])NL;\)73%$Y<G!:1>M]5C]9TXME1,^T]+G/4[;(IU8Q8SNA<0 >@H*T_Q
M22<3AZ#@RMYYQ9E\!=-+8)76\'FZ2%@Z3P/V"&/L[YV+116P@/(B2>ENK(3&
MCB*0!<$9A"QF52VL&M/-!R,\7NWOO2Z,YM+ZAP6;'JD^_807B_-^U1<)SD8Z
M[X.I'LZV<!=I;AI7F\Z= R@I?!FV3QPK*PBI%=;!/'&5Y$LFBJ2-#/2 B\2[
MCU9. T;@*-:H7/L!9ZOWF,?;O<>$9]QP/6%CT06*P1LLC#6M.QTO+9=4S@"O
M,$H#"!S$D;F@\B[BJM ":&LD.NQ*KZ%]V'6'_A+=)]-LWA/JUHZP+5.P_=OM
M4E%^9!S$Z":0D,>O_SAY=?3JW=M=TD5^M$VZR)N>%,EPO,QD@]>0L1^XVG#3
MYYV6_)TBJ[GFCP.2C !E*@;^/!VM&\+NVLLS]<^DX'6UMQ>V3^DDR$I9FKV5
MT6XIW#'2XP;V:9P%M8T]"]A._%)5=EV5XZM.*ZA9U3;+IG>6,B"_I$AN1*?.
M2IPY4Z5)_YW0OOP6E>.Q_?3-V_=<IV;^?CU5&6KF ].8[PE'5K'+8_;%K#S
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M2#O/XB\BT8.RY+8<F](0BXP,G84GF8M2N1C77W-JWDCX<?E*VE;FZ$MZ_)'
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M@J<7$UA<U1M.?VZI'A@S[ZCO=)0>J?&@_]/%17_K*WLXIV:6E1JB>_BTU6S
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M(DDT9 %!*2QS(H^6*.V,>UZ8U&F*K=+#H$=<[8.LNY +ITBA%,%DPMO;.W@
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M]']02P$"% ,4    " #,-5=<YG1K%"H#  #<"P  $0              @ $
M    9VEL9"TR,#(V,#(R,BYX<V102P$"% ,4    " #,-5=<51H H/T*  !_
MA@  %0              @ %9 P  9VEL9"TR,#(V,#(R,E]L86(N>&UL4$L!
M A0#%     @ S#577'N(,.Q9!P  T%<  !4              ( !B0X  &=I
M;&0M,C R-C R,C)?<')E+GAM;%!+ 0(4 Q0    ( ,PU5URNE459OB\  -+A
M   1              "  146  !T;3(V-S T-&0Q7SAK+FAT;5!+ 0(4 Q0
M   ( ,PU5USX28$3 T$  -I/ 0 5              "  0)&  !T;3(V-S T
M-&0Q7V5X,3 M,2YH=&U02P$"% ,4    " #,-5=<9^<1;1W2 0!IA@L %
M            @ $XAP  =&TR-C<P-#1D,5]E>#(M,2YH=&U02P$"% ,4
M" #,-5=<^,&PE\$;  "!:   %0              @ &'60( =&TR-C<P-#1D
B,5]E>#DY+3$N:'1M4$L%!@     '  < S $  'MU @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm267044d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gild-20260222.xsd" xlink:type="simple"/>
    <context id="AsOf2026-02-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2026-02-22</startDate>
            <endDate>2026-02-22</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-02-22" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-02-22" id="Fact000004">0000882095</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-02-22" id="xdx2ixbrl0017">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="AsOf2026-02-22" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-02-22" id="Fact000010">2026-02-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-02-22" id="Fact000011">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-02-22" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-02-22" id="Fact000013">0-19731</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-02-22" id="Fact000014">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-02-22" id="Fact000015">333 LAKESIDE DRIVE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-02-22" id="Fact000016">FOSTER CITY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-02-22" id="Fact000018">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-02-22" id="Fact000019">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-02-22" id="Fact000020">574-3000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-02-22" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-02-22" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-02-22" id="Fact000023">true</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-02-22" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-02-22" id="Fact000025">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-02-22" id="Fact000026">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-02-22" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-02-22" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
